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 1 
CHAPTER 1 
 
INTRODUCTION
1
 
 
Inflammation in the central nervous system 
Inflammation is a component of the immune response that is characterized by edema, 
pain and increased blood flow and is defined by activation and recruitment of peripheral immune 
cells and the release of cellular signaling molecules known as cytokines (Medzhitov, 2008). It is 
typically initiated in response to injury, autoimmune activation or infiltration of infectious agents 
and enables the body to neutralize harmful stimuli, remove necrotic cells and repair damaged 
tissue (Medzhitov, 2008). Inflammation is normally an acute process, with built-in feedback 
mechanisms in place to reduce production of pro-inflammatory cytokines that maintain its 
activation (Medzhitov, 2008). Consequently, disruption of these feedback mechanisms can lead 
to a state of chronic inflammation, an event that is characterized by consistently elevated levels 
of inflammatory cytokines and implicated in cancers, Crohn’s disease, inflammatory bowel 
disease and rheumatoid arthritis (Rubin et al., 2012, Straub and Schradin, 2016). 
While inflammation is well-characterized in the periphery, less is known regarding how it 
is initiated and regulated in the central nervous system (CNS). The CNS consists of the retina, 
brain and spinal cord and is formed primarily of post-mitotic neurons and glia. For better part of 
the last century, it was commonly accepted that the CNS was “immune privileged” due to: 1) the 
presence of the blood-brain-barrier (BBB), which separates the CNS from the peripheral blood  
____________________________________ 
1
 Portions of this chapter were published as Echevarria FD (2014) Interleukin-6 signaling in the 
central nervous system: Pointing the finger at trans-signaling in neuroinflammatory-mediated 
neurodegeneration. VRN 6.  
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supply and 2) the lack of dendritic cells, which targets T-cells to invading pathogens (Carson et 
al., 2006). This suggested that the CNS did not respond to cytokines released during peripheral 
inflammation and did not initiate any type of inflammatory response. While now known to be 
grossly exaggerated, this definition of immune privilege had merit. Studies revealed that 
injection of pathogens into the CNS parenchyma resulted in little to no inflammatory response 
compared to peripheral skin injection and tissue grafts to survive longer when placed within the 
CNS parenchyma than when placed underneath the skin (Medawar, 1948, Perry et al., 1997). 
This definition was also conducive to the construction of the CNS, which makes it more sensitive 
to responses associated with inflammation. The retina, brain and spinal cord are encased in 
spaces with little structural flexibility (eye, skull and vertebrate column respectively) and 
therefore cannot tolerate infiltration of peripheral immune cells and increased pressure associated 
with the influx of fluid seen with edema (Carson et al., 2006). Finally, inflammatory mediators 
released by peripheral immune cells have the potential to be neurotoxic and lead to cell death, 
which is problematic in a cell population that cannot readily regenerate (Hendriks et al., 2005).   
Over the last 30 years however, research in neuro-immunology led to a paradigm shift, 
effectively describing that not only can the CNS respond to cytokines released during peripheral 
inflammation, but that the CNS is capable of releasing cytokines as well (Carson et al., 2006). 
This process was coined “neuroinflammation” and is implicated not only in protecting the CNS 
from infection and injury, but in the development and maintenance of neuronal networks as well 
(Deverman and Patterson, 2009, Xanthos and Sandkuhler, 2014). Neuroinflammation is 
primarily characterized by cytokine release from neurons and glia as well as changes in glial 
morphology (Frank-Cannon et al., 2009, Xanthos and Sandkuhler, 2014). Unlike peripheral 
inflammation, neuroinflammation generally lacks peripheral immune cell recruitment, vascular 
 3 
changes, and edema (Ransohoff and Brown, 2012). To compensate, glia (e.g astrocytes, 
microglia, and retina-specific Müller glia) serve as the resident immune cells and deal with 
invading pathogens and diseased cells directly (Ransohoff and Brown, 2012). Similar to 
peripheral inflammation, the process of cytokine release in neuroinflammation is tightly 
regulated. While acute induction is essential for CNS development, maintenance and protection 
(Deverman and Patterson, 2009, Xanthos and Sandkuhler, 2014), failure to properly down-
regulate cytokine release long after the initial insult can lead to a state of chronic 
neuroinflammation (Lucas et al., 2006). In this state, the integrity of the blood-CNS-barrier 
becomes compromised, peripheral immune cells infiltrate the CNS and prolonged elevations in 
neurotoxic agents (e.g. reactive oxygen/nitrogen species, glutamate) lead to neuronal cell death 
(Lucas et al., 2006).  Indeed, chronic neuroinflammation is associated with many age-related 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, multiple sclerosis and glaucoma (Soto and Howell, 2014, Deleidi et al., 2015, Williams 
et al., 2017).  
Elucidating how specific cytokines are involved in these neurodegenerative diseases as 
well as CNS development and homeostasis is important for: 1) development of new therapies 
towards neurodegenerative disease and 2) expanding our knowledge on how the CNS functions 
and responds to stress. This thesis elucidates the impact of constitutive and disease-related  
Interluekin-6 (IL-6) signaling on structure and function of the optic projection. Glaucoma is an 
age-related neurodegenerative disease of retinal ganglion cells (RGCs) and their axons, which 
make up the optic nerve. Like other neurodegenerative diseases, degeneration of RGCs in 
glaucoma follow a specific timeline, where functional deficits precede structural degeneration 
and the RGC axon degenerates prior to the RGC soma (Figure 1.1). Using a number of 
 4 
functional and histological assessments in multiple glaucoma animal models, we can elucidate 
not only if IL-6 signaling contributes to degeneration in glaucoma, but where among the 
proposed timeline does IL-6 signaling contribute to degeneration in glaucoma. 
 
 
Figure 1.1. Proposed timeline of RGC degeneration in glaucoma. Disease relevant stressors such 
as Ca
2+ 
dysregulation and metabolic impairment within RGCs, lead to dysfunction in the distal 
portion of the RGC axon including disruption of anterograde axonal transport and the formation 
of axon dystrophies. Later in progression the distal axon begins to degenerate followed by 
proximal degeneration of dendrites within the RGC soma. In the late stage of the disease, 
proximal degeneration of the RGC axon occurs followed by apoptosis of the RGC soma, leading 
to irreversible tissue loss. 
 
Figure from (Calkins, 2012) and used in accordance with Copyright Clearance Center’s 
RightsLink service.  
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The optic projection as a model system 
Studying the effects of cytokines in the CNS can be difficult in an in vivo setting, 
especially for neuroscientists studying neuronal populations within the brain and spinal cord. 
This is primarily due to the skull and vertebral column, components of the skeletal anatomy 
evolved to protect the brain and spinal cord respectively. While indeed protective, these bony 
structures limit accessibility to neuronal populations within the brain and spinal cord.  
Fortunately however, the retina and optic nerve, collectively known as the optic projection, 
allows neuroscientists to bypass these limitations and study a neuronal population that shares 
numerous similarities to those found in the brain and spinal cord (London et al., 2013).  
 
Anatomy of the optic projection 
During embryonic development, the retina forms as a protuberance of the diencephalon 
and as a result is considered part of the CNS (Heavner and Pevny, 2012). The retina is a multi-
layered neural tissue located at the posterior portion of the eye. It consists of five major classes 
of neurons- rod/cone photoreceptors, horizontal cells, bipolar cells, amacrine cells and ganglion 
cells (Heavner and Pevny, 2012) (Figure 1.2). When light hits the retina, photons activate the rod 
and cone photoreceptors, which propagate a graded glutamatergic signal to bipolar cells, which 
in turn releases glutamate onto retinal ganglion cells (RGCs). RGCs are the primary output 
neuron, transforming the graded signal into an action potential. The glutamatergic signal between 
these three neurons is refined by inhibitory neurotransmission (i.e. GABAergic, glycinergic, etc.) 
from horizontal and amacrine cell interneurons. Horizontal cells, which are GABAergic, refine 
the signal between photoreceptors and bipolar cells, while amacrine cells refine the signal 
between bipolar cells and RGCs. Amacrine cells are either GABAergic or glycinergic with 
 6 
subpopulations of GABA-ergic amacrine cells that are also dopaminergic and cholinergic 
(Wassle, 2004).  
 
 
Figure 1.2. Retinal cell types and circuitry. In order to activate the light sensitive photoreceptors 
(rods & cones) in the outer nuclear layer (ONL), light must transverse the entire retina (direction 
of arrow). Transmission of the graded visual signal occurs in a top-down fashion. Activated 
photoreceptors send information through excitatory processes in the outer plexiform layer (OPL) 
to the bipolar cells in the inner nuclear layer (INL). The signal is then sent through excitatory 
processes in the inner plexiform layer (IPL) to the retinal ganglion cell (RGC) bodies in the 
ganglion cell layer (GCL). Prior to reaching the bipolar cells and RGCs, the activity of the signal 
is modulated by horizontal cells and amacrine cells in the OPL and IPL respectively. RGCs 
transform this graded signal into an action potential and send it along their axons in the nerve 
fiber layer. Axons exit the eye at the optic disc where they are myelinated and form the optic 
nerve. Glial cells (astrocytes, Müller Cells and microglia) also reside in the retina and work to 
maintain proper health and function within the retina.  
 
Figure modified from (Calkins, 2012) with permission from DJ Calkins and used in accordance 
with Copyright Clearance Center’s RightsLink service.  
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From their cell bodies, RGCs send action potentials along their axons, which collectively 
exit through the optic disc at the back of the eye and form the optic nerve. Axons within the optic 
nerve synapse at one of several structures within the brain, which are responsible for interpreting 
different aspects of visual input and optimizing the quantity and quality of visual input (Figure 
1.3). The percentage of axons synapsing at each target varies with each mammalian species. In 
primates, including humans, the majority (~85%) of RGC axons project to the lateral geniculate 
nucleus (LGN) of the thalamus (Bunt et al., 1975, Perry et al., 1984), a structure responsible for 
processing details associated with vision including contrast, color, movement and depth 
perception (Livingstone and Hubel, 1988). The LGN then sends this information to the primary 
visual cortex from which it proceeds to higher cortical areas along dorsal and ventral streams. In 
rodents, it is thought that only about 25% of RGC axons project to the LGN (Dreher et al., 1985). 
However, approximately 80% of the RGCs that innervate the LGN also innervate the SC (Ellis et 
al., 2016). The remaining RGC axons send information to structures that optimize that quantity 
and quality of visual input. In humans 10% of RGC axons project to the superior colliculus (SC), 
while approximately 88% of rodent RGCs project to the SC (Dreher et al., 1985, Ellis et al., 
2016). The SC helps coordinate rapid eye movements (i.e. saccades) that assist in collecting as 
much information from our visual field as possible (Kalesnykas and Sparks, 1996, Moschovakis, 
1996). Additional and smaller RGC projections to the  pre-tectum and suprachiasmatic nucleus 
(SCN) are  involved in regulating pupillary eye reflexes and circadian rhythm respectively (Chen 
et al., 2011b).   
Along with neurons, glial cells also populate the optic projection. In the retina, astrocytes 
and Müller cells maintain proper neuronal signaling by siphoning extraneous potassium (K
+
), 
calcium (Ca
2+
) and glutamate from the extracellular space (Vecino et al., 2016) (Figure 1.2).  
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Together with endothelial cells, astrocytes and Müller cells wrap their processes around the 
retinal vasculature to form the protective blood-retinal barrier (Vecino et al., 2016). At the optic 
nerve head, astrocytes converge on the unmyelinated RGC axons to form the glia lamina, which 
 
Figure 1.3. Eye specific and topographic maps of RGC connections in the mouse brain. (Left) 
Upon entering the brain, RGCs project primarily to contralateral (red) visual processing areas 
including the lateral geniculate nucleus (LGN) and the superior colliculus (SC). A small 
population of RGCs also makes ipsilateral connections to these structures (green). (Right) RGCs 
project to the LGN and SC in a topographic manner in that RGCs from quadrant of the retina 
(e.g dorsal quadrant, blue) all project to the same area (blue region) in the LGN and SC.   
 
Figure from (Assali et al., 2014) and used in accordance with Copyright Clearance Center’s 
RightsLink service. 
______________________________________________________________________________ 
 
provides structural support and insulation (Sun et al., 2009). In primates, this is accompanied by 
a porous scaffold of extracellular matrix called the lamina cribosa (Vecino et al., 2016). Exiting 
the lamina, RGC axons enter the retrolaminar transition zone, where the axons are myelinated by 
oligodendrocytes for saltatory conduction just prior to exiting the globe (Vecino et al., 2016). 
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Microglia, similar to the rest of the CNS, serves as the resident macrophage in the retina, optic 
nerve head and myelinated optic nerve, surveying for and phagocytosing biological material that 
could be pathogenic (Vecino et al., 2016). 
 
The optic projection as a model of the CNS 
Two primary advantages that allow the optic projection to serve as an exceptional model 
for studying the CNS are the similarities RGCs have to other CNS populations, the highly 
conserved nature of retinal structure and its increased accessibility (London et al., 2013). While 
physically separate from the brain and spinal cord, RGCs are highly comparable to projection 
neurons found elsewhere in the CNS. RGCs display classic morphological components of 
neurons, including a cell body, dendrites and an axon. The axon, while unmyelinated in the 
retina, is myelinated by oligodendrocytes as it exits the globe. Unlike other structures in the 
CNS, retinal architecture is highly conserved within and even between species (Hoon et al., 
2014). In all vertebrates, the retina is composed of three cellular layers and two synaptic layers 
containing five major neuronal classes (Hoon et al., 2014). While the total number of cells within 
each neuronal class varies greatly between species, variation decreases with increasing genetic 
similarity. For example, while significant variation of retinal cell number still exists between 
different inbred strains of mice, the variability within each inbred strain is extremely minimal 
(Williams et al., 1996, Williams and Moody, 2003, Keeley et al., 2014). For some species and 
elements of the circuit, we even know the approximate number of synapses between cell types 
(Chen and Chiao, 2014, Behrens et al., 2016). This increases our ability to detect neuron loss due 
to injury/disease and thus, characterize earlier and more modest pathology.  
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 In terms of accessibility, the absence of bony structures coupled with a transparent 
window (i.e. cornea) at the anterior portion of the eye allows for unparalleled access to a 
neuronal population in vivo (London et al., 2013). This is even more so when using rodents to 
study the optic projection, as the proximal portion of the optic nerve is accessible without 
invasive surgery. These characteristics enable neuroscientists to not only visualize and track 
retinal pathology in real time, but introduce injury and/or potential therapeutic agents directly to 
RGCs with minimal effort or extraneous injury (London et al., 2013). 
Comparable to other CNS neurons, mechanical injury to RGC axons within the optic 
nerve leads to gliosis, active transport deficits, structural degeneration, and lastly, apoptosis of 
the cell body (Crish and Calkins, 2011, Calkins, 2012). Similar to other CNS axons, optic nerve 
axon regeneration is limited due to factors that inhibit neurite outgrowth (London et al., 2013). 
RGC degeneration is also manifested in many brain diseases including Parkinson’s disease and 
Alzheimer’s disease (London et al., 2013), further corroborating the strong link between the 
retina and the brain. In Parkinson’s disease (PD), patients suffer from motor dysfunction due to a 
deficiency in dopamine (Archibald et al., 2009). As the retina utilizes dopamine to encode 
differences in contrast, many patients with PD also experience defects in retinal function and 
thinning of the retina (Inzelberg et al., 2004, Moschos et al., 2011). In patients with Alzheimer’s 
disease (AD), accumulation of amyloid-B and phosphorylated tau in the brain are associated with 
areas of neuron degeneration (Wenk, 2003). Similar accumulations are seen in the retina of both 
AD patients and mouse models of AD (Guo et al., 2010a, Chiu et al., 2012, Sivak, 2013). 
Interestingly, the accumulation of amyloid-β is also prevalent in the optic neuropathy glaucoma 
(Sivak, 2013), suggesting a link between AD and glaucoma. Indeed, a number of studies report a 
higher prevalence of glaucoma in patients affected by AD (Cesareo et al., 2015).  
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Glaucoma: Neurodegeneration of the optic nerve 
 Glaucoma is a collection of degenerative optic neuropathies that results in continuous 
vision loss caused by progressive degeneration of RGCs (Calkins, 2012). It is the number one 
cause of irreversible blindness and the second leading cause of blindness worldwide, with 60 
million people affected worldwide in 2010 (Quigley and Broman, 2006). While genetics and race 
can influence the chances of developing glaucoma, age and sensitivity to intraocular pressure 
(IOP) are the two primary risk factors (Calkins, 2012). Similar to other neurodegenerative 
diseases, there is no therapy available that completely halts or reverses neuronal degeneration in 
glaucoma. Current treatments, which aim to lower IOP, only slow down RGC degeneration and 
subsequent vision loss (Calkins, 2012). 
 
Clinical manifestations of glaucoma 
Degeneration of RGCs in glaucoma leads to both functional and structural manifestations 
that are utilized by clinicians for diagnosis and monitoring disease progression. Progressive loss 
of RGC axons leads to increased ”cupping” or excavation of the optic disc, a phenomenon that 
causes the center of the optic disc, known as the optic cup, to enlarge in comparison to the optic 
disc (Quigley, 1985, Kalesnykas and Sparks, 1996, Moschovakis, 1996) (Figure 1.4). Loss of 
RGC axons also leads to thinning of the retinal layer where RGC axons reside, known as the 
retinal nerve-fiber layer (NFL) (Hood and Kardon, 2007) (Figure 1.2). Using fundoscopy and 
optical coherence tomography (OCT), clinicians can monitor nerve cupping and RNFL thinning 
respectively during routine eye exams. To assess vision loss, clinicians commonly utilize 
perimetry, an exam that involves the patient fixing their gaze at a specific point while a light 
flashes at different locations in the patient’s visual field (Yaqub, 2012).  
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Figure 1.4. Formation and progression of optic disc cupping in glaucoma. The optic disc is 
where RGC axons collect to exit the eye and to form the optic nerve. (A, A’) A fundus image of 
a healthy optic disc. The slightly cupped shape indicative of the central cup (inner circle, A’) is 
the location where RGC axons come together to exit the eye. Notice the large rim (area between 
optic disc and central cup), which is indicative of a small optic cup-to-disc (c/d) ratio (0.2 c/d in 
A’). This measurement is used by clinicians to diagnose and track glaucoma. (B, B’) As 
glaucoma progresses and axons are lost, the central cup gets larger and the cup-to-disc ratio 
increases (0.7 c/d in B’). (C, C’) In individuals with severe glaucoma, the central cup represents 
almost all of the optic disc area (0.99 c/s in C’).  
 
Figure modified from (Bourne, 2012) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License.  
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Areas in the visual field where light flashes are not perceived constitute areas of visual deficits 
known as scotomas (Figure 1.5). Scotomas generally begin at the periphery of the temporal 
portion of the retina before progressing through either the superior or inferior poles and 
terminating at the nasal end of the retina (Levin, 2001, Yaqub, 2012) (Figure 1.5). This translates 
into a perceived loss of peripheral vision, which is affected before central vision. In a large 
number of patients, scotoma formation goes unnoticed until well formed (Health Quality, 2006), 
stressing the importance of yearly eye exams to catch structural pathology early.  
 
Figure 1.5. Visual loss in human glaucoma patients. (A-D) Representations of visual field maps 
collected using standard perimetry from glaucoma patients with varying degrees of vision loss. 
Each map is from a patients left eye. Dark areas correspond to areas of decreased visual 
sensitivity. (A) Map of an individual with no apparent visual field deficits, except for the natural 
blind spot present in all individuals caused by the optic nerve head. (B-C) Glaucoma typically 
affects peripheral vision first as noted by scotomas in the periphery of the visual field that 
progress to an arcuate defect. (D) Map from a late stage patient shows the individual only retains 
their central vision.  
 
Figure from (Broadway et al., 2013) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
 
Glaucoma: Age-related sensitivity to ocular hypertension 
It has long been theorized that the primary insult to RGCs in glaucoma occurs at the optic 
nerve head (ONH), where RGC axons come together to form the optic nerve (Calkins, 2012). A 
current hypothesis describes the ONH and the surrounding scleral tissue as a biomechanical 
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structure, comprised of elastic connective tissue and glial cells that protect RGC axons from the 
stress and strain caused by normal eye movements and IOP (Burgoyne et al., 2005). In the clinic, 
glaucoma is typically split into three subtypes: open angle glaucoma (OAG), closed angle 
glaucoma (CAG), and normotensive glaucoma (NTG) (Shields, 2008, Hollands et al., 2013, 
Weinreb et al., 2014). While all result in the aforementioned clinical profile, the mechanism 
responsible is different among all three.  
In OAG and CAG, consistent IOP elevation or ocular hypertension (> 21 mm/Hg) is the 
major causative factor, thus the importance of recording IOP measurements during routine eye 
exams (Quigley, 1993, Nongpiur et al., 2011). IOP is the fluid pressure within the anterior 
chamber of the eye and is determined by the net outcome of aqueous humor production and 
drainage (Weinreb et al., 2014). Aqueous humor is produced by the ciliary body, where it flows 
towards the angle formed by the cornea and iris (i.e. iridocorneal angle), and drains into the 
bloodstream through the trabecular meshwork (Figure 1.6). Normal IOP in humans ranges from 
10-20 mmHg; however, recent data in non-human primates suggests that IOP constantly 
fluctuates, with overall changes of 15-40mmHg occurring from second to second (Downs et al., 
2011, Downs, 2015a). During ocular hypertension, the dynamics of aqueous humor drainage 
become disrupted, leading to a buildup of aqueous humor in the anterior chamber. In CAG, 
disrupted outflow is caused by a occlusion or collapse of the iridocorneal angle, preventing 
aqueous humor from accessing the trabecular meshwork (Nongpiur et al., 2011). CAG is  
generally asymptomatic; however, a small percentage of patients experience large increases in 
IOP (> 30 mmHg), causing intense ocular pain, nausea and intermittent blurring (Salmon, 1999). 
In OAG, IOP elevation is not attributable to physical obstruction drainage canals, rather it is 
associated with altered fluid dynamics of various etiologies (Freddo and Gong, 2009). This often 
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gradual increase in IOP elevation typically goes un-noticed in patients (Quigley, 1993). In both 
OAG and CAG, the resulting IOP elevation is transduced from the anterior portion of the eye to 
the ONH. This culmination of IOP mediated stress is thought to alter the biomechanical 
properties of the ONH, leading to compression of the un-myelinated  axons at the ONH and 
initiation of glaucoma specific RGC degeneration (Calkins, 2012).  
While IOP elevation is a risk factor for glaucoma, some individuals with ocular 
hypertension do not develop glaucoma. Conversely, a significant portion of glaucoma patients 
develop normotensive glaucoma, a form of the disease that forms and progresses without ocular 
hypertension (Heijl et al., 2002, Iester et al., 2012). However, NTG patients still benefit from 
therapies designed to lower IOP. These two observations suggest that defining glaucoma as a 
disease caused by IOP elevation is an oversimplification. Like other neurodegenerative diseases, 
the risk of developing glaucoma increases with age, with individuals over the age of 55 being 
seven times more likely to become affected (Crish and Calkins, 2011). Throughout aging, the 
sclera and ONH lose elasticity and become increasingly rigid, mainly due to increased collagen 
deposition in the extracellular matrix (ECM) by astrocytes and astrocyte hypertrophy in the ONH 
(Albon et al., 1995, Downs, 2015b). It is hypothesized that these changes prevent the sclera and 
ONH from efficiently absorbing the mechanical stress and strain caused by normal IOP 
fluctuations, leaving RGC axons more sensitive and vulnerable to damage (Burgoyne et al., 
2005, Downs, 2015b). This suggests that glaucoma is not due to IOP elevations per se, but is 
rather due to changes in sensitivity to IOP (Calkins, 2012). 
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Figure 1.6. Aqueous humor dynamics in the eye. (A) Aqueous humor is constantly produced by 
the ciliary body in order to nourish and moisten the avascular tissues in the eye. Aqueous humor 
flows towards the anterior portion of the eye where it subsequently drains through the trabecular 
meshwork in Schlemm’s canal and into the episcleral vein. The net outcome between aqueous 
humor production and drainage determines the intraocular pressure (IOP) of the eye. (B) In open 
angle glaucoma (OAG) (left), aqueous humor drainage through Schlemm’s canal is 
compromised due to an obstruction or degeneration of the trabecular meshwork. In closed angle 
glaucoma (CAG) (right), the iris collapses, preventing aqueous humor from reaching Schlemm’s 
canal. In both situations, IOP becomes elevated.  
 
Figure adapted from (Weinreb et al., 2016) and used in accordance with Copyright Clearance 
Center’s RightsLink service. 
______________________________________________________________________________ 
 
Progression of glaucoma in the optic projection 
RGC degeneration in glaucoma occurs along a specific temporal sequence of events that 
is similar to that observed in other neurodegenerative conditions, including Alzheimer’s Disease, 
Parkinson’s Disease and ALS (Crish and Calkins, 2011). Glaucoma is nicknamed the “silent 
thief of sight”, as the disease is generally asymptomatic in nature until vision loss is noticed. 
Unfortunately, the onset of vision loss coincides with significant disease progression (Calkins, 
2012). However, evidence suggests that functional deficits (e.g. axon transport, electrical 
activity) of RGCs precede structural degeneration, while the RGC soma persists well after the 
axon has degenerated (Figure 1.7). This suggests a potential window for future therapies in not 
only rescuing functional deficits before RGCs degenerate, but regenerating axons in RGCs that 
have lost them. In order to develop such therapies, an understanding of the events that lead to 
RGC loss is needed. While our understanding is still incomplete, studies using animal models of 
glaucoma have shed light on these events leading up to RGC loss.  
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Animal Models of Glaucoma 
 Animal models have and continue to provide invaluable insight into the manifestation, 
progression and treatment of RGC degeneration in glaucoma. While it is known that ocular 
hypertension does not automatically equate to glaucoma in humans, the majority of glaucoma 
models incorporate naturally-occurring or induced IOP elevation to reproduce the clinical 
features of the disease. Two such models that have been utilized historically and compose a 
significant portion of my thesis studies include the inducible microbead occlusion model of  
glaucoma (Sappington et al., 2010) and the DBA/2J mouse model of inherited glaucoma (John et 
al., 1998, Anderson et al., 2002, Libby et al., 2005a).  
 Artificial induction of IOP elevation has historically and continues to be utilized to model 
glaucomatous pathology across mammalian models (Johnson and Tomarev, 2010, Bouhenni et 
al., 2012). While artificial induction can only model short term exposure (typically < 8 weeks) to  
elevated IOP, they allow scientists to test the impact of age and genetics on glaucomatous 
pathology. Generally, all models elevate IOP by preventing aqueous humor drainage. While 
some models impede drainage by occlusion of the trabecular meshwork (Levkovitch-Verbin et 
al., 2002, Sappington et al., 2010, Ito et al., 2016), others impede aqueous humor drainage into 
the surrounding vasculature (Garcia-Valenzuela et al., 1995, Morrison et al., 1997, WoldeMussie 
et al., 2001). While studies show that all these models result in some form of glaucomatous 
pathology, the microbead occlusion model has become the method of choice for modeling 
glaucoma (Sappington et al., 2010, Della Santina et al., 2013, Ward et al., 2014, Bond et al., 
2016, Ito et al., 2016). In this model, a single injection of microbeads leads to a robust 20-35% 
elevation in IOP that is sustained for at least 4 weeks and is reproducible across cohorts 
(Sappington et al., 2010). Unlike other methods that induce 50-100% increases in IOP, ocular 
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Figure 1.7. Critical steps in RGC degeneration in glaucoma. (A) A representative healthy RGC 
in the optic projection. (B) Upon a disease relevant stressor (e.g. age, elevated IOP) RGC axons 
in the optic nerve head become stressed, leading to glial reactivity of astrocytes within the optic 
nerve head (1). The chronic stress at the optic nerve head leads to a series of events within the 
RGC projection including axon transport failure (2), distal to proximal axonopathy (3), synapse 
elimination on dendrites due to microglia (4) followed by  dendritic retraction (5) and distal 
terminal loss. (C) The cumulative impact of this stress initiates apoptosis within the RGC soma. 
At this point the axon has significantly degenerated and is replaced by a glial scar in the optic 
nerve.  
 
Figure adapted from (Calkins and Horner, 2012) with permission from DJ Calkins and used in 
accordance with Copyright Clearance Center’s RightsLink service. 
______________________________________________________________________________ 
 
hypertension in the microbead model better represents IOP elevation seen in patients with 
moderate OAG, thus providing a more physiological representation of the primary disease type. 
Additionally, the amount of surgical injury induced by the microbead occlusion model is 
minimal compared to other models, as measured by the lack of ocular ischemia and neo-
vascularization (Goldblum and Mittag, 2002, Pang and Clark, 2007).  
 While the microbead occlusion model is valuable when testing how glaucomatous 
degeneration is affected by specific genes or age, it’s acute nature prevents us from modeling the 
temporal progression of the disease in response to age related increases in IOP that are seen in a 
large number of OAG and CAG patients. For these studies, the DBA/2J inbred mouse line is 
more appropriate. The DBA/2J mouse is one of the oldest inbred mouse strains and contains 
mutations in the Gpnmb and Tyrp1 genes (Anderson et al., 2002). These mutations lead to iris 
pigment dispersion and iris stromal atrophy respectively, causing iris pigment to detach from the 
iris and clog the trabecular meshwork, obstructing aqueous outflow (John et al., 1998, Chang et 
al., 1999). This again more closely models CAG and more specifically, exfoliation glaucoma, 
which is caused by iris pigment dispersion in humans (Ritch, 2002). While some DBA/2J mice 
experience ocular hypertension at 3 months of age, the majority of DBA/2J mice present with 
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IOP elevation by 5-6 months of age (Inman et al., 2006). Despite the advantage the DBA/2J 
mouse has in more closely representing the human condition, the degree of variability in IOP 
elevation (2.5mmHg-8mmHg), onset of IOP elevation  (3-6 months of age), and degree of 
pathology can confound interpretation of data when using this model to test potential therapies 
(Inman et al., 2006, Calkins, 2012).  
 
Deficits in Axon Transport 
Subsequent to the initial insult at the optic nerve head, the earliest sign of glaucomatous 
pathology in the optic project are deficits in axon transport (Crish et al., 2010) (Figure 1.7). Axon 
transport is the process in which neurons transport cargo, such as organelles, lipids, proteins and 
synaptic vesicles from their soma towards synaptic terminals (anterograde transport) or from 
synaptic terminals to their soma (retrograde transport). Cargo is transported along microtubule 
roadways composed of the cytoskeletal protein tubulin by specialized motor proteins known as 
kinesin and dynein, which utilize ATP for anterograde and retrograde transport respectively 
(Maday et al., 2014). Like in other neurons, proper axon transport is vital to multiple aspects of 
RGC function, including delivery of neurotransmitters for signaling, supplying neurotrophic 
factors for cell survival and redistributing mitochondria to meet energy requirements (DiStefano 
et al., 1992, Calkins, 2012, Saxton and Hollenbeck, 2012).  
The temporal progression of axon transport deficiencies in glaucoma are best 
characterized in studies using the DBA/2J mouse. In analyzing anterograde axon transport, Crish 
and colleagues (Crish et al., 2010) injected the anterograde tracer CTB into the vitreal space and 
measured its localization in RGC projection sites in the brain. Deficits in the SC occurred as 
early as 3 months of age, with near complete loss of CTB label by 12 months. Additionally, 
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deficits were sectorial in nature, starting close to the periphery and moving towards the optic 
disc. Despite loss of CTB signal in the SC, CTB signal still appeared in more proximal 
projections (LGN) and in RGC soma, suggesting that anterograde transport failure progresses in 
a distal to proximal fashion. Separate studies evaluating retrograde transport by injecting the 
neural tracer fluorogold (FG) into the SC and quantifying the number of RGCs with FG uptake, 
did not observe deficits in FG+ RGCs until 6-8 months of age (Buckingham et al., 2008). This 
coupled with the observation that almost complete ablation of FG+ RGCs isn’t seen until about 
13-15 months of age, argues that anterograde transport is lost before retrograde transport 
(Buckingham et al., 2008). Dengler-Crish and colleagues (Dengler-Crish et al., 2014) 
corroborated this hypothesis by measuring anterograde and retrograde transport in the same 
cohort of DBA/2J mice. While the authors did not compare age of transport deficit onset, they 
reported that anterograde transport deficits were significantly larger than retrograde deficits in 
DBA/2J mice between 9-12 months of age.  
An obvious suggestion to axon transport loss in the DBA/2J mouse would be axon 
degeneration. However, examination of DBA/2J mice at 10-12 months of age with significant 
transport deficits revealed substantial preservation of RGCs, axons and RGC synaptic terminals 
in the SC (Crish et al., 2010). In other neurodegenerative disorders, axon transport blockade is 
associated with disruptions in cytoskeletal organization, suggesting that components mediating 
transport within the axon might be compromised in glaucoma (Chevalier-Larsen and Holzbaur, 
2006). Indeed, reports in the DBA/2J mouse point to modifications in cytoskeleton related 
proteins (i.e. neurofilaments, microtubules) as the primary cause of axon transport deficits 
(Dengler-Crish et al., 2014, Wilson et al., 2016). While microtubules provide the substrate in 
which motor proteins use to transport cargo, neurofilaments are transported along the axon to 
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help stabilize microtubule structure (Maday et al., 2014). In DBA/2J mice, studies show 
neurofilament pathology, including accumulation and phosphorylation, occurs prior to axon loss 
(Howell et al., 2007b, Soto et al., 2008, Wilson et al., 2016). Studies in other neurodegenerative 
disorders show excessive phosphorylation slows down its kinesin mediated transport down the 
axon, causing it to accumulate and impede transport of other cargo. In later stages of pathology 
(10-12 months), significant degeneration of neurofilaments and microtubules occur (Wilson et 
al., 2016). This loss of microtubules may also be due to the initial aggregation of neurofilaments 
as excessive phosphorylation impairs its affinity for microtubules, causing microtubules to 
become disorganized and aggregate (Wang et al., 2012). 
Deficits in axon transport are also present in models of acute ocular hypertension. 
However, progression occurs much more rapidly. In models where IOP is elevated 100-1000% 
above normal, failure of anterograde transport occurs within hours. In one of the first reports 
characterizing axon transport following IOP elevation in non-human primates, Quigley and 
colleagues (Quigley and Anderson, 1976) show that anterograde transport deficiencies start only 
after two hours of inducing ocular hypertension, with full failure occurring after 8 hours. 
Additionally, reversing IOP back to physiological levels for 4 hours following ocular 
hypertension significantly mitigated axon transport failure, suggesting that short term deficits can 
be rescued. In rodents subjected to the microbead model, multiple studies report a 40-50% deficit 
in anterograde transport only after 4-6 weeks of moderate IOP elevation in mice (Ward et al., 
2014, Bond et al., 2016), while another study shows similar deficits in rats after only 2 weeks of 
similar IOP elevation (Crish et al., 2010). Similar to anterograde transport, loss of retrograde 
transport also occurs quickly in induced glaucoma models. In a follow up to Quigley and 
Anderson’s study, Minckler and colleagues (Minckler et al., 1977) reported that 12 hours of 
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100% IOP elevation in non-human primates is sufficient to obstruct retrograde transport. In 
rodent studies, 8 weeks of IOP elevation via microbead injection led to a ~45% reduction in FG+ 
RGC density (Chen et al., 2011a), while 100% IOP elevations for 1 week led to over a 70%  
decrease in FG+ RGC density (Salinas-Navarro et al., 2009).  
 
RGC dysfunction  
Subsequent to deficits in axon transport, RGC dysfunction becomes prominent in 
glaucoma (Porciatti, 2015). The majority of these abnormalities are centered on RGC responses 
to light based stimuli, which can eventually lead to scotoma formation and vision loss. In both 
patients and animal models, RGC dysfunction can be measured using electrophysiological 
recording techniques such as electroretinography (ERG) and visual evoked potentials (VEP). 
These techniques measure the electrical response, portrayed as a waveform, of the RGC soma 
and cortical RGC inputs respectively, using either a series of flashing lights (FERG/FVEP) or a 
patterned stimulus (PERG/PVEP). RGC dysfunction in the ERG and VEP waveforms is usually 
reported as a muted waveform response, with significant deficits in the amplitude and latency of 
characteristic waveform components (Porciatti, 2015).  
In the clinic, abnormalities to both the PERG and VEP waveforms are noted prior to 
vision loss and structural degeneration (Parisi et al., 2006, Banitt et al., 2013, Jafarzadehpour et 
al., 2013). Specifically with PERG, one study reporting a timeline of 8 years between PERG 
abnormalities and thinning of the RNFL layer (Banitt et al., 2013). Similar findings in the 
DBA/2J mouse show that degeneration of the PERG waveform occurs early, with one study 
showing PERG defects 2-4 months prior to significant axon degeneration and RNFL thinning 
(Howell et al., 2007a, Saleh et al., 2007, Baltan et al., 2010, Domenici et al., 2014). In inducible 
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models, PERG/PVEP dysfunction also occurs prior to structural defects (Marx et al., 1988, 
Holcombe et al., 2008, Alsarraf et al., 2014). Corroborating the ERG/VEP waveform deficits, 
multi-electrode or single cell recordings of RGCs following 2-4 weeks of acute ocular 
hypertension show alterations in spontaneous rate and light induced activity (Della Santina et al., 
2013, Ward et al., 2014). Equivalent to deficits in axon transport, PERG/VEP changes may be 
reversible prior to vision loss as various studies show treatment with IOP lowering therapies or 
various neuroprotective agents can prevent and reverse PERG/VEP deficits in both patients and 
DBA/2J mice (Sehi et al., 2010, Sullivan et al., 2011, Domenici et al., 2014, Porciatti, 2015, 
Feng et al., 2016).  
 
Axon degeneration 
Subsequent to functional deficits and degradation of the axon cytoskeleton, degeneration 
of the axon structure starts to transpire (Figure 1.7). Axon degeneration in most glaucoma studies 
is characterized by loss of axon density or total number of axons within the nerve (Calkins, 
2012). Similar to deficits in the SC, axon loss in glaucoma is sectorial, with patches of 
degenerating axons clustered together (Schlamp et al., 2006, Soto et al., 2011). Following axon 
degeneration, astrocyte processes fill in the gap and create a glial scar which helps maintain the 
volume of the optic nerve and the integrity of the remaining axons (Calkins, 2012, Lye-Barthel et 
al., 2013).  
In DBA/2J studies, loss of axons is reported to occur as early as 10 months, with some 
studies not noting significant axon degeneration until 13 months. It appears as if axon 
degeneration is more sensitive to IOP elevation than age, as several studies in the DBA/2J mouse 
show axon loss is associated to the degree of IOP elevation (Libby et al., 2005a, Inman et al., 
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2006). The impact of IOP elevation is also prevalent in inducible models. Multiple microbead 
studies in rodents show significant axon degeneration (20%-25%) following 4-6 weeks of 
moderate IOP elevation (Sappington et al., 2010, Ward et al., 2014, Bond et al., 2016), while 
models that incorporate larger IOP elevations report between 30%-50% axon degeneration 
(Lambert et al., 2011, Kitaoka et al., 2013). Similar to the DBA/2J mouse, a meta-analysis of 
inducible glaucoma studies show that axon degeneration increases linearly with increasing IOP, 
further corroborating the impact of IOP in axon degeneration (Calkins, 2012).  
The two primary mechanisms in which axon degeneration occurs in the CNS are “dying 
back” and Wallerian degeneration. Depending on the model used to recapitulate the disease, 
reports indicate both mechanisms may be relevant to the pathology of glaucoma (Calkins, 2012). 
The ‘dying back’ phenomenon corresponds to distal to proximal degeneration, where axon 
degeneration begins at the most distal end and slowly (weeks to months) progresses towards the 
cell body. In the DBA/2J mouse, studies show that estrogen related receptor beta (ERRβ) signal 
in the SC, a marker of RGC input terminals, persists well after axon transport is compromised 
(Crish et al., 2010). Loss of ERRβ signal is not seen until 13-15 months, when multiple studies 
show significant axonopathy (Crish et al., 2010). Additionally, analysis of degenerating axons 
along the optic nerve shows that distal segments present with significantly more degeneration 
than proximal segments, indicative of distal to proximal progression (Schlamp et al., 2006, Crish 
et al., 2010).  
Following large (>100%) acute IOP elevations, studies in rodents and monkeys show 
structural pathology of the optic nerve soon after induced IOP elevation, including axonal 
swelling and protein accumulation, suggesting early axonopathy occurs at the ONH (Kompass et 
al., 2008, Joos et al., 2010, Chidlow et al., 2011). In one study the author’s show increased axon 
 27 
loss in proximal portions of the optic nerve relative to distal portions after 2 weeks of 100% IOP 
elevation before evening out at 4 weeks (Beirowski et al., 2008).  This is indicative of Wallerian 
degeneration, a form of pathology seen in models of axotomy in which degeneration begins at 
the distal portion of the injury and progresses rapidly in a proximal to distal manner (Calkins, 
2012). Therefore, it is possible that intense IOP elevation commonly seen in inducible with large 
IOP elevation models leads to an “axotomy like” injury at the ONH, leading to a Wallerian 
degeneration profile (Crish and Calkins, 2011).  
Regardless of mechanism of axon degeneration, it is evident from both DBA/2J and 
inducible models that axon degeneration precedes loss of the ganglion cell soma (Calkins, 2012). 
In their comprehensive study, Buckingham and colleagues did not note significant decreases in 
structural RGC density until 18-21 months of age in the DBA/2J mouse (Buckingham et al., 
2008). Additionally, in the aforementioned meta-analysis of inducible glaucoma models, 
ganglion cell loss is 2-3X less than axon loss across all IOP exposures (Calkins, 2012). Finally, 
comparison of electrical responses from both RGC soma (PERG) and input terminals (VEP) in 
two year old DBA/2J mice shows complete degradation of the signal from RGC axon inputs, 
whereas RGC soma responses are diminished, but present (Heiduschka et al., 2010a).  
 
Synapse elimination and dendritic pruning. 
In the CNS, dendrites are branched projections of a neuron that receive electrochemical 
information from axons of efferent neurons via synapses. In the retina, RGC dendrite synapses 
connect with axons of their input bipolar and amacrine cells. In glaucoma and other 
neurodegenerative diseases, elimination of synapses and subsequent dendritic pruning precede 
neuronal cell loss (Calkins, 2012) (Figure 1.7). A current hypothesis suggests that synapse 
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elimination in glaucoma is driven by the compliment cascade, a mechanism of the neuro-immune 
system that targets cellular material for phagocytosis and removal. In the DBA/2J mouse, several 
studies show that PSD-95, a marker of synapses, is reduced in RGC dendrites at 10-11 months of 
age (Stevens et al., 2007, Berry et al., 2015). In one study, this down-regulation of PSD-95 was 
accompanied by an upregulation of C1q, a compliment protein that targets synapses for 
elimination by microglia (Stevens et al., 2007). This hypothesis was corroborated by a more 
recent study showing that genetic or pharmaceutical inhibition of C1q prevents early synapse and 
dendrite degeneration in both the DBA/2J and microbead models of glaucoma (Williams et al., 
2016). Additionally, the loss of synapses may be related to deficiencies in neurotrophic factors 
associated with deficits in axon transport.  
Following synapse elimination, dendrites undergo degeneration resulting in a loss of 
complexity and coverage of their dendritic branches. This is evident in the DBA/2J, where 
dendritic remodeling and shrinkage are prevalent in 11-12 month old mice (Jakobs et al., 2005, 
Berry et al., 2015). In various inducible models involving mice, cats, monkeys or rats, elevation 
of IOP led to decreases in dendritic field radius, total dendritic length and number of dendritic 
branches (Weber et al., 1998, Shou et al., 2003, Berry et al., 2015). Additionally, these studies 
suggest that certain types of RGCs are more susceptible to damage. In the primate study, parasol 
RGCs display greater dendritic loss than midget RGCs, while alpha RGCs display greater 
dendritic loss than beta RGCs in the cat (Weber et al., 1998, Shou et al., 2003).  Regardless of 
species, it appears as if dendritic changes occur prior to soma shrinkage and axon pathology, 
suggesting that RGC dendrites are affected sooner than other parts of the RGC.  
Recent studies using the microbead model provides further insight into the progression of 
dendritic degeneration and the more susceptible RGC types (Feng et al., 2013, El-Danaf and 
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Huberman, 2015). In one study, groups of mice with different fluorescently tagged RGCs 
underwent 7 days of IOP elevation (El-Danaf and Huberman, 2015). The authors reported that 
unlike populations of RGCs that stratify their dendrites in the ON sub-lamina of the IPL, those 
that stratify dendrites in the OFF sub-lamina undergo significant reductions in dendritic length 
and dendritic field area. The susceptibility of OFF-type RGCs to elevated IOP was corroborated 
by Della Santa and colleagues (Della Santina et al., 2013), who showed functional deficits of 
specific OFF-type RGCs prior to dendritic degeneration, suggesting that changes in RGC activity 
are not necessarily due to structural changes. 
 
Vision loss 
Aside from RGC death, vision loss is thought to be one of the final stages of glaucoma. 
In a meta-analyses looking at RGC density in the retina and corresponding deficits in the visual 
field from patients as measured by perimetry, only 25-35% of RGCs are lost in areas of the retina 
that contained visual field deficits (Harwerth and Quigley, 2006, Medeiros et al., 2013). These 
results suggest that vision loss occurs prior to RGC soma loss. While measuring visual field loss 
using perimetry is appropriate in a clinical setting, it is not very feasible in animal models, 
especially rodents. To measure vision loss in rodents, researchers commonly use the optokinetic 
reflex test, a paradigm involving the rodent’s natural optokinetic reflex (Thomas et al., 2004, 
Douglas et al., 2005). While the test in unable to correlate visual defects to specific areas of the 
retina, it is able to measure the animal’s overall visual acuity and contrast sensitivity thresholds. 
While not commonly used in the clinic, studies have reported deficits in the optokinetic response 
in glaucoma patients (Tong et al., 2002). 
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Glaucoma- related vision loss is present in both inducible glaucoma models and the 
DBA/2J mouse. In one study using the microbead model in mice, visual acuity threshold 
decreases almost 50% throughout the 30 day period of IOP elevation, with Brn3a+ RGC density 
also decreasing about 50% (Della Santina et al., 2013). Interestingly, another microbead study 
didn’t see 50% decreases in visual acuity until after 6 months of elevated IOP (Feng et al., 2016). 
At a similar time point as presented in the former study, the latter study only saw 25% decreases 
in visual acuity. In the DBA/2J mouse, one study shows reductions of 30 and 200% decreases in 
visual acuity and contrast sensitivity thresholds respectively between 6 week old and 8 month old 
mice (Burroughs et al., 2011). Another study shows a similar 30% reduction in visual acuity 
threshold at 8 months, which progresses to 60% at 14 months of age. In the latter study, this 
corresponded to a 30% and 75% decrease in Brn3a+ RGC density (Rangarajan et al., 2011). 
While the majority of these studies show comparable decreases between visual acuity and 
Brn3a+ RGC density correspond with decreases in visual acuity, Brn3a+ labeling of RGCs in 
glaucoma is controversial. Several studies show that Brn3a is down-regulated in intact RGCs 
compromised by induced IOP elevation (Guo et al., 2009, Guo et al., 2010b), suggesting loss of 
Brn3a signal is more indicative of RGC dysfunction than loss.  
 
The Final Step: RGC Apoptosis 
Following the degeneration of axon transport, RGC function, dendritic structure and axon 
structure, RGC cell bodies succumb to these multitudes of stressors and become the last 
component of the RGC to degenerate (Figure 1.7). In the DBA/2J mouse significant loss of 
RGCs, as measured in one study using a disease independent marker, doesn’t occur until around 
18 months of age (Buckingham et al., 2008). Even in acute inducible models where loss of RGCs 
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occur within a week of IOP elevation, studies reporting both RGCs and axon counts show 
significantly less RGC loss compared to axon loss (Calkins, 2012). Consistent with other deficits 
in glaucoma, RGC loss is sectorial, with RGC loss occurring in clusters (Calkins, 2012). 
Ample evidence from both human and animal tissue suggests that the mechanism behind 
RGC death in glaucoma is “programmed cell death” or apoptosis a (Qu et al., 2010, Crish and 
Calkins, 2011). Unlike necrosis, a form of cell death that results from cellular injury such as 
lysis, apoptosis does not lead to expulsion of intracellular contents, which can damage 
surrounding cells. Instead, apoptosis is a tightly regulated and controlled process that condenses 
and breaks up organelles and DNA within the plasma membrane (Qu et al., 2010).  Like all 
mammalian cells, apoptosis can be initiated via two pathways: the extrinsic pathway and the 
intrinsic pathway, with evidence showing relevancy of both pathways in glaucoma (Qu et al., 
2010, Nickells, 2012).  
The extrinsic pathway, also known as the death receptor pathway, involves extracellular 
signals (i.e. Fas ligand; FasL and tumor necrosis factor alpha; TNFα) that bind to cell surface 
receptors (i.e. Fas, TNFR) on the plasma membrane. Binding of these signals to their receptors 
on the cell surface leads to activation of “initiator” caspase 8, which is responsible for initiating 
apoptosis. Activated caspase 8 then activates “effector” caspases 3, 6, and 7 which are 
responsible for degradation of cellular components. Indeed, several studies show that FasL, Fas, 
TNFα, TNFR and caspases -8 and -3 are involved in certain inducible glaucoma models 
(McKinnon et al., 2002, Huang et al., 2005, Kim and Park, 2005, Ju et al., 2006, Nakazawa et al., 
2006, Levkovitch-Verbin et al., 2007, Qu et al., 2010). An upregulation of these factors is also 
found in the iris and ciliary body of the DBA/2J mouse (Zhou et al., 2005); however, the 
upregulation is most likely due to apoptosis of pigmented cells of the iris that detach and occlude 
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the trabecular meshwork. Interestingly, no reports could be found characterizing an upregulation 
of these factors in the glaucomatous retina of the DBA/2J mouse.  
While the extrinsic pathway is facilitated on external signals, the intrinsic pathway is 
catalyzed by internal signals, specifically those that come from mitochondria (Qu et al., 2010). 
Specifically, cellular stress leads to mitochondria dysfunction, prompting members of the pro-
apoptotic family Bcl-2 (i.e. Bax, Bid, Bad) to release cytochrome c. In the healthy mitochondria, 
cytochrome c is involved in the electron transport chain, which produces energy for the cell in 
the form of ATP. Once released into the cell, cytochrome c binds to the apoptotic protease 
activating factor -1 (APAF-1), ATP and pro-caspase-9 to form the apoptosome. Once the 
apoptosome is formed, pro-caspase-9 is cleaved into caspase-9, serving as an initiator to activate 
the effector caspase-3. Similar to the intrinsic pathway, components of the extrinsic pathway are 
also upregulated in glaucoma, including cytochrome c, members of the Bcl-2 family and caspase 
-9 (Qu et al., 2010). However, the relevancy of the extrinsic pathway is highlighted  by studies in 
Bax deficient mice, where RGCs are spared from apoptosis in the DBA/2J model of glaucoma 
(Libby et al., 2005b). 
 
Neuroinflammation and a role for IL-6 in RGC survival 
A number of mechanisms are suggested for facilitating RGC pathology in glaucoma 
including neutrotrophin deprivation, oxidative stress, Ca
2+
 dysregulation and neuroinflammatory 
processes (Qu et al., 2010). Within the last decade however, the role of neuroinflammation has 
been extensively studied due to observations of increased glial reactivity at multiple “stages” in 
glaucomatous degeneration of RGCs (Soto and Howell, 2014) (Figure 1.7). While the exact 
neuroinflammatory signaling mechanisms behind specific events in glaucoma are not yet known, 
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gene and protein expression profiles of ONH and retinal samples from glaucoma patients and 
animal models provide insight into the inflammatory processes occurring during early stages of 
the disease. Elucidating mechanisms of early neuroinflammation are important, as it provides 
information on potential mechanisms that occur prior to significant degeneration. Targeting these 
mechanisms may lead to potential therapies not involved with lowering IOP. Based on these 
studies, early neuroinflammatory pathways involve the complement cascade, Toll like receptor 
(TLR) signaling, and cytokine release (Williams et al., 2017). 
 
The complement system 
The complement system is a component of the immune system that assists in targeting 
microbes or damaged cells for removal by cell lysis and subsequent phagocytosis. The 
complement system is composed of three pathways: classical, lectin and alternative (Williams et 
al., 2017). In the classical pathway, damaged cells upregulate or are tagged by the C1 complex. 
This leads to activation of other complement proteins (i.e. C3, C5, C9), which are responsible for 
the formation of the membrane attack complex (MAC), a structure that promotes cell 
lysis/apoptosis. In glaucoma, studies suggest that different outcomes in glaucoma are attributed 
to specific components of the classical pathway (Stasi et al., 2006, Steele et al., 2006, Stevens et 
al., 2007, Howell et al., 2011, Panagis et al., 2011, Howell et al., 2013). For example in DBA2/J 
mice, up-regulation of C1q occurs in response to IOP elevation and co-localizes with PSD-95 
synapses in the dendrites of RGCs in the IPL (Stevens et al., 2007). As mentioned previously, 
these changes are followed by synapse elimination, dendritic pruning, and RGC dysfunction. 
Genetic or pharmaceutical inhibition of C1 ameliorates dendritic changes and subsequent 
degeneration in both DBA/2J and inducible models (Howell et al., 2011, Williams et al., 2016). 
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Despite the reported role of C1 in DBA/2J glaucoma, the overall impact of the classical 
complement system was unknown until just recently. The DBA/2J inbred strain is naturally 
deficient in C5, a necessary component in MAC formation. To determine its effect on DBA/2J 
specific glaucoma, Howell and colleagues (Howell et al., 2013) backcrossed a functional C5 
gene from the C57Bl/6J mouse into the DBA/2J mouse. Interestingly, while significantly more 
DBA/2J
C5; B6 
display severe axon pathology 6 weeks earlier than WT DBA/2J mice, no 
difference in pathology is noted by 12 months of age. This suggests that the presence of C5 is 
sufficient to promote axonopathy early in disease, but it is not necessary.  
 
TLR Activation 
TLRs are a group of pattern recognition receptors that recognize surface proteins found 
on pathogens (Yu et al., 2010). Currently, 13 types of TLRs (11 in humans) have been 
characterized, with each one recognizing a different ligand. Aside from pathogen recognition, 
TLR2 and TLR4 can recognize host specific ligands, specifically signals implicated in stress (Yu 
et al., 2010). In glaucoma, these include upregulation of heat shock proteins or changes in ECM 
composition (Sakai et al., 2003, Luo et al., 2010). Upon recognition of its specific ligand, TLRs 
activate signaling cascades that lead to the release of neuroinflammatory factors such as 
cytokines. In the retina, TLRs are typically found on glial cells in the retina, although some 
studies suggest some neuronal populations express them as well (Luo et al., 2010, Xu and Wang, 
2016). In respect to glaucoma, multiple types of TLRs are upregulated (Luo et al., 2010). 
Additionally, TLR gene polymorphisms, specifically TLR4, are associated with both 
normotensive and open angle glaucoma in three separate populations (Shibuya et al., 2008, 
Takano et al., 2012, Navarro-Partida et al., 2017). While the specific phenotypes of these 
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mutations are not yet known, it is plausible to suggest that they exacerbate neuroinflammatory 
mechanisms in some way. Indeed, studies using genetic or pharmaceutical inhibition of TLR4 in 
models of optic nerve crush or retinal ischemia/reperfusion, show decreases in glial reactivity 
and cytokine production, while at the same time inhibiting RGC loss (Dvoriantchikova et al., 
2010, Morzaev et al., 2015, Nakano et al., 2017).  
 
Cytokine Release 
While complement proteins and toll like receptors assist retinal cells in recognizing 
whether neighboring cells are compromised, the subsequent release of cytokines from glial cells 
facilitates survival or apoptosis of stressed RGCs. One of the more studied cytokines in 
glaucoma is TNFα. Along with a number of studies reporting roles for TNFα in the vitreous, 
retina and optic nerve of glaucoma patients and animal models (Yuan and Neufeld, 2000, 
Nakazawa et al., 2006, Tezel, 2008, Yang et al., 2011, Cueva Vargas et al., 2015), a number of 
TNFα gene polymorphisms are associated with increased chances of developing glaucoma (Lin 
et al., 2003a, Mossbock et al., 2006, Bozkurt et al., 2012, Xin et al., 2013). As a known initiator 
of the extrinsic pathway of apoptosis, it is not surprising to suggest that TNFα is directly 
responsible for RGC pathology in glaucoma. In fact, several studies in various glaucoma models 
show that genetic or pharmaceutical inhibition of TNFα signaling is neuroprotective to RGCs 
(Nakazawa et al., 2006, Cueva Vargas et al., 2015). In addition to promoting apoptosis, there is 
evidence to suggest that TNFα mediates cell survival by activating the transcription factor NFκB 
(Tezel, 2008). Upon activation, NFκB initiates transcription of other cytokines (i.e. IL-6) that are 
capable of initiating signaling cascades that prevent apoptosis (Sappington and Calkins, 2006, 
Sappington et al., 2006).  
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IL-6 as a potential target in glaucoma 
In the optic projection, recent studies from us and others show involvement of the 
cytokine IL-6 in facilitating RGC survival in response to various stressors. In the healthy retina, 
IL-6 is constitutively released (Sims et al., 2012). However in response to elevated IOP, IL-6 
levels increase in the retina and optic nerve head (Sappington et al., 2006, Cvenkel et al., 2010, 
Johnson et al., 2011, Chidlow et al., 2012). In vitro, elevated hydrostatic pressure leads to IL-6 
release from microglia, which when supplied to RGCs, protects them from pressure induced 
apoptosis (Sappington et al., 2006). IL-6 also facilitates axon regeneration and in some instances 
prevents degeneration of RGCs in response to optic nerve crush (Leibinger et al., 2013, 
Leibinger et al., 2016). However, it is unclear whether IL-6 impacts RGC axonopathy similarly 
in response to a more subtle chronic injury in vivo as seen in glaucoma.  
 
Interleukin-6 impacts CNS function 
The IL-6 family of cytokines 
IL-6 is the founding member of the glycoprotein-130 (gp130) family of cytokines, which 
also includes IL-11, IL-27, IL-31, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor 
(LIF), cardiotrophin-1 (CT-1), cardiotrophin-2 (CT-2) and cardiotrophin-like cytokine factor-1 
(CLCF-1) (Erta et al., 2012). This family is named for their common use of gp130, with the 
exception of IL-31, to initiate signal transduction (Mousa and Bakhiet, 2013). While functional 
redundancy between the members of the gp130 family exists, gene KO studies in mice of 
specific gp130 ligands and receptors provide evidence of individual roles within the body, 
including specific roles in the CNS (Mousa and Bakhiet, 2013).. 
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First characterized as a factor in T-cell activation, B-cell maturation, and the acute-phase 
response in the mid 1980’s, IL-6 has since earned a pleotropic reputation with roles in lipid 
metabolism, insulin resistance, hematopoiesis, osteogenesis and myogenesis (Franchimont et al., 
2005, Hoene et al., 2013, Hunter and Jones, 2015). However, soon after its initial 
characterization, separate studies published in 1988 and 1989 implicated IL-6 as neurotrophic 
factor, capable of promoting a neuronal phenotype in neuroblast precursors and extending 
survival of mature neurons in vitro (Satoh et al., 1988, Hama et al., 1989). Since then, a plethora 
of in vitro and in vivo reports have corroborated these initial observations while also providing 
evidence for a role in exacerbating neurodegeneration (Erta et al., 2012).  
 
IL-6 signal transduction 
IL-6 signaling is mediated by IL-6 binding to its alpha receptor (IL-6Rα) followed by 
recruitment and binding to the signal transduction receptor gp130. While there is controversy 
over the number of IL-6 and IL-6Rα involved in the signaling complex, it is accepted that two 
copies of gp130 are required for IL-6 dependent gp130 signal transduction (Grotzinger et al., 
1999). Gp130 signal transduction occurs in the cytoplasmic tail of gp130 (Heinrich et al., 1998). 
Near the plasma membrane, two proline rich regions known as box motifs recruit and bind 
tyrosine kinases including JAK1 and JAK2 (Heinrich et al., 1998). Prior to IL-6 mediated gp130 
dimerization, JAKs reside in an inactive state on the gp130 box motifs. In response to gp130 
dimerization, the JAKs on each gp130 unit are brought into close proximity, causing a mutual 
phosphorylation event between them (Heinrich et al., 1998). The phosphorylated JAKs are then 
capable of phosphorylating a number of more distal tyrosine residues on gp130 (Heinrich et al., 
1998). Interestingly, each residue phosphorylated corresponds to different signaling cascades. 
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For example, phosphorylation of the tyrosine at position 767 (Y767) or 814 (Y814) leads to 
STAT3 phosphorylation, while phosphorylation of Y905 or Y915 leads to STAT1 
phosphorylation (Heinrich et al., 1998). Activation of the MAPK/ERK and Akt/mTOR pathway 
appears to be mediated by phosphorylation of Y759 (Heinrich et al., 1998). Phosphorylation of 
STAT1/3, ERK and mTOR influences gene expression associated with proliferation, cell 
survival or production of neuroinflammatory mediators (Erta et al., 2012). 
To regulate IL-6/gp130 signaling, the cell has multiple regulatory mechanisms in place. 
For example, the phosphatase SHP2 acts on phosphorylated JAKs to prevent subsequent 
activation of distal tyrosine residues (Heinrich et al., 1998). In the nucleus, the protein inhibitor 
of activated STAT (PIAS) protein attaches itself to phosphorylated STATs, inhibiting STAT 
mediated transcription (Heinrich et al., 1998). One of the more recently characterized 
mechanisms involves STAT mediated transcription of suppression of cytokine signaling-1 and -3 
(SOCS-1,-3) genes. Following translation, SOCS-1 and SOCS-3 act not only on phosphorylated 
JAK to prevent subsequent gp130 and STAT1/3 phosphorylation, but also on naïve JAK to 
prevent their initial phosphorylation (Heinrich et al., 1998).    
 
IL-6: Classical vs Trans-signaling 
The pleotropic nature of IL-6 signaling is facilitated through two pathways: classical and 
trans-signaling (Scheller et al., 2011a) (Figure 1.8). Classical signaling involves a membrane 
bound IL-6Rα (mIL-6Rα), while trans-signaling incorporates a soluble form of the IL-6Rα (sIL-
6Rα) (Scheller et al., 2011a). In humans, synthesis of sIL-6Rα occurs by alternative splicing of 
IL-6Rα mRNA or cleavage of mIL-6Rα by metalloproteases (i.e. ADAM10, ADAM17), while 
mice only produce sIL-6Rα by proteolytic cleavage (Scheller et al., 2011a). While the 
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consequences of the pathways are not well understood, the current literature suggests different 
roles for classical and trans-signaling (Hunter and Jones, 2015). In the naïve state, it is believed 
classical signaling is dominant due to minute levels of IL-6 (1-5pg/ml) and sIL-6Rα (25-35 
ng/pg) in the plasma (Hunter and Jones, 2015). Classical signaling is also associated with more 
homeostatic functions including glucose metabolism, T-cell differentiation, regeneration of 
intestinal epithelial cells, and hematopoiesis (Hunter and Jones, 2015). However, in response to a 
local injury, the increase in sIL-6Rα and shift towards IL-6 trans-signaling acts as an “alarmin”, 
recruiting neutrophils and peripheral macrophages to the injury site to prevent infection and 
promote healing (Hunter and Jones, 2015).  
 
Expression and regulation of IL-6 in the CNS 
Following the discovery that IL-6 is capable of acting as a neurotrophic factor, questions 
were asked regarding where IL-6 and its receptors were expressed in the CNS. Various in vitro 
studies indicate that neurons and glial cells are able to express IL-6, IL-6Rα, and gp130 to some 
degree (Tada et al., 1994, Marz et al., 1998, Lee et al., 2002, Erta et al., 2012). In contrast, 
endothelial cells of the CNS vasculature only express IL-6 and gp130 (Reyes et al., 1999, 
Chalaris et al., 2007). In vivo, IL-6, IL-6Rα, and gp130 are expressed in the retina, striatum, 
hippocampus, hypothalamus, cortex, cerebellum and dorsal root ganglia (Schobitz et al., 1992, 
Yan et al., 1992, Gadient and Otten, 1993, Schobitz et al., 1993, Gadient and Otten, 1994a, b, 
1995, Vallieres and Rivest, 1997, Chidlow et al., 2012, Sims et al., 2012). Similar to the 
periphery, gp130 expression is higher compared to IL-6 and IL-6Rα in the CNS  (Vallieres and 
Rivest, 1997). 
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Figure 1.8. IL-6 signals in a classical and trans fashion. (A) In classical signaling, IL-6 binds to 
a membrane bound IL-6Rα (mIL-6Rα) followed by two copies of gp130. From there, multiple 
signaling pathways can be initiated including JAK/STAT, MAPK/ERK and Akt/mTOR. (B) In 
trans-signaling, the matrix metalloproteases ADAM10 and ADAM17 cleave mIL-6Rα to form 
sIL-6Rα. Unlike other soluble receptors, sIL-6Rα serves as an agonist by binding IL-6 in the 
extracellular space followed by binding to gp130 on the cell surface. This allowed sIL-6Rα to 
confer IL-6 sensitivity to cells that do not express mIL-6Rα. In humans, but not mice, a soluble 
form of gp130 also exists, which serves to inhibit trans-signaling. 
 
Figure adapted from (Erta et al., 2012) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
 
Infection, injury and even basal activity are capable of influencing IL-6 expression in the 
CNS. In vitro, application of the bacterial endotoxin lipopolysaccharide (LPS) or pro-
inflammatory cytokines IL-1β and TNF-α induce Il-6 mRNA expression in glial cells (Sawada et 
al., 1992, Lee et al., 1993, Sebire et al., 1993) and neurons (Sebire et al., 1993). Up-regulated 
production of IL-6 from glia is also seen in vivo after peripheral injection of LPS in mice (Beurel 
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and Jope, 2009). In animal models of CNS trauma, IL-6 elevation is seen after seizure 
(Lehtimaki et al., 2003), acute IOP elevations (Sanchez et al., 2003, Johnson et al., 2011, 
Chidlow et al., 2012), optic nerve crush (Chidlow et al., 2012, Leibinger et al., 2013), brain 
ischemia (Hagberg et al., 1996, Loddick et al., 1998, Clark et al., 1999, Ali et al., 2000), closed 
head injury (Shohami et al., 1994) and peripheral nerve injury (Arruda et al., 1998). In the clinic, 
IL-6 elevation in both serum and CSF is also seen in people who have experienced traumatic 
brain injuries (Shohami et al., 1994, Kossmann et al., 1995, Kossmann et al., 1996, Bell et al., 
1997, Arruda et al., 1998, Hans et al., 1999a, Hans et al., 1999b, Woiciechowsky et al., 2002, 
Winter et al., 2004). Interestingly, even acute physiological stressors are capable of influencing 
IL-6 expression. For example, application of NMDA or depolarization of the plasma membrane 
induces IL-6 expression (Sallmann et al., 2000), suggesting that basic neuronal activity can 
induce IL-6 release. In addition, mechanical stressors such as elevations in pressure can also 
induce IL-6 expression in both glia and neurons (Sappington and Calkins, 2006, Sappington et 
al., 2006, Crish et al., 2010).  
 
IL-6 in neurodegeneration: friend or foe? 
Previously, it was mentioned that chronic neuroinflammation is associated with 
neurodegenerative disease. Indeed, increased levels of IL-6 are reported in Alzheimer’s (Blum-
Degen et al., 1995), Parkinson’s (Mogi et al., 1996), multiple sclerosis (Maimone et al., 1997), 
Huntington’s (Dalrymple et al., 2007) and glaucoma (Chen et al., 1999, Takai et al., 2012, 
Huang et al., 2014, Du et al., 2016). However, whether IL-6 released in chronic 
neuroinflammation is beneficial or detrimental to neuronal survival is a topic of controversy. In 
basal conditions, exogenous IL-6 is capable of improving cell viability and promoting cell 
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differentiation (Satoh et al., 1988, Hama et al., 1989). When coupled with a specific stressor, pre-
treatment with IL-6 prevents apoptosis in neural cells exposed to NMDA (Toulmond et al., 1992, 
Yamada and Hatanaka, 1994, Peng et al., 2005), elevated hydrostatic pressure (Sappington et al., 
2006), increased intracellular calcium (Umegaki et al., 1996), and certain toxins (Spittau et al., 
2012) (Leibinger et al., 2013), suggesting that IL-6 is neuroprotective. This is further 
corroborated in some in vivo models of CNS injury. In response to focal brain injury, GFAP-IL-6 
mice present with mitigated neuronal apoptosis at the injury site and quicker healing time 
compared to WT mice (Penkowa et al., 2003). In contrast, Il-6-/- mice show a worsened CNS 
pathology after mechanical brain injury (Penkowa et al., 1999, Penkowa et al., 2000, Penkowa et 
al., 2001), optic nerve crush (Leibinger et al., 2013), brain ischemia (Clark et al., 2000), and 
dorsal column crush (Cafferty et al., 2004).  
Conversely, other evidence suggests that IL-6 is neurotoxic. Previously, it was mentioned 
that over-expression of IL-6 leads to significant changes in CNS development that lead to 
functional deficits. In addition to that, over expression of IL-6 leads to progressive 
neurodegeneration of the cerebellum by 3 months of age in GFAP-IL-6 mice (Campbell et al., 
1993). In addition, IL-6 deficient mice are resistant to EAE mediated axon degeneration and 
demyelination as well as glutamate toxicity and age related degeneration in forebrain GABA-
ergic interneurons (Samoilova et al., 1998, Dugan et al., 2009).  
Recent observations suggest that classical and trans-signaling mediate the respective 
neuroprotective and neurotoxic outcomes associated with IL-6 signaling. In the CNS, GFAP-IL-
6 mice genetically modified to produce sgp130 are protected from the pathological phenotypes 
caused by IL-6 over expression (Campbell et al., 2014). Additionally, intra-cerebroventricular 
injection of sgp130 protects senescent mice from LPS mediated deficits in learning and memory, 
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social behavior and locomotion (Burton et al., 2011, Burton and Johnson, 2012, Burton et al., 
2013). These results are not surprising as IL-6 trans-signaling is implicated in the pathology of 
various diseases in the periphery including Crohn’s disease, inflammatory bowel disease and 
rheumatoid arthritis (Scheller et al., 2011a, Hunter and Jones, 2015). Blocking trans-signaling 
using sgp130 improves disease outcome in certain mouse models of these diseases and a clinical 
trial for sgp130 in inflammatory bowel disease is currently in development (Scheller et al., 
2011a, Hunter and Jones, 2015). While therapies targeting both classical and trans-signaling are 
already in use in human patients, the homeostatic functions of classical signaling suggests an 
advantage in only targeting trans-signaling (Scheller et al., 2011a, Hunter and Jones, 2015). This 
is especially true in the CNS, where classical signaling may have roles in hippocampal 
neurogenesis and other yet-characterized processes (Bowen et al., 2011). 
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Specific Aims of Dissertation 
The objective of this thesis project is to characterize the role of IL-6 (interleukin-6) in 
RGCs during conditions of homeostasis and glaucoma related disease. Our central hypothesis is 
that IL-6 activity has opposing roles in the healthy and glaucomatous RGC projection.  
Specifically, IL-6 promotes IOP-related RGC degeneration, but is necessary for proper 
development and function of a healthy RGC projection. This hypothesis is based on: 1) previous 
studies showing elevation of IL-6 in response to ocular hypertension and other chronic stressors, 
2) reduced CNS degeneration in response to mitigation or ablation of IL-6 signaling, and 3) in 
vivo studies in Il-6-/- mice showing structural and functional deficits in the central and peripheral 
nervous systems. To test our central hypothesis, we have developed these specific aims: 
 
Aim 1: Establish the expression profile for IL-6 machinery in response to glaucoma-related 
stressors. The production of the soluble IL-6Rα isoform and subsequent trans-signaling is a 
hallmark of many neurodegenerative diseases. Our working hypothesis that IL-6Rα shifts from a 
membrane to a soluble isoform in response to glaucoma related stressors. In young (4mo) and 
aged (8mo) DBA/2J and C57 retina, we will: (1) determine protein concentration of gp130, (2) 
determine the population of (m) or soluble (s) IL-6Rα. In DBA/2J retina we will also (3) measure 
the relationship between IL-6Rα isoform and RGC health.   
 
Aim 2: Determine whether IL-6 influences RGC degeneration caused by ocular 
hypertension.  Elevated levels of IL-6 are present in neurodegenerative disease, including 
glaucoma. Our working hypothesis is that IL-6 promotes RGC degeneration caused by ocular 
hypertension. We will examine whether genetic ablation of IL-6 protects against RGC 
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degeneration associated with microbead- induced ocular hypertension. We will assess RGC 
degeneration by: (1) measuring anterograde axon transport from RGCs to the superior colliculus, 
(2) quantifying changes in axon survival and (3) measuring deficits in threshold visual acuity. 
Within the retina we will also (4) quantify changes in microglia and astrocyte glia populations. 
 
Aim 3: Identify the outcomes of constitutive IL-6 signaling in the naïve optic projection.   
IL-6 deficiency leads to structural and functional deficits in the central and peripheral nervous 
systems. Our working hypothesis is that constitutive IL-6 signaling is necessary for proper 
development and function of the optic projection. In naive WT and Il-6-/- mice we will: (1) 
assess the laminar structure of the retina (2) assess the cortical response to a light induced 
stimulus, (3) assess axon transport latency from RGCs to the superior colliculus, (4) quantify size 
and degree of myelination in axons of the optic nerve structure in the myelinated optic nerve, and 
(5) assess cytoskeletal morphology of RGC axons in the retina.  
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CHAPTER 2 
 
ELEVATED PRESENCE OF THE SOLUBLE IL-6Rα IN  
RESPONSE TO GLAUCOMA RELATED- STRESSORS
2 
 
 
Introduction  
A common theme surrounding the majority of neurodegenerative diseases is age, with the 
average age of onset for PD, AD, ALS, and glaucoma occurring after the age of 50 (Blumberg et 
al., 2015, Boland and Platt, 2015). One hypothesis for the correlation between age and 
neurodegenerative disease involves age related chronic inflammation  (Deleidi et al., 2015). As 
we age, the culmination of genetic and environmental stressors on our immune system causes 1) 
an increased production of inflammatory cytokines and 2) a decrease in our ability to terminate 
an inflammatory response (Franceschi et al., 2000, Licastro et al., 2005, Deleidi et al., 2015). In 
the CNS, this imbalance between pro-inflammatory and anti-inflammatory mechanisms results in 
a state of chronic neuroinflammation. Not surprisingly, chronic neuroinflammation is a common 
component of age-related neurodegenerative disease including AD, PD, HD, MS and glaucoma 
(Soto and Howell, 2014, Deleidi et al., 2015, Williams et al., 2017). The pro-inflammatory 
cytokine IL-6 is upregulated in chronic neuroinflammation and is associated with 
neurodegenerative disease, including RGC degeneration in glaucoma (Chen et al., 1999, Ghanem 
et al., 2011, Erta et al., 2012, Sims et al., 2012). In the retina, IL-6 is constitutively expressed by 
RGCs and glia (Sims et al., 2012). However, elevated pressure, a risk factor for glaucoma can  
_______________________________________ 
2 
Portions of this chapter were published as: Echevarria et al., (2013) Stressor-dependent 
Alterations in Glycoprotein 130: Implications for Glial Cell Reactivity, Cytokine Signaling and 
Ganglion Cell Health in Glaucoma. J Clin Exp Ophthalmol 4. 
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elevate IL-6 release from RGCs and glia (Sappington et al., 2006, Cvenkel et al., 2010, Johnson 
et al., 2011, Chidlow et al., 2012, Sims et al., 2012). Interestingly, the impact of IL-6 signaling in
 
respect to retinal neurodegeneration is variable. While we have presented evidence that IL-6 
protects RGCs from pressure induced apoptosis in vitro (Sappington et al., 2006), other studies 
suggest that inflammatory responses producing elevated IL-6 exacerbate pathological conditions 
that can impact RGC survival such as experimental  autoimmune encephalomyelitis and retinal 
ischemia and reperfusion injury (Fisher et al., 2001, Horstmann et al., 2013). 
IL-6 signaling is mediated by IL-6 binding to its alpha receptor (IL-6Rα) followed by 
binding to the signal transduction receptor gp130 on the cell surface (Scheller et al., 2011a). Two 
types of IL-6 signaling exist and correspond to a specific IL-6Rα isoform. In its membrane-
bound isoform (mIL-6Rα), IL-6Rα mediates classical IL-6 signaling, while its soluble isoform 
(sIL-6Rα) mediates trans-signaling (Scheller et al., 2011a). Unlike some soluble receptors that 
serve as antagonists to their specific ligand, sIL-6Rα acts as an agonist. This is accomplished by 
sIL-6Rα binding to IL-6 in the periphery, followed by associating with and activating gp130 on 
the cell surface (Scheller et al., 2011a). Regardless of IL-6Rα isoform however, the IL-6/IL-
6Rα/gp130 complex initiates signaling through similar signal transduction pathways, including 
JAK/STAT, MAPK/ERK and AKT/mTOR (Rose-John, 2013). A soluble form of gp130 
(sgp130) is also characterized in humans, but not mice (Scheller et al., 2011a). Unlike sIL-6Rα, 
sgp130 only serves as an antagonist, selectively binding the IL-6/sIL-6Rα complex. As it has no 
inhibitory effect on the IL-6/mIL-6Rα, it is believed that sgp130 is produced to specifically 
regulate IL-6 trans-signaling (Scheller et al., 2011a). While the full complement of cellular 
responses induced by both classical and trans-signaling are not yet known, classical signaling is 
thought to be involved with homeostatic processes, while trans-signaling is implicated in a 
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variety of chronic inflammatory diseases in the periphery including inflammatory bowel disease, 
rheumatoid arthritis and Crohn’s disease (Scheller et al., 2011a, Hunter and Jones, 2015).  
Recent studies also show a role for trans-signaling in CNS degeneration/ dysfunction 
following chronic stressors (Burton et al., 2011, Burton and Johnson, 2012, Burton et al., 2013, 
Campbell et al., 2014). However, trans-signaling or the presence of the soluble receptor has not 
been associated to a specific neurodegenerative disease. Previous work in the lab indicates that 
expression and localization of IL-6 and IL-6Rα become more spatially variable in response to 
age and elevated IOP, two primary risk factors in glaucoma (Sims et al., 2012). However, it is 
not known whether these stressors include alterations in IL-6Rα receptor isoform or gp130, both 
of which can influence IL-6 mediated signaling. In this chapter, we tested how age and IOP 
elevation affects expression and localization of mIL-6Rα, sIL-6Rα and gp130 using the DBA/2J 
mouse model of glaucoma. DBA/2J mice are relevant to human forms of glaucoma as they 
develop IOP elevation and subsequent RGC pathology in an age dependent manner (Chang et al., 
1999, Anderson et al., 2002, Inman et al., 2006). We then correlated glaucoma related changes in 
IL-6Rα isoform and gp130 expression to RGC integrity. Together, these results suggest that a 
shift from IL-6 classical to trans-signaling could be a pathological component of glaucoma.  
 
 
 
 
 
 
 
 49 
Materials and Methods 
Animals 
4 month and 8 month male DBA/2J mice, age matched C57Bl/6J (C57) mice, and 4 
month male and female B6;129SF2/J mice were obtained from Jackson Laboratories (Bar 
Harbor, Maine). Mice were housed in accordance with the National Institutes of Health 
guidelines. All study procedures conformed to the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use 
Committee of Vanderbilt University Medical Center. Animals were maintained on a 12-hour 
light/12-hour-dark cycle and were given unrestricted access to food and water.  
 
IOP measurements 
We obtained IOP measurements from all DBA/2J mice a minimum of once per month 
beginning at 3 months of age. IOP for each eye was calculated as the mean of 5-10 
measurements and evaluated at least monthly using a tonometer (TonoLab; Reichert, Depew, 
NY), as previously described (Inman et al., 2006, Sappington and Calkins, 2008, Crish et al., 
2010). The average IOP for DBA/2J mice used all studies was 15.2 + 1.48 mmHg and 18.4 + 
2.30mmHg for 4 month and 8 month old mice, respectively. The average IOP for DBA/2J mice 
was 15.2 + 1.48 mmHg and 18.4 + 2.30 mmHg for 4 month and 8 month old mice, respectively. 
 
Tissue preparation 
For fresh tissue analyses, mice were sacrificed via cervical dislocation followed by 
decapitation. Eyes were enucleated, flash frozen on dry ice and stored at -80°C until use. For 
fixed tissue analyses, For histological assays, mice were euthanized with an overdose of 
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pentobarbital and perfused trans-cardially with 100ml of 1X PBS (Sigma Aldrich, St. Louis, 
MO) followed by 100ml of 4% paraformaldehyde (PFA; Electron Microscopy Sciences, 
Hatfield, PA). Whole eyes were enucleated and post-fixed in 4% PFA for at least 24 hours at 
4°C. Whole eyes and whole retina were prepared for cryo-sectioning and whole mount 
immunohistochemistry, respectively, as previously described (Echevarria et al., 2013, Echevarria 
et al., 2016) 
 
Lipopolysaccharide (LPS) stimulation  
For fixed tissue experiments, B6;129SF2/J mice (n = 5) received intravitreal injection of 
2μl of 5μg/ul LPS (LPS; Cat# L4391-1MG, Sigma) in the right eye, while the left eye served as 
an internal control and received an equal volume injection of saline. For fresh tissue experiments, 
B6;129SF2/J mice received 2μl of 5mg/μl LPS in the right eye and an equal volume injection of 
saline in the left eye (n=15) or no experimental manipulation (n = 10). All mice were sacrificed 
and tissue collected 6 hours post LPS/saline injection.  
 
Gp130 and soluble IL-6Rα quantification  
To quantify gp130 and sIL-6Rα in retinal lysates, soluble and trans-membrane protein 
fractions were isolated and analyzed using the Milliplex™ Map Mouse Soluble Cytokine 
Receptor Magnetic Bead Panel immunoassay kit (cat# MSCRMAG-42K; Millipore). Soluble 
and membrane fractions were separated from retinal lysates (5 retinas/ sample), using the 
ProteoExtract® Trans-membrane Protein Extraction Kit (cat# 71772-3; Millipore) according to 
manufacturer’s instructions. Quality controls and standards were run concurrently with 
experimental samples. Each control, standard and sample was run in duplicate. Total protein 
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concentrations were determined using a BCA Protein assay (cat# 23227; Thermo-Fisher). Value 
reported for gp130 was recorded from the transmembrane fraction, as soluble gp130 is not 
expressed in mice. For sIL-6Rα, the value reported in the data is the concentration of IL-6Rα (pg 
IL-6Rα/ml/μg total protein) measured in the soluble fraction of a sample as a percentage of the 
total IL-6Rα concentration (soluble + membrane fraction).  
 
Neural transport tracing 
For neural tracing studies, mice received an intravitreal injection of CTB (2μl; 10μg/ul) 
conjugated to Alexa Fluor-594 (cat# C-22842; Life Technologies) 48 hours prior to sacrifice, as 
previously described (Echevarria et al., 2013, Formichella et al., 2014). CTB labeling in fixed, 
whole mounted retina was imaged with an inverted confocal microscope (Olympus FV-1000; 
Center Valley, PA) through the Vanderbilt University Medical Center Cell Imaging Shared 
Resource Core. Three dimensional z-stack images of the retina were acquired using a digital 
camera and image analysis software (FV-100 ASW; Olympus). For each retina, at least 5 
pseudo-random images were acquired in mid central/mid-peripheral areas at 60x magnification 
through the ganglion cell and nerve fiber layers. CTB intensity in whole mounted retina was 
measured using Image J software (National Institute of Health). Intensity is reported in arbitrary 
units and is the average intensity found within the entire image. 
 
Immunohistochemistry 
Immunolabeling of whole eye cryosections was performed, as previously described 
(Echevarria et al., 2016). Sections were co-labeled with primary antibodies against epitopes in 
the cytoplasmic domain (rabbit anti-IL-6Rα/M20; 1:50; cat# SC660; Santa Cruz) and 
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extracellular domains (rat anti-IL-6Rα/CD126; 1:300; cat# MAB18301; R&D Systems) of IL-
6Rα. Primary antibody binding was detected by fluorophore-conjugated secondary antibodies: 
anti-rabbit Dylight 488 (1:200; cat# 711-486-152; Jackson ImmunoResearch) and anti-rat 
rhodamine red-x (1:200; cat# 712-296-150; Jackson ImmunoResearch). Sections were imaged 
using a Nikon Ti Eclipse microscope (Nikon Instruments Inc.) equipped with FITC/TRITC/Cy5 
filters for epifluorescence. Fluorescent images at 20x magnification were captured using a 
CoolSNAP HQ
2
 black and white camera (Roper Scientific).Whole-mount immunohistochemistry 
was performed as previously described (Sims et al., 2012, Echevarria et al., 2013, Echevarria et 
al., 2016). Whole retinas were labeled with the primary antibodies described above or gp130 (rat 
anti-gp130 (1:12.5; cat# MAB4681; R&D Systems) and the following secondary antibodies: 
anti-rabbit Dylight 647 (1:200, cat# 711-605-152; Jackson ImmunoResearch) and anti-rat Alexa 
Fluor 488 (1:200, cat# 712-545-150; Jackson ImmunoResearch).  Quantification of gp130 
intensity was done as described in neural tracing studies. 
 
Co-localization analysis  
Co-localization between antibodies recognizing the cytoplasmic (M20) and extracellular 
domains (CD126) of IL-6Rα was quantified by observer grading. A co-localization grading 
between 1 and 4 was assigned to each confocal micrograph by an observer blind to experimental 
cohorts. A score of 1 was assigned to images with the least co-localization of immunolabeling 
and a score of 4 was assigned to images with the most co-localization (Figure 2.2). Scores of 2 
and 3 were assigned to images with more/less co-localization than images scored with 1 and 4, 
respectively.   
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Statistical analysis: 
Statistical analysis was conducted with SigmaPlot Version 11.1 (Systat Software Inc, San 
Jose, CA). For comparison of two populations of data passing normality and equal variance 
criteria, a student’s t-test was performed. For data sets which failed normality and equal variance 
criteria, a Mann-Whitney RANK Sum Test was used. Data sets that passed normality and equal 
variance criteria were represented as bar graphs or point plots. Data sets that did not pass 
normality and equal variance criteria were represented as box plots. For all, p-values < 0.05 were 
considered statistically significant. 
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Results 
Glaucoma-related stressors promote sIL-6Rα production. 
Both age and elevated IOP are risk factors for glaucoma (Crish and Calkins, 2011). To 
determine whether these stressors alter gp130 and IL-6Rα demographics in retina, we examined 
aging alone in C57Bl/6J (C57) mice and aging plus elevated IOP using the DBA/2J mouse. We 
first examined protein levels of IL-6Rα isoforms in soluble and trans-membrane fractions of 
protein lysates from retina of young (4mo) and aging (8mo) C57 and DBA/2J mice. We found 
that the sIL-6Rα isoform accounted for approximately 47% of total IL-6Rα (IL-6Rα soluble 
fraction + IL-6Rα membrane fraction) in aging C57 retina, compared to 5% in young retina 
(p<0.001; Figure 2.1A). In aging DBA/2J mice with elevated IOP, sIL-6Rα accounted for nearly 
25% of total IL-6Rα in retina, compared to 8% in young DBA/2J mice with normal IOP 
(p=0.023; Figure 2.1B). For gp130 protein, no protein was detected in soluble fractions. In 
membrane fractions, gp130 protein levels were significantly elevated by 33% in aging C57 retina 
compared to young retina (p<0.05; Figure 2.1C). Although not statistically significant, there is 
also a trend towards decreased gp130 protein expression in aging DBA/2J retina, as compared to 
young C57 retina (p=0.06; Figure 2.1D).  
 
sIL-6Rα increases in response to acute inflammatory stress in the retina.   
Examining the potential relevance of IL-6 trans-signaling to glaucoma presented a key 
technical hurdle. The most widely studied models of glaucoma are rodent models. In rodents, 
sIL-6Rα is produced by proteolytic cleavage that frees the extracellular domain from existing 
mIL-6Rα (Garbers et al., 2011, Scheller et al., 2011b). As such, the two isoforms differ only by 
the presence or absence of the intracellular domain. While this hurdle can be rather easily  
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Figure 2.1 Glaucoma related stressors affect gp130 and IL-6Rα isoform expression (A,B) 
Graphical representation of percentage of sIL-6Rα (IL-6Rα in soluble fractions) compared to 
total IL-6Rα (IL-6Rα in soluble and membrane fractions) from retina protein lysates from young 
(4 month; white) and aging (8mo; gray) C57 (A) and DBA/2J (B) mice. Age leads to significant 
increases in percent sIL-6Rα in both C57 (p<0.001, Mann-Whitney RANK Sum Test) and DBA 
(p<0.023, student’s t-test). Dashed lines in box plot indicate median value. Error bars in bar 
graph indicate standard deviation. (C,D) Bar graphs of retinal gp130 protein concentration (pg 
gp130/ml/μg total protein) in membrane fractions of young (4mo; white) and aging (8mo; gray) 
C57 (C) and DBA/2J (D) mice. Normal aging leads to a significant increase in retinal gp130 in 
C57 (p<0.05, student’s t-test), while aging coupled with IOP elevation leads to a trend towards a 
decrease in retinal gp130 in DBA/2J. (p=0.06, student’s t-test). *= p<0.05. Error bars in bar 
graphs indicate standard deviation. 
 
Parts of this figure are taken from (Echevarria et al., 2013) and used in accordance with the 
Creative Commons Attribution-Non Commercial 4.0 International License. 
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addressed in biochemical assays, our previous work indicates spatial regulation of IL-6 signaling 
is highly relevant in glaucoma. To differentiate sIL-6Rα and mIL-6Rα in fixed tissue, we devised 
a co-immunolabeling strategy with antibodies against the C-terminal (M20; intracellular) and N-
terminal (CD126; extracellular) portions of IL-6Rα. Utilizing different secondary antibodies to 
label the M20 (green) and CD126 (red) antibodies respectively, mIL-6Rα (yellow) can be 
differentiated from sIL-6Rα (red) (Figure 2.2A). 
To validate our IL-6Rα isoform outcomes in retina, we first examined sIL-6Rα and mIL-
6Rα expression and localization in response to gram-negative endotoxin lipopolysaccharide 
(LPS), a well-described inducer of IL-6 trans-signaling (de Vos et al., 1994, Mo and Streilein, 
2001, Rosenbaum et al., 2011). In one group of young (4mo) mice, we injected 10μg (2μl) of 
LPS into the vitreal cavity of the right eye, while injecting an equal amount of diluent (saline) in 
the left eye. Another group served as controls and received no injection. Six hours after injection, 
we separated membrane and soluble protein fractions from all samples and probed for IL-6Rα, 
using a high-throughput ELISA. In naïve and saline retinas, the sIL-6Rα isoform accounted for 
approximately 13.1% and 16.7% of all retinal IL-6Rα, respectively (p>0.05; Figure 2.2B). In 
LPS-treated retina, sIL-6Rα concentrations increased significantly to account for nearly 25.2% of 
all IL-6Rα (p=0.014; Figure 2.2B). To determine localization patterns for sIL-6Rα and mIL-
6Rα, we co-immunolabeled whole eye sections from LPS- and saline-injected mice with 
antibodies against the extracellular and intracellular segments of IL-6Rα, as described above 
(Figure 2.2C). Retina from saline-injected mice exhibited strong immunolabeling with both 
antibodies, particularly in the outer (OPL) and inner plexiform (IPL) layers, the ganglion cell 
layer (GCL) and the nerve fiber layer (NFL; Figure 2.2C). Signal from the two antibodies 
strongly co-localized in these layers (Figure 2.2C). However, labeling intensity for the  
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Figure 2.2. sIL-6Rα production increases in the retina in response to LPS. (A) Schematic of 
dual-immunolabeling technique to differentiate sIL-6Rα and mIL-6Rα in situ. Tissue is 
immunolabeled with two anti- IL-6Rα antibodies. One antibody recognizes an epitope in the 
extracellular domain of the IL-6Rα protein (CD126; red), while the second antibody recognizes 
an epitope in the intracellular domain (M20; green). Co-localization of the antibodies (yellow) 
identifies intact mIL-6Rα. Separation of red and green labeling identifies sIL-6Rα and the 
cleaved intracellular domain, respectively. (B) Graphical representation of percentage of sIL-
6Rα compared to total IL-6Rα (membrane + soluble fractions) detected in the soluble fraction of 
retina protein lysates from naïve retina (white) or 6 hours after intravitreal injection of 10μg LPS 
(black) or saline (gray). Error bars indicate standard deviation. *= p<0.05. (C-D) Representative 
images (20X) of retina 6 hours post saline (C) or 10μg LPS (D) injection co-immunolabeled with 
CD126 (red) and M20 (green) antibodies against IL-6Rα. Retina from saline-injected mice 
exhibits strong co-localization of CD126 and M20 antibodies (yellow; mIL-6Rα) within the GCL 
and INL layers. LPS injection leads to a robust increase in CD126 signal (red; sIL-6Rα) in cell 
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membranes of RGCs in the GCL layer as well as decreased co-localization (yellow) of CD126 
with M20 (green) labeling. Scale bar represents 20μM and is applicable to all images. ONL: 
outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform 
layer, GCL: ganglion cell layer, NFL: nerve fiber layer. 
______________________________________________________________________________ 
intracellular (M20) segment tended to be higher than that of the extracellular (CD126) segment, 
particularly in RGC somas (Figure 2.2C). In contrast, retina from LPS-injected mice exhibited a 
marked increase in the intensity of CD126 labeling with far fewer instances of M20-CD126 co-
localization (Figure 2.2D). Thus, our immunohistochemical data corresponded well with our 
traditional biochemical assays for detection of sIL-6Rα and mIL-6Rα.  
 
sIL-6Rα is most strongly associated with RGC soma in glaucomatous retina. 
To determine the spatial attributes of sIL-6Rα production in glaucoma, we examined 
localization of sIL-6Rα and mIL-6Rα in young and aging DBA/2J mice, which represents both 
aging- and IOP-related stressors. Using the dual-labeling technique described in Figure 2.2A, we 
examined localization of IL-6Rα isoforms in the GCL and NFL of whole-mounted retina. We 
quantified the degree of co-localization (yellow signal) between the red (CD126) and green 
(M20) signals of the two isoforms on a 4 point scale, with 4 representing near complete co-
localization and 1 representing near complete separation (Figure 2.3A). Although there were 
varying degrees of localization across retinal images from both young and aging DBA/2J (Figure 
2.3A), the majority of images from young DBA/2J retina presented with co-localization of M20 
and CD126, especially in RGC soma (Figure 2.3A; left). In contrast, the majority of images from 
aging DBA/2J retina exhibited clear separation of C-terminal and N-terminal IL-6Rα labeling 
that both associated with RGCs (Figure 2.3A; right). Quantification of co-localization by grading  
confirmed extracellular and intracellular domains of IL-6Rα were co-localized more frequently 
in young DBA/2J retina than in aging DBA/2J retina (p=0.022; Figure 2.3B). 
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Figure 2.3. Glaucoma-related sIL-6Rα is associated with RGCs. (A) Confocal micrographs 
(60X) images of the GCL and NFL in whole mount retina from young (4mo; left) and aging (8 
mo; right) DBA/2J mice co-immunolabeled with CD126 (red) and M20 (green) antibodies 
against IL-6Rα. Score of 1 represents little co-localization (red and green separation), while a 
score of 4 indicates greatest co-localization (yellow). Scale bar represents 20μM and is 
applicable to all images. (B) Point plot depicting co-localization grading for individual images of 
whole mount retina from 4mo (white) and 8mo (gray) DBA/2J mice. There is a significant 
decrease in co-localization score in 8mo DBA/2J compared to 4mo DBA/2J (p<0.05, student’s t-
test). The mean co-localization score is indicated by the black bar. Error bars represent standard 
deviation. * = p<0.05. 
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sIL-6Rα localization is related to RGC integrity 
One component of glaucomatous pathology in the DBA/2J mouse is decreased uptake 
and intra-retinal transport of the active uptake, active transport neural tracer CTB by RGCs 
(Crish et al., 2010, Formichella et al., 2014). To measure RGC integrity, we delivered CTB to 
young and aging DBA/2J mice via intravitreal injection and imaged whole-mounted retina 3 
days later. As a control for normal aging, we also delivered CTB to age matched C57 mice. We 
quantified CTB uptake and intra-retinal transport by quantifying CTB fluorescent intensity in 
images controlled for eccentricity. In retina from young C57, aging C57 and young DBA/2J 
mice, CTB was robustly detected across the retina, with expected variances in CTB intensity 
related to eccentricity (Figure 2.4A-C). In contrast, retina from aging DBA/2J mice exhibited 
varying degrees of uptake and intra-retinal transport in areas of equivalent eccentricity (Figure 
2.4D). Furthermore, consistent with previous findings, CTB labeling in the soma persisted longer 
than that in the unmyelinated segment of RGC axons (Figure 2.4D) (Crish et al., 2010). 
Quantification of mean CTB labeling within each image revealed that CTB intensity did not 
differ between young and aging C57 mice (p>0.05; Figure 2.4E). However, CTB labeling 
intensity was 55% lower in aging DBA/2J retina than in young DBA retina (p<0.001; Figure 
2.4E) 
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Figure 2.4. Age-dependent IOP elevation is associated with decreased CTB uptake and intra-
retinal transport by RGCs. (A-D) Representative confocal micrographs (60X) of CTB labeling 
(red) in whole-mount retina from young (4mo) C57 (A), aging (8mo) C57 (B), young DBA/2J 
(C) and aging DBA/2J (D) mice. In accordance with eccentricity-dependent RGC soma and axon 
density, CTB intensity is higher in central regions of young C57, aging C57, and young DBA 
retina than peripheral regions (A-C). Aging DBA/2J retina exhibit decreased CTB intensity in 
both central and peripheral regions of the retina (D). Scale bar represents 20μM and is applicable 
to all images. (E) Graphical representation of mean CTB intensity across all retinal areas in 
young (4mo; white) and aging (8mo; gray) C57 and DBA/2J retina shows a significant decrease 
in CTB uptake in aging DBA (p<0.001, Mann-Whitey RANK Sum Test), but not aging C57 
(p=0.093, Mann-Whitey RANK Sum Test), when compared to young DBA/2J and young C57, 
respectively. Dashed line indicates median value. * = p<0.001. 
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To determine whether spatial variations in sIL-6Rα corresponded to spatial differences in 
RGC integrity, we examined spatial coincidence of sIL-6Rα localization and degree of CTB 
labeling intensity in the ganglion cell/nerve fiber layer of whole-mounted retina from young and 
aging DBA/2J mice. In young DBA/2J mice, images from central retina, and thus higher CTB 
intensity, tended to display higher co-localization scores for M20 and CD126 (Figure 2.5A). 
Correspondingly, images from peripheral retina, and thus lower CTB intensity, represented the 
lowest co-localization scores in this group (Figure 2.5A). As reported above, co-localization of 
M20 and CD126 was generally less appreciable in aging DBA/2J retina than in young DBA 
retina (Figure 2.5B). Within this shifted range of co-localization scores, images with low M20 
and CD126 co-localization scores corresponded to lower CTB intensity and vice versa, 
regardless of eccentricity (Figure 2.5C). This was confirmed by Pearson correlation analysis, 
which indicated no significant relationship between the M20-CD126 co-localization score and 
CTB labeling intensity in young DBA/2J mice (R
2
=0.406, p=0.07; Figure 2.5C), but a significant 
and positive correlation in aging DBA/2J mice (R
2
=0.668, p<0.01; Figure 2.5C).  
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Figure 2.5. sIL-6Rα is primarily associated with RGCs exhibiting poor CTB uptake and 
transport. (A,B) Representative confocal micrographs (60X) of CTB labeling (top; red) and 
CD126 (red) and M20 (green) co-immunolabeling (bottom) in whole-mount retina from young 
(4mo) (A) and aging (8mo) (B) DBA/2J mice. Co-localization of CD126 and M20 
immunolabeling is greatest in areas with robust CTB labeling for both young and aging DBA/2J 
retina. This effect is eccentricity-dependent in young mice (A), but eccentricity-independent in 
aging DBA/2J mice (B). Scale bar represents 20μM and is applicable to all images. (C) Scatter 
plot depicting CD126/M20 co-localization grading as a function of CTB labeling intensity in 
each image of whole-mount retina from young (4mo; white) and aging (8mo; gray) DBA/2J 
mice. Numbers next to data points correspond to the representative images in (A,B). Pearson 
correlation analysis indicated no significant relationship between the M20-CD126 co-
localization score and CTB labeling intensity in young DBA/2J mice (R
2
=0.406, p=0.07), but a 
significant and positive correlation in aging DBA/2J mice (R
2
=0.668, p<0.01). 
______________________________________________________________________________ 
Gp130 expression is not a reliable predictor of RGC integrity 
 While increased production of sIL-6Rα can influence the impact of IL-6 signaling, both 
sIL-6Rα and mIL-6Rα require gp130 to initiate an IL-6 dependent signaling cascade (Scheller et 
al., 2011a). Therefore, significant changes in gp130 protein expression within RGCs could 
influence the effect of increased sIL-6Rα localization to RGCs. To address this caveat, we 
measured gp130 fluorescent signal and CTB signal from the ganglion cell and nerve fiber layers 
of whole-mount retina in another cohort of young and aging DBA/2J mice. Similar to our 
biochemical data from whole retina (Figure 2.1B), there was no age-dependent difference in 
gp130 fluorescent intensity within the GCL/NFL layer of the DBA/2J retina (Figure 2.6A). In 
respect to CTB intensity within RGCs, the average CTB intensity was significantly decreased in 
the aging DBA/2J (p<0.05; Figure 2.6A), putting it in line with our CTB intensity measurements 
from the IL-6Rα cohort (Figure 2.4E). To determine if differences in gp130 intensity spatially 
corresponded with changes in CTB intensity, we plotted CTB intensity measurements as a 
function of gp130 intensity measurements from both young and aging DBA/2J retina. 
Interestingly, we observed a slight negative relationship between gp130 intensity and CTB 
intensity in young DBA/2J mice, where areas containing higher CTB intensity presented with 
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relatively lower gp130 intensity. However, Pearson correlation analysis indicated no significant 
relationship between gp130 and CTB intensity (R
2
=-0.265, p=0.143; Figure 2.6C). In aging 
DBA/2J mice, no observed or calculated relationship was present (R
2
=-0.0525, p=0.803; Figure 
2.6D). 
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Figure 2.6. No significant relationship between gp130 expression and CTB uptake of RGCs. (A-
B) Quantification of fluorescent intensity of gp130 signal (A) and CTB uptake (B) in the 
ganglion cell and nerve fiber layers of mid central to mid peripheral regions of whole-mounted 
retina from young (4mo; white) and aging (8mo; DBA/2J) DBA/2J mice. No significant 
difference in gp130 intensity was noted between age groups (p=0.330, student’s t-test; A). 
Similar to the IL-6Rα cohort, this cohort of 8mo DBA/2J showed significantly less CTB 
intensity within RGCs (p<0.05; student’s t-test; B). (C-D) Scatter plots depicting gp130 labeling 
intensity as a function of CTB labeling intensity in each image of whole-mount retina from 
young (4mo; C) and aging (8mo; D) DBA/2J mice. Pearson correlation analysis indicated no 
significant relationship between gp130 intensity and CTB labeling intensity in 4mo DBA/2J 
mice (R
2
=-0.265, p=0.143) or 8mo DBA/2J mice (R
2
=-0.0525, p=0.803). *=p<0.05. 
 
Parts of this figure are adapted from (Echevarria et al., 2013) and used in accordance with the 
Creative Commons Attribution-Non Commercial 4.0 International License. 
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Discussion 
Chronic neuroinflammation is a recognized component of age-related neurodegenerative 
disease, including glaucoma (Soto and Howell, 2014, Deleidi et al., 2015, Williams et al., 2017).  
Previous studies show that the cytokine IL-6 is elevated in response to glaucoma related stressors 
(Sappington et al., 2006, Cvenkel et al., 2010, Johnson et al., 2011, Chidlow et al., 2012, Sims et 
al., 2012). In other areas of the CNS, IL-6 mediated activation of gp130 via its soluble isoform is 
associated with neurodegeneration (Burton et al., 2011, Burton and Johnson, 2012, Burton et al., 
2013, Campbell et al., 2014). We previously reported that spatial variability of IL-6 and IL-6Rα 
in the retina increases in response to glaucoma-related stressors (Sims et al., 2012). Here, we 
follow up on that study by measuring changes in gp130 protein concentration and IL-6Rα 
isoform demographics induced by aging and IOP. Overall, we provide evidence that the shift in 
IL-6Rα isoform towards increased sIL-6Rα may be relevant for declining RGC integrity in 
glaucomatous retina. 
Our biochemical analysis of gp130 revealed that normal aging (C57 mice) led to 
significant increases of retinal gp130, while aging coupled with IOP elevation (DBA/2J mice) 
trended towards a decrease (Figure 2.1). The latter finding is in contrast with another study in the 
retina, showing increased gp130 protein levels up to 48 hours following NMDA exposure 
(Inomata et al., 2003). This raises the possibility that gp130-mediated signaling is induced early 
following acute injury, but is downregulated with chronic insults, such as IOP-induced 
glaucoma. As gp130 is required for IL-6 mediated signaling, changes in gp130 availability can 
influence the magnitude of a cell’s response to IL-6. In regards to IL-6Rα, elevated sIL-6Rα 
production occurred with normal aging (aging C57 mice) and aging plus elevated IOP (aging 
DBA/2J mice) (Figure 2.1). This demonstrates that aging alone is sufficient to shift IL-6Rα 
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demographics towards the sIL-6Rα isoform and that this age-related shift remains with the 
introduction of elevated IOP. A shift in the sIL-6Rα isoform indicates a reciprocal shift away 
from mIL-6Rα-mediated classical signaling and towards sIL-6Rα-mediated trans-signaling. As 
such, these data suggest that glaucoma-related stressors promote IL-6 signaling through the 
trans-signaling mechanism.   
RGCs are the principal cell types that undergo degeneration in glaucoma. In delineating 
how induction of IL-6 trans-signaling may relate to RGC degeneration in glaucoma, two factors 
are of particular importance: when and where. These two factors are important with respect to 
both RGC degeneration and IL-6 signaling. IL-6, IL-6Rα and gp130 are constitutively expressed 
by RGCs (Sims et al., 2012) (Figure 2.1) and thus, are sensitive to IL-6 mediated signaling. We 
previously reported that  glaucoma-induced changes in IL-6 signaling are not uniform across the 
retina, but instead occur in smaller micro-domains such that, a glaucomatous retina contains 
areas of both enhanced and reduced IL-6 signaling (Sims et al., 2012). Similarly, indicators of 
RGC degeneration also exhibit spatial patterning, where pockets of dysfunction and degeneration 
are evident in a single subject (Crish et al., 2010, Lambert et al., 2011, Formichella et al., 2014, 
Ward et al., 2014). The temporal pattern is also relevant for RGC degeneration which progresses 
from functional deficits to structural degeneration over time (Buckingham et al., 2008, Crish et 
al., 2010, Calkins and Horner, 2012) 
Although our data cannot address all of the “when” and “where” components empirically, 
we can draw some reasonable conclusions that speak to these factors. Using a dual-labeling 
histological approach, we examined the spatial localization of sIL-6Rα relative to mIL-6Rα and 
correlated the localization pattern with uptake and intra-retinal transport of the neural tracer 
CTB. First, we validated our dual-labeling approach with LPS, which is well-known to induce 
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sIL-6Rα production and IL-6 trans-signaling (de Vos et al., 1994, Mo and Streilein, 2001, 
Rosenbaum et al., 2011) (Figure 2.2). Consistent with our biochemical data, we found that mIL-
6Rα, as identified by co-localization of our antibodies targeting the C- and N-terminals of IL-
6Rα, was predominant and distributed rather uniformly in retina from young (4mo) DBA/2J 
mice (Figure 2.3). In contrast, retina from aging (8mo) DBA/2J mice exhibited an overall 
decrease in co-localization between the two antibodies and numerous regions with clear 
separation of labeling, indicating the presence of sIL-6Rα. Again, this corresponded well with 
our biochemical data (Figure 2.3). Upon examination of spatially-coincident CTB tracing, we 
found that areas of aging DBA/2J retina with low CTB intensity contained primarily the sIL-6Rα 
isoform. Likewise, areas with higher CTB intensity contained a mix of sIL-6Rα and mIL-6Rα. 
This positive correlation between mIL-6Rα (co-localization) and RGC integrity, as measured by 
CTB uptake and intra-retinal transport, was highly significant (Figure 2.5).  
Throughout CNS and the periphery, it is believed that gp130 protein concentration is 
higher than that of IL-6Rα (Zhao et al., 2008, Erta et al., 2012, Hsu et al., 2015). This suggests 
that the release of sIL-6Rα increases the propensity for IL-6 signaling events to occur in domains 
where IL-6 is released. That being said, the amount of available gp130 at any given time is the 
final indicator of how IL-6 signaling impacts the system. Similar to our measurements in whole 
retina, our measurements within the area where RGCs reside suggest no changes in gp130 
protein content in response to age-related increases in IOP (Figure 2.6). Additionally, unlike sIL-
6Rα localization data, decreases in CTB intensity did not correlate to gp130 intensity (Figure 
2.6). This suggests that: 1) changes in gp130 are not reliable indicators of RGC integrity in the 
DBA/2J mouse and 2) sensitivity to IL-6 signaling in the DBA/2J model of glaucoma is 
facilitated by sIL-6Rα production and not by gp130. 
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In the context of the known progression of CTB transport deficits in DBA/2J mice (Crish 
et al., 2010, Formichella et al., 2014, Bond et al., 2016), we can infer a temporal relationship 
between induction of IL-6 trans-signaling and progression of RGC degeneration. The highest 
values for CTB labeling represented detectable signal in both the RGC soma and the 
unmyelinated segment of the RGC axon. The lowest values for CTB labeling represented 
detectable signal only in the soma (Figures 2.4 and 2.5). Based on these data, we propose that the 
shift from IL-6 classical signaling to IL-6 trans-signaling is likely to occur near the mid-point in 
disease progression, well after the onset of functional deficits (i.e. axon transport) in RGC axons, 
but prior to structural degeneration of the RGC axon.  
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CHAPTER 3 
 
IL-6 DEFICIENCY ATTENUATES RGC AXONOPATHY  
AND GLAUCOMA RELATED- VISION LOSS
3 
 
Introduction
 
IL-6 signaling is associated with a variety of CNS pathologies including RGC 
degeneration in glaucoma (Chen et al., 1999, Ghanem et al., 2011, Erta et al., 2012, Sims et al., 
2012). In the previous chapter, we showed that the soluble isoform of IL-6Rα, a marker of 
pathogenic IL-6 trans-signaling, is upregulated in RGCs compromised by glaucoma related 
stressors (Chapter 2). While this provides additional evidence of the association between IL-6 
signaling and glaucoma, it does not elaborate on the direct contribution of IL-6 signaling to RGC 
pathology. Elsewhere in the CNS, its classification as either protective or destructive to neuronal 
populations continues to be highly contested. In support of the idea that IL-6 signaling is 
protective, pre-treatment of various neurons with IL-6 in vitro prevents apoptosis in neural cells 
exposed to a number of physiological stressors (Yamada and Hatanaka, 1994, Pavelko et al., 
2003, Sappington et al., 2006, Spittau et al., 2012, Fang et al., 2013, Perigolo-Vicente et al., 
2013, Chucair-Elliott et al., 2014). In vivo however, the effect of IL-6 on neuronal health is 
variable, as studies suggest that IL-6 signaling promotes both viability and dysfunction 
(Campbell et al., 1993, Bluthe et al., 2000, Fisher et al., 2001, Sparkman et al., 2006, Mukaino et 
al., 2010, Burton et al., 2011, Burton and Johnson, 2012, Burton et al., 2013) 
 
_______________________________________
 
3 
Portions of this chapter were published as: Echevarria et al., (2017) Interleukin-6 Deficiency 
Attenuates Retinal Ganglion Cell Axonopathy and Glaucoma-related Vision Loss. Front. Neuro. 
11:318 
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depending on the model of CNS injury. In the optic projection, IL-6 protein is upregulated near 
retinal ganglion cells (RGCs) and their axons in rodent models of glaucoma (Sappington and 
Calkins, 2008, Chidlow et al., 2012, Sims et al., 2012, Wilson et al., 2015). Like elsewhere in the 
CNS, the role of IL-6 in RGC axonopathy is unclear. Application of recombinant IL-6 to RGCs 
in vitro prevents pressure-induced apoptosis (Sappington et al., 2006). In vivo, while IL-6 
appears to protect RGCs and enhance axon regeneration following optic nerve crush in some 
studies (Leibinger et al., 2013, Leibinger et al., 2016), other studies indicate that IL-6 deficiency 
protects against RGC loss in response to glutamate excitotoxicity and optic nerve crush (Fisher et 
al., 2001).    
While there are advantages to using glaucoma model systems that involve a more acute, 
severe injury such elevated hydrostatic pressure in vitro or optic nerve crush in vivo, they don’t 
accurately model the modest, chronic stress that is consistent with IOP elevation in human 
glaucoma. To better elucidate the impact of IL-6 signaling on RGC axonopathy in response to 
ocular hypertension, we comprehensively examined and compared optic nerve morphology, 
visual acuity, active axonal transport and retinal glial reactivity in IL-6 deficient (Il-6-/-) and 
wildtype (WT) mice following 8 weeks of ocular hypertension using the microbead occlusion 
model of glaucoma (Sappington et al., 2010). Together, our data indicates that IL-6 deficiency 
prevents glaucoma-induced deficits in visual function and optic nerve structure without 
improvement in axon transport or reduction in microglia reactivity. This suggests that IL-6 may 
play specific role in the progression of RGC axonopathy from functional deficits to structural 
degeneration.    
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Materials and Methods 
Animals 
7-9 month old male and female Il-6-/- mice (B6;129S2-IL6
tm1kopf
/J) and respective 
genomic controls (B6;129SF2/J) were used for all experiments. Il-6-/- mice contain a neomycin 
selection cassette in exon 2 of the Il-6 gene preventing transcription of the mRNA product (Kopf 
et al., 1994). Founder mice were obtained from Jackson Laboratories (Bar Harbor, ME) and 
experimental mice were bred and genotyped in-house using the following primers provided by 
Jackson Labs: 5’-TTC-CAT-CCA-GTT-GCC-TTC-TTG-G-3’, 5’-TTC-TCA-TTT-CCA-CGA-
TTT-CCC-AG-3’ and 5’-CCG-GAG-AAC-CTG-CGT-GCA-ATC-C-3’. Mice were housed in 
accordance with NIH guidelines and maintained on a 12hr light/dark cycle with ad libitum access 
to standard mouse chow and water. This study was carried out in accordance with the ARVO 
statement for the use of animals in ophthalmic and vision research and was approved by the 
IACUC of Vanderbilt University Medical Center. 
 
Induction of ocular hypertension using the microbead occlusion model 
Acute IOP elevation was induced in WT and Il-6-/- mice using the microbead occlusion 
model, as previously described (Sappington et al., 2010) (Figure 3.1). For anterograde axonal 
transport, axon density measurements and retinal gliosis, a cohort of 5-6 mice from both 
genotypes received a unilateral injection of 1.5μl (1×106 microbeads/mL) of 15μm polystyrene 
beads conjugated to an Alexa Fluor 488 chromophore. The contralateral eye served as a surgical 
control and was injected with an equal volume of saline. For experiments looking at visual acuity 
and corneal thickness, 7-11 mice from both genotypes received bilateral injections of 1.5μl 
microbeads and a separate cohort of mice served as controls and received bilateral injections of 
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an equivalent volume of saline. All mice received two microbead/saline injections 4 weeks apart 
to raise IOP for a total of 8 weeks. Following IOP elevation, mice were euthanized and perfused 
as previously described (Chapter 2). Eye and brain tissue were stored in 4% PFA at 4°C until 
use. 
 
Figure 3.1. Induction of ocular hypertension by microbead induced occlusion of aqueous humor 
outflow. 15μm polysterene microbeads are injected into the anterior chamber with a glass pipette 
(top right). Over a period of 24 hours, the beads settle and accumulate at the iridocorneal angle 
(bottom), blocking aqueous humor from draining through the trabecular meshwork in Schlemm’s 
canal.  
_____________________________________________________________________________ 
 
IOP measurements 
IOP was measured in awake, behaving mice, using a Tonolab rebound tonometer 
(TonoLab; Reichert, Depew, NY), as previously described (Echevarria et al., 2013; Formichella 
et al., 2014; Echevarria et al., 2016). Prior to initial injection, mean baseline IOP for each mouse 
was calculated from approximately 60 individual readings taken over a period of 6 days (10 
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measurements/day) within a two week timeline. Following microbead or saline injections, 
weekly IOP was determined as the mean of 20-30 measurements, taken over 2-3 days (10 
measurements/day) each week for a total of 8 weeks. IOP measurements were taken at the same 
time of day to remove any effect of circadian rhythm on IOP measurements. To avoid corneal 
irritation and discomfort, 0.5% proparacaine anesthetic drops (Akorn Inc, Lake Forest, IL) and 
lubricating eye drops were applied to each eye before and after IOP measurements were taken 
respectively.   
 
Immunohistochemistry 
Fixed whole-mounted retinas were bisected and processed for either astrocyte or 
microglia labeling as previously described (Sappington et al., 2009, Crish et al., 2010, Echevarria 
et al., 2013, Echevarria et al., 2016). We used primary antibodies against glial fibrillary acidic 
protein (GFAP, 1:500; Cat# Z033429-2; DAKO) to label astrocytes and ionized calcium-binding 
adapter molecule-1 (Iba-1, 1:250; Cat# 019-19741; WAKO) to label microglia. Secondary 
antibodies were used at a concentration of 1:200 and consisted of donkey α-rabbit attached to a 
Rhodamine Red-X fluorophore (Cat# 711-295-152; Jackson Immuno Labs). 
 
Quantification of glial coverage 
GFAP or Iba1 labeling in fixed, whole-mount retina were imaged at 60X using an 
inverted confocal microscope (Olympus FV-1000; Center Valley, PA) through the Vanderbilt 
University Medical Center Cell Imaging Shared Resource Core. 7-9 pseudo-random z-stack 
images in the mid central/mid-peripheral areas through the ganglion cell (GCL) and nerve fiber 
layers (NFL) of the retina were acquired using a digital camera and image analysis software (FV-
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100 ASW; Olympus). GFAP and Iba1 percent area was calculated using NIS elements AR 
software (Nikon Instruments, Melville, NY). The area (mm
2
) of the image containing above 
background signal intensity of Iba1 or GFAP was calculated and reported as a percentage of the 
total area of the image. Total area of each image and background signal threshold was equal 
among all images. Microglia cell density was calculated by counting the number of Iba1 positive 
cell soma and dividing the counts by the area of the image.  
 
Anterograde axon transport measurements 
Anterograde axonal transport capabilities of RGCs were assessed with cholera toxin beta-
subunit (CTB) conjugated to a 488 fluorophore. Briefly, mice were given a 1.5-2µl intravitreal 
injection of CTB (10μg/µl in sterile ddH2O; Cat# C-34775, Life Technologies) using a 33 gauge 
needle attached to a Hamilton syringe under 2.5% isoflurane anesthesia. Five days after CTB 
injection, mice were euthanized with pentobarbital and perfused trans-cardially with 100ml of 
1X PBS (Sigma Aldrich, St. Louis, MO) followed by 100ml of 4% paraformaldehyde (PFA; 
Electron Microscopy Sciences, Hatfield, PA). To quantify axon transport, whole brains were 
cryopreserved in 30% sucrose for 24-48 hours at 4°C. Using a sliding microtome, 50µm sections 
were obtained through the superior colliculus (SC). CTB signal in these sections was imaged en 
montage at 10X, using a Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, 
NY). Anterograde axonal transport was quantified as previously described (Crish et al., 2010) 
(Figure 3.2). Briefly, the SC from each image was outlined and CTB signal above background 
was divided by total pixel area to determine the volume of SC with CTB labeling. This value was 
used to create a colorimetric 2D retinotopic map of CTB transport ranging from 0% (blue) and 
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100% (red). Intact transport was defined as percent area with CTB signal > 70% density 
(red/yellow).  
 
 
Figure 3.2. RGC to SC CTB transport measurements and resulting retinotopic map. (A) Images 
of serial brain sections through the SC with CTB signal (red) are arraigned in a rostral to caudal 
fashion (A1). Images are run through a custom macro where the SC is traced manually (A2). (B) 
The macro then calculates the average pixel intensity along each row of pixels (graphs). These 
measurements are then run through a second macro where each row is converted into a 
colometric label (below graphs in B) and then lined up rostral to caudal to reconstruct the 
retinotopic map of CTB transport in the SC. Intensity measurements 70% above background are 
represented as warmer colors (red/yellow) and indicate intact transport. Anything below 70% is 
represented as cooler colors (green/blue) and indicates transport deficits.  
 
Image graciously provided by DJ Calkins and modified with his permission to fit the needs of 
this thesis. 
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Quantification of axon density and optic nerve area 
Axon density was measured in semi-thin sections of optic nerve, as previously described 
(Sappington et al., 2010, Ward et al., 2014). Briefly, optic nerves were post fixed at least 48 
hours in 2.5% glutaraldehyde and embedded in epon. Semi-thin (700nm) cross-sections of optic 
nerve near the chiasm were stained with 1% p-Phenylenediamine (PPD) and 1% toluidine blue to 
highlight myelin and glia, respectively. Optic nerve cross-sections were imaged en montage at 
100X magnification on an upright Olympus Provis AX (Olympus, Melville, NY) microscope. To 
calculate axon density, a 50x50μm grid mask was placed on the montaged image using NIS 
elements AR software and the number of axons was manually counted by a blind-observer in 8-
10 squares of the grid. Each square counted was equal in area (0.0025 mm
2
). To measure nerve 
area, the circumference of the entire nerve was traced in montaged images of optic nerve cross-
sections. Nerve area was calculated as the area (mm
2
) within this outline, using NIS elements 
software.   
 
Psychophysical visual testing  
The optokinetic response is a naturally occurring reflex that serves as a functional tool for 
quantitative analyses of visual system function in mice (Douglas et al., 2005). Briefly, each 
mouse was placed on a platform surrounded by four LCD computer monitors. A sinusoidal 
grating of alternating white and black bars rotating in either a clock-wise or counter clock-wise 
fashion was projected on the monitors. Mice able to perceive the moving stimulus produced a 
reflexive movement of the head in the direction of the stimulus. The visual acuity of each mouse 
was measured by changing the spatial frequency of the black and white bars. The visual acuity 
threshold was determined as the highest spatial frequency for which reflexive tracking was 
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noted.  The presence of the reflexive head movement was recorded by an observer using a 
camera mounted above the mouse.  Mice were tested for baseline visual acuity threshold 1-2 
weeks before microbead/saline injection and 4 and 8 weeks post-initial microbead/saline 
injection. 
 
Corneal imaging using Spectral Domain Optical Coherence Tomography (SD-OCT) and 
quantification of corneal thickness 
Mice were anesthetized with a ketamine/xylazine cocktail (80 µg/5 µg/gram of mouse), 
pupils were dilated with 0.5% Tropicamide and eyes lubricated with tear drops. Live volumetric 
scans of the cornea were obtained using SD-OCT running the Bioptogen ultra-high resolution 
spectral domain OCT system with cornea bore (Bioptogen, Morrisville, NC). Quantification of 
injury area was done using Image J software (National Institute of Health). 
 
Statistical analysis 
Statistical analysis was conducted with SigmaPlot Version 11.1 (Systat Software Inc, San 
Jose, CA). For baseline and delta baseline IOP comparisons between WT and Il-6-/-, a Mann-
Whitney Rank Sum test and a One-Way ANOVA with Holm-Sidak post-hoc correction was 
done respectively. For post injection IOP comparisons, a One-Way ANOVA on RANKS with 
Dunn’s post hoc correction was done. For corneal wound area measurements, a two-tailed t-test 
was done between WT and Il-6-/- mice at each time point. Differences in visual acuity 
throughout the 8 week experimental time course were assessed with a One-Way Repeated 
Measures ANOVA between baseline visual acuity, acuity at 4 weeks post initial injection and 8 
weeks post initial injection within each experimental group. Differences between all 
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experimental groups at each time point were assessed with a One-Way ANOVA with Holm-
Sidak post-hoc correction. Differences in percent baseline visual acuity at 8 weeks between all 
experimental groups were assessed with a One-Way ANOVA on RANKS with Dunn’s post hoc 
correction. All other comparisons were made with a One-Way ANOVA on RANKS with Dunn’s 
post hoc correction (percent glia coverage, microglia cell density) or a One-Way ANOVA with 
Holm-Sidak post-hoc correction (SC transport, axon density/nerve area). For all, p-values less 
than 0.05 were considered statistically significant. 
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Results 
IL-6 deficiency does not affect microbead-induced elevations in IOP     
To examine the impact of IL-6 deficiency on the progression of IOP-induced RGC 
neurodegeneration, we utilized the microbead occlusion model (Sappington et al., 2010) of 
glaucoma to elevate IOP for a total of 8 weeks in WT and Il-6-/- mice. Baseline IOP was slightly 
lower (4%) in Il-6-/- mice, compared to WT mice (p<0.01; Figure 3.3A; left). Microbead 
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Figure 3.3. IL-6 deficiency does not affect magnitude and duration of microbead induced ocular 
hypertension. (A; left) Boxplot of baseline (BL) IOP of WT (white) and Il-6-/- (gray) mice from 
all experimental cohorts prior to microbead/saline injection. Baseline IOP of Il-6-/- mice is 
decreased by 4% compared to baseline IOP of WT mice. (A; right) Line plot (mean + SEM) 
showing baseline and weekly post saline (circle) or microbead (diamond) IOP in WT (white) or 
Il-6-/- (gray) eyes. Arrows indicate time of saline/microbead injections. Throughout the 8 week 
experiment, microbead injected eyes from both WT and Il-6-/- show a 15-20% increase in IOP 
compared to baseline measurements and saline injected eyes. (B) Bar graph of average IOPs 
(mean + SEM) taken post initial microbead (gray) or saline (white) injection in WT and Il-6-/- 
mice. A significant IOP increase in microbead- injected eyes versus saline- injected eyes is seen 
in both genotypes. A genotype specific IOP reduction is seen in both saline- and microbead- 
injected Il-6-/- mice. (C) Boxplot showing magnitude of IOP difference in saline (white) and 
microbead (gray) injected WT and Il-6-/- mice compared to baseline measurements. A 
significant elevation in IOP is present in microbead- injected eyes compared to saline- injected 
eyes in both genotypes. However, no genotype specific differences in IOP seen. *=p<0.05. n=26-
34 eyes/genotype/condition. Dashed lines in box plot indicate median value.  
 
Figure from (Echevarria et al., 2017) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
 
injection increased IOP by 15-20%, as compared to saline-injected controls for both genotypes 
(WT; p<0.001, Il-6-/-; p<0.001, Figure 3.3A; right and Figure 3.3B). In accordance with baseline 
IOP measurements, the mean IOP (mmHg) for both saline- (p<0.05) and microbead-injected 
(p<0.05) was lower in Il-6-/- mice than their WT counterparts (Figure 3.3B). However, with 
respect to baseline IOP, the magnitude of IOP elevation was similar (~2.5 mmHg) in microbead-
injected WT and Il-6-/- mice (p>0.05, Figure 3.3C). 
 
Il-6-/- mice exhibit deficits in corneal wound healing 
Previous studies indicate Il-6-/- mice exhibit deficits in wound healing (Lin et al., 2003b, 
McFarland-Mancini et al., 2010). As the microbead/saline injections require puncturing of the 
cornea, we used spectral-domain optical coherence tomography (SD-OCT) imaging to monitor 
corneal healing throughout the 8 week experiment. Two weeks following intra-cameral injection 
of saline or microbeads in WT eyes, SD-OCT imaging revealed complete healing of the 
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epithelial layer and near complete healing of the stroma and endothelial layers at the injection 
site (Figure 3.4A). In Il-6-/- mice, the corneal wound appeared to heal at the epithelial surface, 
but the wound remained in the stroma and endothelial layers even at 8 weeks post injection 
(Figure 3.4B). Quantification of corneal injury revealed that the corneal wound was 2-fold larger 
in Il-6-/- mice than in WT mice throughout the 8 week experiment (p<0.05; Figure 3.4C).  
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Figure 3.4. Il-6-/- mice present with defects in corneal wound healing following microbead/ 
saline injection. (A) Representative images of corneal wounds at 2, 4 and 8 weeks post initial 
injection in WT mice. Insert (A; far left) outlines layers of the cornea. 2 weeks after corneal 
puncture due to saline or microbead delivery, WT mice left display small gaps in the corneal 
stroma and endothelium (yellow dotted lines). The size of the injury persists after 4 (middle) and 
8 (right) weeks after injury. (B) Representative images of corneal wounds at 2, 4 and 8 weeks 
post injection in Il-6-/- mice. Il-6-/- mice however, present with significantly larger gaps 2 weeks 
(left)  in the corneal stroma after puncture that also persists at 4 (middle) and 8 (right) weeks 
after injury. (C) Bar graph showing quantification of corneal injury area (mean + STDEV). Il-6-
/- mice have significantly larger corneal injuries at all time points. *=p<0.05. n=9 
eyes/genotype/group. Scale bars= 100μm for all images.  
 
Figure from (Echevarria et al., 2017) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
_____________________________________________________________________________ 
 
IL-6 deficiency does not prevent IOP-induced deficits in anterograde axon transport 
Previous reports indicate that functional deficits in anterograde axon transport along the 
optic projection precede structural degeneration of RGC axons in glaucoma (Crish et al., 2010, 
Crish et al., 2013). To measure and compare active anterograde transport in RGC axons, we 
injected the active uptake, active transport tracer cholera toxin beta subunit (CTB) into the 
vitreous of Il-6-/- and WT mice 8 weeks after the initial microbead or saline injection. We 
measured anterograde transport of CTB from RGC soma in the retina to RGC terminals in the 
superior colliculus (SC) by quantifying CTB labeling in serial sections of SC and generating 2D 
reconstructions of CTB labeling in the SC. In WT mice, 8 weeks of elevated IOP led to a ~50% 
decrease in CTB transport to the SC, as compared to saline-injected mice (p<0.001, Figure 3.5C; 
left). Interestingly, in Il-6-/- mice, IOP elevation also resulted in a ~50% decrease in CTB 
transport (p<0.001, Figure 3.5C; right). Similar to previously published studies (Crish et al., 
2010, Lambert et al., 2011, Ward et al., 2014), these deficits occurred in a sectoral manner, 
extending from the periphery towards the optic disc in WT and Il-6-/- mice (Figure 3.5A-B). No 
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differences in axon transport were noted between genotype in saline-injected animals (p>0.05, 
Figure 3.5C). 
     
 
Figure 3.5. IL-6 deficiency does not affect CTB transport deficits caused by elevated IOP. (A-B) 
Representative coronal sections through the superior colliculus (SC) and respective retinotopic 
heat maps after 5 days of CTB transport in WT (A) and (B) Il-6-/- mice. Outlines in coronal 
sections indicate areas of transport deficits. Dashed lines in map indicate position of coronal 
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section. Density of the CTΒ signal for heat maps range from 0% (blue) to 50% (green) to 70% 
(yellow) to 100% (red). Numbered, dashed lines in retinotopic maps indicate the location of 
respective coronal section and white circles indicate position of the optic disk (OD). Medial (M) 
and rostral (R) orientations are indicated. (C) Bar graph showing average percent intact transport 
(mean + STDEV, >70% density of CTB signal; red/yellow areas) from SC following saline 
(white) or microbead (gray) injection in WT (left) and Il-6-/- (right) mice. SC from both 
microbead- injected WT and Il-6-/- mice show a ~50% deficit in intact axon transport compared 
to saline- injected mice. *=p<0.05. n=5-6 SC/genotype/condition. Scale bars= 500μm for all 
images.  
 
Figure from (Echevarria et al., 2017) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
 
IL-6 deficiency preserves optic nerve structure following IOP elevation 
In glaucoma, degeneration of the optic nerve starts at the distal end of the optic nerve and 
progresses in a distal to proximal fashion (Crish et al., 2010). Therefore, we focused our 
examination of optic nerve axons to the distal half of the optic nerve closest to the chiasm. 
Unlike the distal optic nerve of saline-injected WT mice (Figure 3.6A; top), the distal optic nerve 
of microbead-injected WT mice presented with signs of structural pathology, including increased 
glial infiltration and degenerating axon profiles (Figure 3.6A; bottom). This was accompanied by 
a slight enlargement in nerve area (Figure 3.6C; left) and a 15% decrease in myelinated axon 
density, as compared to saline-injected mice (p<0.05, Figure 3.6; left). In contrast, while distal 
optic nerves from microbead-injected Il-6-/- mice presented with some gliosis, no change in 
degenerating axon profiles were noted (Figure 3.6B). Similarly, there were no measurable 
changes either in nerve area (Figure 3.6D; right) or myelinated axon density (p>0.05, Figure 
3.6C; right), as compared to saline-injected Il-6-/- mice. However, independent of IOP, optic 
nerves from Il-6-/- mice contained approximately ~15% fewer RGC axons than those from WT 
mice (p<0.05, Figure 3.6C). 
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Figure 3.6. IL-6 ablation mitigates axonopathy caused by IOP elevation. (A-B) Representative 
100X montaged optic nerve cross sections from WT (A) and Il-6-/- (B) optic nerves following 
saline (top) or microbead (bottom) injection. Black box in montaged image (left) corresponds to 
location of zoomed images highlighting axon and glia (right). IOP elevation results in increased 
glial infilatration (black arrows) and degenerative axon profiles (white arrow heads) in optic 
nerves from microbead injected WT, but not Il-6-/- mice. (C) Bar graph of average (mean + 
STDEV) myelinated axon density measurements in WT and Il-6-/- mice following saline (white) 
or microbead (gray) injection. Saline- injected Il-6-/- mice show a genotype specific decrease in 
myelinated axon density compared to saline- injected WT mice. However, microbead- injected 
WT eyes show a significant 15% decrease in myelinated axon density compared to saline- 
injected WT eyes, while no difference is seen between microbead- and saline- injected Il-6-/- 
eyes. (D) Bar graph of average nerve area (mean + STDEV) among groups shows no significant 
difference. *=p<0.05. n=40-50 density measurements/genotype/group. Scale bars= 50μm for 
100X montaged optic nerves and 10μm for zoomed images.  
 
Figure from (Echevarria et al., 2017) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
 
IL-6 deficiency preserves visual acuity following IOP elevation 
Loss of vision in glaucoma is irreversible and is caused by degeneration of RGC axons 
(Calkins, 2012). To determine whether the axon degeneration seen in our cohort was sufficient to 
induce deficits in visual acuity threshold, we performed bilateral injections of microbeads in one 
cohort of WT and Il-6-/- mice. A second cohort received bilateral injections of saline. We 
measured visual acuity by optomotry every four weeks for the duration of the experiment. Over 
the course of 8 weeks, microbead-injected WT mice exhibited significant depreciation of visual  
acuity at each time point compared to baseline, resulting in an overall 22% decrease in visual 
acuity (p<0.001 for all, Figure 3.7A; gray). However, in saline-injected WT mice, visual acuity 
did not significantly differ from baseline at either time point (p>0.05, Figure 3.7A; white). 
Comparison of visual acuity between saline- and microbead-injected WT mice revealed a 
significant ~15% decrease in both raw visual acuity (p<0.05, Figure 3.7C) and percent baseline 
visual acuity (p<0.05, Figure 3.7D). In Il-6-/- mice, visual acuity dropped 8% with either saline 
(p<0.01) or microbeads (p<0.05), as compared to baseline acuity (Figure 3.7B). However, this 
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initial reduction in visual acuity did not differ between saline- and microbead-injected Il-6-/- 
mice (p>0.05, Figure 3.7C,D) and remained unchanged between 4 and 8 weeks for both groups 
(saline: p>0.05; microbead: p>0.05; Figure 3.7B). That this slight decrease in visual acuity was 
noted in both saline- and microbead-injected Il-6-/- mice and remained stable for the 8 week 
experiments suggest that it is likely due to the observed deficits in corneal wound healing (Figure 
3.4). No difference in visual acuity was noted between WT and Il-6-/- mice at any time point 
(p>0.05, Figure 3.7C).  
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Figure 3.7. Il-6-/- mice are resistant to IOP-induced deficits in visual acuity. (A) Bar graph 
showing average visual acuity threshold (mean + SEM) of WT mice at baseline (BL) and 4 and 8 
weeks post initial saline (white) or microbead (gray) injection. WT mice injected with 
microbeads show a significant decrease in visual acuity at both 4 weeks and 8 weeks post-
injection compared to baseline. (B) Bar graph showing average visual acuity threshold (mean + 
SEM) of Il-6-/- mice at baseline and 4 and 8 weeks post initial saline (white) or microbead (gray) 
injection. Il-6-/- mice injected with either saline or microbeads show a significant decrease in 
visual acuity at 8 weeks compared to baseline. (C) Line graph comparing visual acuity of WT 
saline (white circle), WT microbead (white diamond), Il-6-/- saline (gray circle) and Il-6-/- 
microbead (gray diamond) at each time point. Visual acuity decreases significantly in 
microbead-injected WT mice compared to saline-injected WT mice. Visual acuity does not differ 
between saline- and microbead- injected Il-6-/- or between genotypes. (D) Boxplot of the 
percentage visual acuity remaining at 8 weeks compared to baseline measurements for WT and 
Il-6-/-. WT mice injected with microbeads show a significant decrease in the remaining visual 
acuity when compared to the saline- injected WT mice. Il-6-/- mice injected with microbeads 
show no difference in the remaining visual acuity when compared to the saline injected Il-6-/- 
cohort. *=p<0.05, **= p<0.001. n=13-17/group. Dashed lines in boxplot indicate median value 
of data set.  
 
Figure from (Echevarria et al., 2017) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
IL-6 deficiency enlarges the microglia population in retina 
Recent studies suggest that changes in glial reactivity in the retina occur in response to 
IOP elevation in both genomic and inducible models of glaucoma (Martin et al., 2003, 
Sappington and Calkins, 2006, Inman and Horner, 2007, Bosco et al., 2008, Johnson and 
Morrison, 2009, Johnson et al., 2011, Echevarria et al., 2013, Lye-Barthel et al., 2013, 
Formichella et al., 2014, Hines-Beard et al., 2016). To determine whether IL-6 plays a role in 
glial reactivity associated with RGC axonopathy, we performed a morphological analysis of 
astrocyte and microglia reactivity in retina. We visualized astrocytes and microglia in whole-
mount retina from saline- and microbead- injected WT and Il-6-/- mice with immunolabeling 
against the astrocyte- specific label glial fibrillary acidic protein (GFAP) and the microglia- 
specific marker ionized calcium binding adaptor molecule (Iba-1). We quantified percent area 
coverage of GFAP+ astrocytes and Iba-1+ microglia. Our previous work indicates that percent 
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area coverage is a highly reliable measure of reactivity that accounts for both increases in density 
and hypertrophy, two hallmarks of gliosis (Formichella et al., 2014). GFAP immunolabeling 
revealed no gross genotype- or IOP-dependent changes in astrocytic morphology (Figure 3.8A). 
This was confirmed by quantification of percent area coverage, which indicated no significant 
difference in the retinal area covered by GFAP+ astrocytes with respect to either IOP or 
genotype (p>0.05 for all; Figure 3.8C). In contrast, Iba-1 immunolabeling revealed qualitative 
changes in microglia  
 
Figure 3.8. IL-6 deficiency affects microglial coverage regardless of IOP. (A-B) Representative 
60X confocal images depicting GFAP+ astrocyte (green; A) and Iba1+ microglia (green; B) 
 92 
labeling in whole mount retina of microbead- and saline- injected WT and Il-6-/- eyes. (C) 
Boxplot of percent coverage of GFAP+ astrocytes in saline (white) and microbead (gray) 
injected WT (left) and Il-6-/- (right) eyes. No genotype or IOP dependent changes were 
calculated. (D) Boxplot of percent coverage of Iba1+ microglia in saline- (white) and microbead- 
(gray) injected WT (left) and Il-6-/- (right) eyes. While an IL-6 dependent increase in percent 
coverage of microglia is seen in both saline and microbead- injected eyes, only an IOP dependent 
decrease is seen in microbead- injected WT eyes. (E) Boxplot of Iba1+ microglia cell density 
(counts/mm
2
) in saline- (white) and microbead- (gray) injected WT (left) and Il-6-/- (right) eyes. 
IOP dependent decreases in microglia counts are evident in microbead- injected eyes are evident 
in both WT and Il-6-/- eyes. *=p<0.05. n=6-8 images/eye/condition/genotype. Scale bars= 30μm 
for all images. Dashed lines in boxplot indicate median value of data set.  
 
Figure from (Echevarria et al., 2017) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License.. 
______________________________________________________________________________ 
that appeared to relate to both genotype and IOP (Figure 3.8B). Quantification of percent area 
coverage revealed that Iba-1+ microglia covered 32% more area in retina from saline-injected Il-
6-/- mice versus WT mice (p<0.05; Figure 3.8D). Microbead-induced IOP elevation decreased 
the percent area covered by Iba-1+ microglia by 45% in WT retina (p<0.05) as compared to 
saline-injected controls (Figure 3.8D). Although the mean percent area covered was 30% lower 
in microbead- injected Il-6-/- mice, this did not reach statistical significance (p>0.05, Figure 
3.8D). Comparing genotypes, more retinal area remained covered by microglia in microbead 
injected Il-6-/- mice than in WT mice (p<0.05, Figure 3.8E). Based on qualitative assessment, 
IOP-induced changes in percent area coverage appeared to arise from changes in microglia 
density (Figure 3.8B). To quantitatively test this observation, we measured the density of Iba-1+ 
microglia across all experimental groups. We found that microbead-induced IOP elevation 
decreased the density of microglia by 37% in WT retina (p<0.05) and by 36% in Il-6-/- mice 
(p<0.05), as compared to saline-injected controls (Figure 3.8E). There was no significant 
difference in microglial density between WT and Il-6-/- mice regardless of treatment (p>0.05; 
Figure 3.8E). 
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Discussion 
IL-6 is broadly associated with neurodegeneration across the CNS. However, the impact 
of IL-6 signaling on neurodegeneration is controversial, with studies reporting both beneficial 
and detrimental effects (Erta et al., 2012, Campbell et al., 2014). The present work investigated 
the relevance of IL-6 signaling to RGC axonopathy following microbead-induced ocular 
hypertension. By comparing functional and structural outcomes of IOP elevation on RGC 
axonopathy in Il-6-/- and WT mice, we were able to link IL-6 signaling with specific events in 
RGC axonopathy. These studies delineate a role for IL-6 in the progression from functional 
deficits to structural degeneration within the axonopathy continuum. Secondarily, our data also 
indicated a role for IL-6 in corneal wound healing and potentially IOP regulation.        
Glaucoma is associated with elevated IOP and current therapies, directed towards 
lowering IOP, delay pathology (Calkins, 2012). Not surprisingly, animal models of glaucoma are 
generally characterized by elevated IOP and subsequent degeneration of RGCs (Johnson and 
Tomarev, 2010, Bouhenni et al., 2012). Our data indicates that IL-6 deficiency modestly, but 
significantly, decreases baseline IOP by ~4% compared to WT (Figure 3.1). This differential in 
baseline IOP was maintained following IOP elevation via microbead injection, such that the 
relative magnitude in IOP elevation was equivalent between the genotypes (Figure 3.1). There is 
some indication that modulation of IL-6 signaling accompanies IOP elevations in human 
patients, including both primary open angle and angle closure glaucoma (Takai et al., 2012, 
Engel et al., 2014, Huang et al., 2014, Du et al., 2016). However, in a recent study of porcine 
anterior segment, IL-6 did not appear to alter outflow facility that determines IOP (Birke et al., 
2011). Our data suggest that, at least in mice, IL-6 signaling may impact the IOP “set-point”. 
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However, it is unclear whether this results from direct modulation of aqueous humor dynamics 
or from IL-6 signaling during development of the anterior chamber.  
The microbead occlusion model is an inducible model of glaucoma that elevates IOP by 
intracameral injection of microbeads (Figure 3.1) (Sappington et al., 2010). This intracameral 
injection requires a small diameter (approx. 100μm) puncture in the cornea. OCT imaging 
revealed that IL-6 deficiency prevented stitching and filling of the stromal and endothelial layers 
of the cornea, which was visible in WT mice within 2 weeks of puncture (Figure 3.2). 
Interestingly, the epithelial layer of the cornea in Il-6-/- mice was indistinguishable from WT 
mice (Figure 3.3). This suggests that IL-6 signaling plays a prominent role in healing of stromal 
and endothelial, but not epithelial, layers of cornea. That a deficit in corneal wound healing was 
noted in our studies is not surprising, as IL-6 is strongly associated with wound healing and 
tissue regeneration in other systems (Blindenbacher et al., 2003, Lin et al., 2003b, Tiberio et al., 
2008, McFarland-Mancini et al., 2010). 
One of the earliest characteristics of RGC degeneration in glaucoma are deficits in active, 
anterograde transport that occurs prior to structural degeneration of the axon and loss of vision.  
(Crish et al., 2010, Crish et al., 2013). Consistent with previously published studies (Sappington 
et al., 2010, Lambert et al., 2011, Ward et al., 2014, Bond et al., 2016), microbead-induced IOP 
elevation in WT mice resulted in a 50% decrease in anterograde transport of CTB to the SC 
(Figure 3.3). Interestingly, Il-6-/- mice exhibited a similar decrease in anterograde transport 
(Figure 3.3). However in respect to axon degeneration and subsequent vision loss, IL-6 
deficiency preserved both the structure of RGC axons and visual acuity following 8 weeks of 
elevated IOP (Figure 3.4 and 3.5). Consistent with previous findings (Sappington et al., 2010, 
Lambert et al., 2011, Ward et al., 2014, Bond et al., 2016), microbead-induced IOP elevation in 
 95 
WT mice resulted in significant loss of RGC axons in the optic nerve and the presence of 
degeneration profiles and macrogliosis (Figure 3.4). This was accompanied by a significant and 
IOP-dependent decrease in visual acuity (Figure 3.5), which is also consistent with previous 
findings (Della Santina et al., 2013). Aside from a genotype-specific decrease in myelinated axon 
density (approx. 15%), we did not see any gross structural abnormalities of the optic nerve 
following IOP elevation in Il-6-/- (Figure 3.4). This lack of structural degeneration was 
supported by no change in visual acuity following IOP elevation, as compared to saline control 
(Figure 3.5). However, it should be noted that, while baseline visual acuity did not differ 
between WT and Il-6-/- mice, visual acuity decreased modestly, but significantly (8%), 
following both saline and microbead injection (Figure 3.5). That this decrease was noted 
following both types of injection and did not change over time, it is highly likely that visual 
acuity was negatively impacted by the observed deficits in corneal wound healing (Figure 3.2). 
Together, these data delineate a temporal window in which IL-6 signaling contributes to RGC 
axonopathy. Specifically, this temporal window begins after the onset of axon transport deficits 
and prior to the onset of structural degeneration and decreased visual function. More generally, 
our data suggest that axon transport deficits and structural degeneration of axons occurs via, at 
least partially, independent mechanisms.     
Our analysis of gliosis in the GCL and NFL revealed a strong association between 
microglia, IOP and IL-6, but no association with astrocyte reactivity. This is contrary to studies 
of astrocyte reactivity in other models, where both retinal astrocyte hypertrophy and hypotrophy 
are associated with elevated IOP. Notably, most of these studies were conducted in either chronic 
models (Inman and Horner, 2007, Formichella et al., 2014) or inducible models with much 
higher IOP elevation (Wang et al., 2000, Gallego et al., 2012). Differences in the duration and 
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magnitude of IOP elevation, as well as severity of RGC pathology, could account for our 
contradictory findings. With respect to microglia, IL-6 deficiency increased the percent area of 
the GCL/NFL that was covered by microglia, as compared to WT (Figure 3.6). Elevated IOP 
decreased the percent area of the GCL/NFL that was covered by microglia in both WT and Il-6-/- 
mice (Figure 3.6). However, more retinal area remained covered by microglia in microbead-
injected Il-6-/- than in WT mice (Figure 3.6). IOP-related reductions in area covered were, at 
least partially, due to a decrease in the density of microglia in the GCL/NFL for both genotypes 
(Figure 3.6). Based on previous literature, changes in microglia density likely arise from 
migration of microglia to other retinal layers, particularly in outer retina (Rojas et al., 2014). In 
contrast, the genotype-dependent increase in microglia coverage is not largely attributable to 
changes in density, as the trend towards increased microglia density failed to reach statistical 
significance. This suggests that increased size and ramification of microglia is likely to 
contribute to the larger representation of microglia in retina of Il-6-/- mice. That IOP-induced 
changes in microglia were similar in Il-6-/- mice and WT suggests that IL-6 does not play a 
causal role in microglia migration or temporal onset of microglia reactivity in this model. 
Furthermore, in combination with our optic nerve and visual function data, expansion of the 
microglia population noted in the GCL/NFL of Il-6-/- retina did not negatively impact 
progression of axonopathy.  
Overall, these findings support a detrimental role for IL-6 in RGC axonopathy, 
particularly with respect to structural degeneration and subsequent visual dysfunction. Prior to 
degeneration, stressed myelinated axons undergo repeated myelination (Crish et al., 2010, Joos et 
al., 2010) leading to the presence of degenerative profiles. We noted fewer degenerating profiles 
in microbead- injected Il-6-/- mice than WT mice and preservation of RGC myelinated axon 
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density in comparison to their respective saline- injected controls. The apparent reduction in 
degenerating profiles may result from the absence of repeated myelination. In the experimental 
autoimmune encephalomyelitis (EAE) model of multiple sclerosis, IL-6 deficiency protects 
against myelin degradation. Multiple studies report that myelin degeneration in the spinal cord 
seen in WT mice affected with EAE is absent in Il-6-/- mice, a result thought to be due to lack of 
infiltrating T-cells (Eugster et al., 1998, Mendel et al., 1998, Okuda et al., 1998, Samoilova et al., 
1998). In the curpizone model of de-myelination, blocking IL-6 signaling pharmacologically 
improved re-myelination following injection (Makinodan et al., 2016). These studies indicate 
that the reduction in degenerating profiles we noted could arise from IL-6 mediated effects on 
myelin, particularly myelin repair. Further studies of axon sub-structure are needed to elucidate 
the impact of IL-6 deficiency on myelin formation. 
As discussed previously, our results showing IL-6 deficiency is protective aligns with 
some IL-6 literature, but not others. Indeed, studies that describe a neuroprotective role for IL-6 
and other IL-6 family members arise primarily from in vitro models and the optic nerve crush 
model. In vitro models utilize RGCs harvested from mechanically dissociated retina following 
transection of the optic nerve and the optic nerve crush model utilizes forceps to directly and 
mechanically injure the optic nerve. In these model systems, IL-6 and several of its family 
members promote regeneration and/or preservation of RGC axons (Mendonca Torres and de 
Araujo, 2001, Schuettauf et al., 2005, Sappington et al., 2006, Chidlow et al., 2012, Leibinger et 
al., 2013, Perigolo-Vicente et al., 2013, Pernet et al., 2013, Ogai et al., 2014, Perigolo-Vicente et 
al., 2014, Xia et al., 2014, Leibinger et al., 2016). Additionally, studies that suggest a neuro-
destructive role for IL-6 tend to utilize models in which RGC axons remain intact and RGC 
degeneration is secondary to a diffuse stressor, like demyelination, retinal detachment and 
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ischemia (Fisher et al., 2001, Dvoriantchikova et al., 2010, Horstmann et al., 2013, Fischer et al., 
2015). Our microbead occlusion model aligns more with the latter form of injury, as RGC axons 
remain structurally-intact and IOP elevation is a diffuse stressor.  
In conclusion, our findings indicate that two defining features of RGC axonopathy - axon 
transport deficits and structural degeneration of axons - likely occur via independent 
mechanisms. That the functional and structural components of RGC axonopathy could be 
mechanistically separated has tremendous implications for therapeutic targeting. Our data 
indicate that IL-6 is part of a mechanism that specifically leads to structural degeneration of 
axons. Furthermore, its absence is sufficient to prevent both structural degeneration of the optic 
nerve and vision loss. Together, our findings support the proposition that functional deficits in 
axon transport represent a therapeutic window for RGC axonopathy and identify IL-6 signaling 
as a strong target for such a therapeutic.  
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CHAPTER 4 
 
IL-6 CONTRIBUTES TO THE DEVELOPMENT  
OF AXONS IN THE OPTIC PROJECTION 
 
Introduction
 
The subject of cytokine signaling in the CNS is primarily focused on its impact in 
neuronal health during chronic neuroinflammation. However, there is increasing evidence that 
cytokine signaling, especially gp130 signaling, is associated with development and maintenance 
of the central and peripheral nervous systems (Mousa and Bakhiet, 2013). While functional 
redundancy between the members of the gp130 family exists, gene ablation studies in mice of 
specific gp130 ligands and receptors provide evidence of individual roles within the nervous 
systems. For example, LIF is responsible for astrocyte differentiation from progenitors during 
CNS development (Bauer et al., 2007), while evidence points to CNTF and LIF facilitating 
Müller cell and photoreceptor development in the retina (Rhee and Yang, 2010). In neurons, 
genetic ablation of OSM leads to deficiencies in certain populations of nociceptive neurons 
(Morikawa et al., 2004), while deficiency of CT-1 or its receptors leads to a decrease in motor 
neuron survival in the brain stem and spinal cord during embryonic development (Oppenheim et 
al., 2001).  
In regards to IL-6, Il-6-/- mice show deficits in temperature sensitivity, pain response 
thresholds and sensory compound action potential (Xu et al., 1997, Murphy et al., 1999, Zhong 
et al., 1999), suggesting a role for IL-6 in responding to noxious stimuli. Indeed, other studies 
show that IL-6/gp130 activation sensitizes nociceptors to noxious stimuli by upregulating 
various members of the mechanosensitive transient receptor potential (TRP) channel family 
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(Andratsch et al., 2009, Malsch et al., 2014). In the CNS, a number of studies point to a role for 
IL-6 in hippocampal mediated learning and memory. For example, gene expression of 
hippocampal IL-6 increases following tasks that are known to induce long-term potentiation in 
the hippocampus, a form of synaptic plasticity that is instrumental to learning and memory 
(Gruol et al., 2014). Indeed, Il-6-/-mice present with decreases in the neural progenitor cell 
population in the sub-ventricular zone, dentate gyrus and posterior peri-ventricle of the 
hippocampus (Bowen et al., 2011), as well as present with significant learning and memory 
deficits (Baier et al., 2009). Aside from the hippocampus, Il-6-/- mice also show altered sleep 
rhythms, hyperactivity, and behaviors associated with decreased depression, increased anxiety 
and aggression (Alleva et al., 1998, Armario et al., 1998, Butterweck et al., 2003, Morrow and 
Opp, 2005, Chourbaji et al., 2006, Kong et al., 2015). In humans, roles for IL-6 signaling not 
directly associated with injury or pathogen mediated disease involve sleep regulation and 
development of several psychiatric diseases. In regards to sleep, plasma levels of IL-6 in humans 
exhibit a circadian rhythm with levels highest at night (Agorastos et al., 2014). Similar to 
rodents, IL-6 appears to specifically regulate the rapid eye movement (REM) stage of sleep 
(Spath-Schwalbe et al., 1998, Hogan et al., 2003). In regards to psychiatric disease, individuals 
with depression have elevated levels of IL-6 in their plasma (Hodes et al., 2016). In mice, IL-6 
activity is thought to contribute to depressive behavior by upregulating the serotonin transporter, 
leading to decreased serotonin in the synaptic space (Kong et al., 2015). Elevated levels of IL-6 
are also seen in people with schizophrenia and autism (Wei et al., 2012). One hypothesis for the 
development of these disorders is due to exposure to IL-6 in utero caused by maternal infection 
(Smith et al., 2007, Khan et al., 2014). Overall, these studies suggest that IL-6 signaling mediates 
development of the CNS. 
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In the optic projection, in vitro studies show a direct relationship between IL-6 
application and increased neurite out growth from RGCs (Chidlow et al., 2012, Leibinger et al., 
2013). In vivo, IL-6 deficiency inhibits axon regrowth following optic nerve crush, while 
intravitreal application of IL-6 improves axon regrowth, suggesting that IL-6 facilitates optic 
nerve axon growth in response to injury (Leibinger et al., 2013). However, it is unknown 
whether similar IL-6 development is involved in the development and maintenance of the mature 
optic projection. To ascertain the role of constitutive IL-6 signaling in the mature optic 
projection we compared gross retinal structure, RGC mediated cortical light responses, axon 
transport, and axon morphology in both the unmyelinated and myelinated optic nerve between 
WT and Il-6-/- mice.  Overall, our data points to a role for constitutive IL-6 signaling in the 
development of axons in the optic projection neurons by influencing organization of 
microtubules. This data along with previously published studies, have broad implications for the 
understanding of constitutive functions of cytokines in the CNS and the development of 
cytokine-based therapies.  
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Materials and Methods 
Animals 
Neonatal (P3, P7, P21) or adult (2-3mo) male and female Il-6-/- mice (B6.129S2-
IL6
tm1kopf
/J) and respective genomic controls (B6129SF2/J) were used for all experiments. For 
experiments utilizing neonates, day of birth was designated P0. Mice were housed in accordance 
with NIH guidelines and maintained on a 12hr light/dark cycle with ad libitum access to standard 
mouse chow and water. All experiments complied with the ARVO statement for the use of 
animals in ophthalmic and vision research and were approved by the IACUC of Vanderbilt 
University Medical Center.  
 
Tissue preparation 
For histological assays, mice were euthanized and perfused as previously described 
(Chapter 2 material and methods).  Eyes, optic nerve and brain were processed as previously 
described (Crish et al., 2010). For assays requiring fresh tissue, mice were sacrificed by cervical 
dislocation followed by decapitation. Eyes were enucleated and snap frozen on dry ice and stored 
at -80°C until use.  
 
Immunohistochemistry 
Labeling of whole-mount retinas, retinal cryosections, optic projections and floating brain 
sections were done as previously described (Sappington et al., 2009, Crish et al., 2010, 
Echevarria et al., 2013, Echevarria et al., 2016). We used primary antibodies against Brn3a 
(1:50; Cat# sc-31984; Santa Cruz) to visualize RGCs, β-Tubulin III (TUJ1, 1:500; Cat#845501; 
BioLegend), SMI-31 (1:1000; cat# SMI-31R; Covance) and Phalloidin (actin, 1:50; Cat# P1951; 
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Sigma) to visualize RGCs and their axons or neurons in the brain,  ERRβ (1:500; Cat# E0156; 
Sigma) to label RGC synaptic terminals in the SC, Cav-1 (1:250; cat# sc-894; Santa Cruz)  to 
highlight Cav-1 localization in the retina and Tau (1:50; cat# sc-1995; Santa Cruz) to highlight 
microtubule associated proteins in axons. Secondary antibodies, if applicable, were used at a 
concentration of 1:200 and consisted of donkey α-host species of primary- 488, Rhodamine Red 
or 647(Jackson ImmunoResearch). 
 
Fluorescent In-situ hybridization 
Generation of IL-6 probes and FISH in whole mount retina were done as previously 
described (Crish et al., 2013). Probes were made against a nucleotide sequence encompassing 
exons 2-5 of Il-6 (nucleotides 107-651 of [NCBI Ref Seq: NM_031168.2]). The transcript 
inserted into the pGEM-T Easy Vector (Promega, Madison WI) was generated by PCR using 
primers to IL-6 (forward 5’-ATCCAGTTGCCTTCTTGGGACTGA-3’ and reverse   
5’TGGCTAAGGACCAAGACCATCCAA-3’).  
 
Anterograde axon transport measurements 
Anterograde axonal transport capabilities of RGCs were assessed with CTB and WGA 
conjugated to a fluorophore, both established markers for active uptake and transport in the optic 
projection (Crish et al., 2010, Lambert et al., 2011, Fernandez et al., 2012, Wong and Brown, 
2012, Echevarria et al., 2013, Formichella et al., 2014, Ward et al., 2014). Briefly, mice were 
given a 1.5-2 µl intravitreal injection of CTB (10ug/µl in sterile PBS; Life Technologies) or 
WGA (20ug/µl in sterile PBS; Life Technologies) using a 33 gauge needle attached to a 
Hamilton syringe under 2.5% isoflurane anesthesia. 3 days after CTB/WGA injection, mice were 
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sacrificed by transcardial perfusion as described above. Quantification of CTB/WGA signal in 
the SC and construction of retinotopic maps was done as previously described (See Chapter 2). 
Creation and quantification of 2D retinotopic map of ERRβ staining within the SC was done in a 
similar fashion. For experiments studying delayed CTB or WGA transport, mice were sacrificed 
5 days after CTB/WGA injection. To confirm uniform CTB/WGA exposure to RGCs, a subset of 
whole-mount retinas were imaged en montage at 20X using confocal microscopy. For tracing 
experiments involving recombinant IL-6, mice were given intravitreal injections of either 500ng 
(250ng/µl in 0.1% BSA; R&D Systems) of recombinant murine IL-6 or 2ul of 0.1% BSA 24 
hours before CTB injection.  
 
Spectral Domain Optical Coherence Tomography (SD-OCT) and quantification of retinal 
layer thickness  
 Live volumetric scans of the retina (1.4mm x 1.4mm x 1.637mm) were obtained using 
SD-OCT (Envisu R22 UHR, Bioptogen, Morrisville, NC) as described elsewhere (Ferguson et 
al., 2014). Each volumetric scan was obtained with the optic nerve head (ONH) at the center and 
consists of 100 axial slices (B-scans) through the retina. Thickness of the total retina and 
individual retinal layers were measured manually using InVivoVue Diver Software (Ver 2.0, 
Bioptogen, Morrisville, NC). Measurements were obtained by placing a 5x5 ROI marker grid on 
the volumetric image, with the center ROI marker corresponding to the optic nerve head. ROI 
markers were equally spaced from each other (0.23mm). At each ROI marker, individual retinal 
layers (GCL/NFL, IPL, INL, OPL, ONL, IS/OS and RPE) as well as total retinal thickness 
(GCL/NFL-RPE) were measured. No measurements were obtained from ROI markers located at 
the optic nerve head or any ROI marker where layers could not be easily measured.  
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Quantification of brain width 
Brain width from brain sections located 0.145mm rostral of Bregma and 1.995mm caudal 
of Bregma were imaged en montage at 5X using a Nikon Eclipse Ti inverted microscope 
(Melville, NY). Width was measured at widest points using NIS-Elements AR software. Bregma 
locations were determined by matching sections measured to most represented section located in 
the Allen Reference Mouse Atlas (Dong, 2008). 
 
FVEPs  
Prior to testing, mice were dark adapted overnight for a period of at least 12 hours. 
Following dark adaptation, mice were anesthetized with an IP injection of a ketamine/xylazine 
cocktail (80/5 µg/gram of mouse) and pupils were dilated using 0.5% Tropicamide. Mice were 
placed in a Ganzfeld dome (Diagnosys, Lowell, MA) containing a heated stage to maintain body 
temperature at 37°C. Platinum needle electrodes (Grass Technologies, West Warwick, RI) were 
placed over the right and left cortex about 2mm lateral of lambda and GenTeal lubricating eye 
drops were applied to prevent drying. Within the ganzfeld dome, phototopic stimulation at 
luminance levels of 0.01 cd·sec/m
2 
were emitted at a frequency of 1 Hz with an inner sweep 
delay of 500 msec, followed by stimulation at luminance levels of 1.0 and 5.0 cd·sec/m
2 
at equal 
frequency. Waveform from each luminance level of each animal was a result of 200 sweeps. 
Waveforms presented (Figure 1) are an average of waveforms from each animal in the cohort. 
Similar to other publications (Sullivan et al., 2011, Bond et al., 2016), N1 is designated as the 
first major depolarization event following the stimulus, while the P1 was designated as the first 
major hyper polarization event following the N1 depolarization event. N1 and P1 amplitude 
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measurements were taken from the N1 trough and P1 peak. Respective time at which the N1 
trough and P1 peak occurred, were designated as N1 and P1 latency.   
 
Psychophysical visual testing  
Baseline visual acuity threshold was determined as previously described (See Chapter 2 
material and methods). 
 
Quantification of RGC somas/axons  
For RGC density, 5-7 pseudo-random z-stack images were taken throughout the mid –
peripheral/mid-central retina at 60X using an Olympus confocal microscope. TUJ1/SMI31 dual 
positive RGCs were counted from each image and divided by the area of the counting field 
(0.101mm
2
) to get RGC density. Approximate total number of myelinated axons from each nerve 
was calculated using the average myelinated axon density multiplied by the area of each nerve. 
Myelinated axon density was measured as previously described (See Chapter 2). 
 
Quantification of axon diameter and gRatio.  
Total axon diameter (myelin sheath + axon) and inner axon diameter (axon only) was 
measured from 100X montaged images of optic nerve sections using NIS-Elements AR (See 
Figure 4.8A). Myelin thickness was calculated using the following formula: (Total Axon 
Diameter – Inner Axon Diameter / 2). gRatio was calculated using the following formula: (Inner 
Axon Diameter/Total Axon Diameter). 
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Immunoblotting.  
Single retinas and western blot processing was done as previously described (Echevarria 
et al., 2016). Probing of Cav-1 and β-actin was accomplished using anti-rabbit Cav-1 (1:250; 
cat# sc-894; Santa Cruz) and anti-mouse β-actin (1:1000; cat# AM4302; Ambion). Secondary 
antibodies utilized were donkey anti-mouse IRDye 680RD (1:1000; Cat# 925-68072; Li-Cor) 
and donkey anti-rabbit IRDye 800CW (1:1000; Cat# 925-32213; Li-Cor). Cav-1 and β-actin 
bands were detected using the Odyssey Infared Imaging System (Li-Cor; Lincoln, NE). Cav-1 
bands were subjected to densitometry analysis (Odyssey Application Software V3.0; Li-Cor) and 
normalized to β-actin. All samples used for densitometry analysis were run on the same gel and 
transferred to the same nitrocellulose membrane.  
 
Statistical Analysis 
Statistical analysis was done using SigmaPlot (version 11.1 SYSTAT). For two 
independent data sets that passed normality and equal variance tests, statistical significance was 
determined using a two-sided t-test. Mann-Whitney Rank Sum Tests were used for data sets that 
did not meet normality and/or equal variance requirements.  p values less than 0.05 were 
considered statistically significant. Number of measurements and specific p-values are indicated 
in results or figure legends.  
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Results 
IL-6 is constitutively expressed by RGCs during post-natal development and in mature 
retina. 
We previously published that IL-6 protein is constitutively present in the adult mouse 
retina (Sims et al., 2012) (Chapter 2). Here, we examined retinal Il-6 mRNA expression 
throughout postnatal development to determine possible cell types responsible for IL-6 release. 
Using in situ hybridization, we examined expression and localization of Il-6 mRNA from retinal 
cryosections of mice from postnatal day (PD) 3 to 21. Starting at PD3, we detected robust in situ 
anti-sense signal in the developing ganglion cell layer (GCL) with some weaker labeling near the 
inner margin of the neuroblast layer (NBL; Figure 4.1A). By PD7, Il-6 labeling in the GCL 
increased in intensity and compaction. Labeling previously associated with the inner margin of 
the NBL transitioned to a band of higher intensity labeling in the inner margin of the now 
developed inner nuclear layer (INL; Figure 4.1B).  By PD21, Il-6 labeling in the GCL increased 
further in intensity and appeared to fill the soma of neurons in this layer (Figure 4.1B). Labeling 
of the INL noted at PD7 dissipated and a novel band of labeling was noted in the outer margin of 
the outer plexiform layer (OPL; Figure 4.1C). No significant signal from the sense probe was 
noted at any of these time points.   
Based on mRNA localization patterns, constitutive Il-6 mRNA expression appears to be 
most consistently and robustly associated with soma in the GCL, suggesting that RGCs are 
constitutively producing IL-6. In 3 month old mice, we examined localization of IL-6 mRNA in 
wholemount retina co-immunolabeled with the RGC-specific marker β-Tubulin (TUJ1). To 
confirm specificity of our probes, we examined expression and localization in WT and Il-6-/- 
mice.  Anti-sense labeling for Il-6 mRNA localized to TUJ1+ positive RGCs in WT (Figure 
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4.1D; left). Anti-sense labeling for Il-6 mRNA was not detected in Il-6-/- mice (Figure 4.1D; 
right). Similarly Il-6 mRNA labeling was not detected following incubation with the sense probe 
in either genotype (Figure 4.1E).  
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Figure 4.1. RGCs express Il-6 mRNA throughout post-natal development. (A-C) Representative 
40X confocal images of retinal cryo-sections displaying Il-6 mRNA expression (green) from 
cells in ganglion cell layer (RGCs) at post-natal day (PD) 3 (A), PD7 (B) and PD21 (C). Cryo-
sections incubated with anti-sense probe towards Il-6 mRNA (left) and control sense probe 
(right). Scale bars for (A-C) = 30μm. (NBL= neuroblast layer, ONL= outer nuclear layer, INL= 
inner nuclear layer, GCL= ganglion cell layer). (D-E) Representative 100X confocal image of 
retinal whole mount from adult (3mo) WT (D) and Il-6-/- mice (E) incubated with an anti-sense 
(AS; left) or sense probe (S; right) towards Il-6 mRNA (right). Signal from AS probe (green) is 
found within β-Tubulin (TUJ1) positive RGCs (D, red; arrow heads) in WT mice (D). No signal 
was present in retinas from Il-6-/- mice (E; right) or during incubation with sense probe (D,E; 
left). Scale bars= (D,E); 20μm. 
______________________________________________________________________________ 
IL-6 deficiency alters retinal layer thickness without impacting gross morphology or 
structure.   
To determine the role of constitutive IL-6 signaling in retina, we first examined overall 
retina morphology and structure in WT and Il-6-/- mice, using spectral-domain optical coherence 
tomography (SD-OCT). We obtained sagittal cross-sections throughout the entire retina and 
measured thickness of individual layers and the entire retina. The gross laminar structure of the 
retina and position and size of the optic nerve head were unremarkable in Il-6-/- mice, compared 
to WT mice (Figure 4.2A,B).  However, quantification of total retinal thickness in SD-OCT 
scans revealed a slight, yet significant 2% reduction in Il-6-/- mice versus WT mice (p<0.001, 
Figure 4.2C). Quantification of layer thicknesses revealed that the reduction of total retina 
thickness was attributable to thinning of the outer plexiform layer (OPL), outer nuclear layer 
(ONL) and retinal pigment epithelium (RPE; p<0.001, Figure 4.2C). However, thinning of these 
layers was offset by a significant increase in thickness of the inner nuclear layer (INL; p<0.001; 
Figure 4.2C).  
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Figure 4.2. IL-6 deficiency does not affect retinal morphology. (A-B) Representative images of 
retinal volumetric scan (A) and retinal cross-sections (B) obtained by SD-OCT outlying retinal 
layer morphology in WT and Il-6-/- mice (n=25 measurements/retina, 16 retina/genotype). Scale 
bars= (A,B); 200μm. Dashed lines in (A) correspond to location of retinal cross sections in (B). 
(C) Box plot of retinal layers (INL, OPL, ONL, RPE) that were significantly different result in a 
small, yet significant, 2% reduction in total retinal thickness in Il-6-/- mice (p<0.001; Mann-
Whitney Rank Sum Test). *=p<0.001.  Dashed lines in boxplots indicate median value. 
GCL/NFL; ganglion cell layer/nerve-fiber layer, IPL; inner plexiform layer, INL; inner nuclear 
layer, OPL; outer plexiform layer, ONL; outer nuclear layer, IS/OS; inner segment/outer 
segment of the photoreceptors, RPE; retinal pigment epithelium, ONH; optic nerve head. 
______________________________________________________________________________ 
 
IL-6 Deficiency Alters the Cortical Response to Light Stimuli 
 Examination of visual function with flash visual-evoked potentials (FVEP) and 
optomotry revealed that modest changes in retinal morphology noted in Il-6-/- mice were 
accompanied by significant alterations to the N1 depolarization event of FVEP waveform 
(Figure 4.3B,C). At light intensities of 1.0 (Figure 4.3B) and 5.0 cd.s/m
2 
(Figure 4.3C), the N1 
depolarization event of Il-6-/- mice was ~20% larger (p=0.042 and p=0.041; left) and ~4-5% 
delayed (p=0.03 and p=0.024; middle) compared to WT mice. No significant difference in 
amplitude (p=0.804; left) and latency (p=0.337; middle) was noted in the N1 depolarization event 
at low light intensity (0.01 cd.s/m
2
, Figure 4.3A). Interestingly, there was no change in amplitude 
or latency of the P1 hyperpolarization event at any light intensity (p>0.05 for all, Figure 4.3A-C; 
right). However, it is important to note that while P1 amplitudes and latencies were 
unremarkable, Il-6-/- waveforms failed to reach baseline WT levels at light intensities of 1.0 and 
5.0 cd.s/m
2
 (Figure 4.3B,C). Despite altered F-VEP waveforms, Il-6-/- mice exhibited normal 
visual acuity, as measured by optomotry (p=0.496, Figure 4.3D). 
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Figure 4.3. Il-6-/- mice present with an impaired cortical response to light.  (A-C) Flash Visual 
Evoked Potential (FVEP) responses at light intensities 0.01 (A), 1.0 (B) and 5.0 cd.s/m
2
 (C) in 
WT and Il-6-/- mice (n=12-15 animals/genotype). Waveform (left) and calculated amplitude and 
latency of waveform components (N1, P1; right) are present for each light intensity. (A) 
Following a 0.1 cd.s/m
2
 light pulse, no significant differences in N1 or P1 amplitude (N1; 
p=0.804, P1; p=0.680, Mann-Whitney Rank Sum Test) or latency (N1; p=0.337, P1; p=0.286, 
Mann-Whitney Rank Sum Test) are present. (B) Following a 1.0 cd.s/m
2 
light pulse, a larger and 
delayed depolarization (N1; arrow) event occurs in Il-6-/-, but not WT mice. Additionally, unlike 
WT mice, the repolarization event (arrow head; P1) does not reach baseline. Quantification of 
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N1 and P1 amplitude and latency at 1.0 cd.s/m
2
, shows a significant difference in amplitude 
(p=0.042, two-tailed t-test) and latency (p=0.03, Mann-Whitney Rank Sum Test). No significant 
difference at 1.0 cd.s/m
2
 noted for P1 amplitude (p=0.450, two-tailed t-test) or latency (p=0.299, 
Mann-Whitney Rank Sum Test). (C) At 5.0 cd.s/m
2
, a similar waveform pattern occurs in Il-6-/- 
mice. Quantification of N1 and P1 components show a significant decrease in the N1 amplitude 
(p=0.041, Mann-Whitney Rank Sum Test) and latency (p=0.024, two tailed t-test). No significant 
difference was noted in the P1 amplitude (p=0.776, Mann-Whitney Rank Sum Test) or latency 
(p=0.091, Mann-Whitney Rank Sum Test). (D) Psycho-visual assessment of visual acuity using 
the optokinetic reflex test, showed no significant difference in visual acuity between WT and Il-
6-/- mice (p=0.496, two-tailed t-test, (n=8-10 mice/genotype). *=p<0.05. Dashed lines in 
boxplots indicate median value. Error bars on bar graphs indicate standard deviation. 
______________________________________________________________________________ 
 
IL-6 Deficiency Impedes Anterograde Axon Transport 
FVEP abnormalities suggest that IL-6 deficiency alters function of the optic projection. 
In mice, 70-80% of RGC axons in the optic nerve project to the superior colliculus (SC) (Dreher 
et al., 1985). To determine whether altered FVEP waveforms arose from changes in the physical 
connectivity of the retina to the superior colliculus, we performed neural tracing in Il-6-/- and 
WT mice, using cholera toxin beta subunit (CTB). CTB is routinely used to trace the RGC 
projection as well as to measure fast axonal transport (Crish et al., 2010, Abbott et al., 2013, 
Ward et al., 2014). In WT mice, CTB labeled the majority of the SC 3 days after intravitreal 
CTB injection (median = 98.131%; Figure 4.4A,C). Interestingly, there was significant 
variability in the degree of CTB transport noted in Il-6-/-, which ranged from almost full 
transport to only 40% (Figure 4.4B,C). In all cases of transport deficiency, areas of low transport 
in the SC corresponded to the area surrounding the optic disc representation and spread outward 
towards the periphery (Figure 4.4B). As a whole, CTB transport to the SC was diminished by 
~10% in Il-6-/- mice (median = 87.000%), as compared to WT mice (p=0.014; Figure 4.4C). 
Examination of earlier terminations in the optic tract revealed similar deficiencies in CTB 
transport, suggesting impairment throughout the RGC projection (Figure 4.4C). This impairment  
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Figure 4.4. Il-6-/-mice present with deficiencies in anterograde transport. (A-B) Representative 
coronal sections through the superior colliculus (SC) and respective retinotopic heat maps after 3 
days of CTB transport in WT (A)  and Il-6-/- mice (B). Arrows in coronal sections indicate areas 
of transport deficits. Density of the CTΒ signal for the heat maps range from 0% (blue) to 50% 
(green) to 70% (yellow) to 100% (red). Numbered dashed lines in retinotopic maps indicate the 
location of respective coronal section and white circles indicate position of the optic disk (OD). 
Medial (M) and rostral (R) orientations are indicated. Scale bars= 500μm for all images. (C) 
Quantification of intact transport (<70% Density). Il-6-/- mice show a significant reduction of 
intact transport 3 days after CTΒ injection when compared to WT mice (p=0.014, Mann-
Whitney RANK Sum test, n=9-12 SC/genotype). (D) Anterograde axon transport is also delayed 
in more rostral areas of the optic projection (dLGN, vLGN) in Il-6-/- mice (right) compared to 
WT mice (left). E Representative 40X images of dual labeled TUJ1/SMI-31 positive RGCs from 
mid-central/mid-peripheral retina in WT (left) and Il-6-/- (right) mice. F. Quantification of RGC 
density showed no significant difference between WT and Il-6-/- mice (p=0.284, two-tailed t-
test, n=5-7 images/retina, 3 retina/genotype).*=p<0.05.  Dashed lines in boxplots indicate 
median value. 
______________________________________________________________________________ 
 
was not due to a decreased number of RGCs in the retina. Immunolabeling with beta-tubulin 
(TUJ1) and neurofilament (SMI-31) confirmed that the distribution RGC soma appeared 
unremarkable and there was no significant difference in the density of RGCs between Il-6-/- and 
WT mice (p=0.284, Figure 4.4D). 
To further ascertain the source of transport impairment, we first examined whether the 
transport impairment reflected a decrease in successful RGC termination in the SC. We 
examined the spatial distribution and density of ERRβ+ RGC terminals in the SC and found that, 
even in areas of CTB deficiency, Il-6-/- mice exhibited full innervation of the SC that was 
comparable to WT mice (Figure 4.5A,B). Next, we determined whether transport impairment 
was due to abnormalities at the site of uptake in the retina. We examined the distribution and 
uptake of CTB in RGC soma (Figure 4.5C,D) and assessed the expression profile of caveolin-1 
(Cav-1; Figure 4.5D,E), an uptake mediator of CTB. In the retina, CTB uptake and localization 
to RGC soma was comparable between WT and Il-6-/- mice. Additionally, Cav-1 also localized 
comparably to RGCs in both genotypes, with densitometric quantification of Cav-1 protein  
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Figure 4.5. Transport deficits not due to impairments in RGC soma of Il-6-/- mice. (A-B) 
Representative images of ERRβ localization in the SC (A) and quantification of ERRβ signal 
density (B) suggests no alteration in the structure of RGC post-synaptic inputs to the SC between 
WT and Il-6-/- mice. Scale bars= 500μm. (C) Representative 10X montaged micrographs of WT 
(left) and Il-6-/- (right) retinas exposed to CTB (green) shows no difference in CTB uptake. 
Scale bar= 500μm. (D) Representative 100X micrographs of retinas exposed to CTB show 
similar uptake of tracer by Brn3a+ (green) RGCs (white arrow heads) in WT (left) and Il-6-/- 
mice (right). Scale bars= 50μm. (E) Localization of CTB uptake protein caveolin-1 (Cav-1) to 
Brn3a+ RGC cell bodies (red; arrowheads) in WT and Il-6-/- mice. Scale bars= 20μm. (F-G) 
Western blot (F) and densitometric quantification of Cav-1 normalized to β-actin (G) shows no 
significant difference between WT (white) and Il-6-/- (gray) mice (p=0.416, two-tailed t-test. 
n=3 retina/group). Error bars indicate standard deviation. 
______________________________________________________________________________ 
 
revealing no significant difference between WT and Il-6-/- retina (p=0.416, Figure 4.5G). 
Finally, we examined whether impairments in CTB transport reflected a decrease in the actual 
rate of transport. We extended the latency of CTB tracing from 3 days to 5 days. After 5 days, 
CTB labeling in the SC of Il-6-/- mice was comparable to that of WT mice (median= 98.945%, 
p=0.671, Figure 4.6A,B). We confirmed this apparent reduction in the rate of axon transport, 
using another neural tracer wheat germ agglutinin (WGA). With a tracing latency of 3 days, Il-6-
/- mice again showed variable (20-90%), yet overall significant, deficiencies in WGA transport 
compared to WT mice (median values, WT; 94.709% intact transport, 3 Day Il-6-/-; 81.381%, 
p=0.004, Figure 4.6C,D,F). As in our CTB transport studies, increasing the tracing latency for 
WGA to 5 days resolved WGA tracing deficiencies in the SC of Il-6-/- mice (median values, 
WT; 94.709% intact transport, 5 Day Il-6-/- 91.589%, p=0.202, Figure 4.6C,E,F).  
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Figure 4.6. Axon transport deficits are due to a delay in axon transport in Il-6-/- mice. (A) 
Representative coronal sections through the SC and respective retinotopic heat maps after 5 days 
of CTB transport in Il-6-/- mice. OD= optic disk. Scale bar= 500 μm. (B) Quantification of intact 
transport reveals similar amounts of intact transport 5 days after CTΒ injection in Il-6-/- mice 
compared to WT mice (p=0.671, Mann-Whitney RANK SUM test, n=8-12 SC/genotype). 
Dashed lines in boxplots indicate median value. (C-E) Transport delays not restricted to CTB. 
Representative coronal sections through the SC and respective retinotopic heat maps after 3 days 
of WGA transport in WT mice (C) and 3 days (D) and 5 days (E) of WGA transport in Il-6-/- 
mice. Arrows in coronal sections indicate areas of transport deficits. Scale bars= 500μm. (F) 
Quantification of intact transport (<70% Density) following 3 (white) or 5 (gray) days of WGA 
injection. Similar significant transport delays in Il-6-/- mice are evident after 3 days of WGA 
transport when compared to WT mice (p=0.004, Mann-Whitney RANK Sum test, n=5-11 
SC/genotype), but similar amounts of intact transport 5 days after WGA injection (p=0.202, 
Mann-Whitney RANK Sum test, n=5-7 SC/genotype). *=p<0.05.  Dashed line in boxplot 
indicates median value.  
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IL-6 Deficiency Increases RGC Axon Diameter  
Our data thus far suggests that IL-6-related changes in the rate of axon transport are 
likely localized to the RGC axon. To examine the impact of IL-6 deficiency on RGC axons 
specifically, we first examined the structural integrity of the optic nerve. Upon dissection, we  
noted that the optic nerve of Il-6-/- mice appeared thinner than that of WT mice, specifically in 
the proximal portion of the optic nerve (Fig. 4.7A). Measurement of nerve length from the eye to 
optic chiasm revealed no difference between the two genotypes (p=0.409, Figure 4.7B). 
However, quantification of total nerve area in cross sections of optic nerve revealed that the 
proximal segment (closer to the globe) was 20% smaller in Il-6-/- mice than that is WT mice 
(p<0.001, Figure 4.7C-E; left). The distal segment of the nerve however, did not differ between 
the two genotypes (p=0.066, Figure 4.7C-E; right). Quantification of optic nerve axon number 
revealed that Il-6-/- optic nerves contained ~20% fewer RGC axons in both proximal (p=0.020) 
and distal (p=0.002) sections, when compared to WT optic nerves (Figure 4.7F).  In the proximal 
segment of the nerve, this IL-6-related decrease in the number of RGC axons corresponds well to 
the smaller overall size of the nerve (Figure 4.7E; left). However, the size of the distal segment 
of the nerve in Il-6-/- did not differ from that of WT mice, suggesting that space in the distal 
nerve is being filled in some other way. As examination of macroglia revealed no obvious 
differences between genotypes (Figure 4.7C,D; right), we next looked at axon morphology, axon 
diameter, myelin thickness and g-ratio in cross-sections of the distal optic nerve. 
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Figure 4.7. Il-6-/- mice have fewer RGC axons. (A) Representative optic nerves from WT (left) 
and Il-6-/- (right) mice show no gross defects besides a slight thinning in the proximal portion 
(arrow heads) of the optic nerve in Il-6-/- mice. Scale bar= 5mm. (B) Quantification of optic 
nerve length reveals no significant difference between genotypes (p=0.409, two tailed t-test, n=5-
8 nerves/genotype). Error bars indicate standard deviation. (C-D) Representative 10X montaged 
images of proximal (left) and distal (right) optic nerve sections from WT (C) and Il-6-/- (D) 
mice. Scale bar= 50μm. Proximal and distal designation noted in A. Boxed regions were 
enlarged to highlight individual glial (arrow heads) and axon (arrows) morphology. Scale bars= 
10μm. (E) Quantification of optic nerve cross-section area shows a significant decrease in 
proximal (p<0.001, Mann-Whitney Rank Sum test), but not distal (p=0.066, Mann-Whitney 
Rank Sum test) portions of optic nerve in Il-6-/- mice compared to WT mice (n=9-10 
nerves/genotype). (F) Quantification of total axons reveals Il-6-/- mice have fewer axons in both 
the proximal (p=0.020, Mann-Whitney Rank Sum test) and distal (p=0.002, Mann-Whitney Rank 
Sum test) portions of the optic nerve compared to WT (n=9-10 nerves/genotype). *=p<0.05. 
Dashed line in boxplots indicates median value. 
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RGC axons in Il-6-/- optic nerve had a larger overall diameter (Dt) compared to WT optic nerve 
(p<0.001, Figure 4.8A,B). This increase in size was due to both a significant increase in inner 
axonal diameter (Di) (p<0.001, Figure 4.8A,C) and myelin thickness (p<0.001, Figure 4.8A,D). 
The corresponding increases in inner axon diameter and myelin thickness maintained a g-ratio 
(Di/Dt) of 0.627um in Il-6-/- optic nerve, which did not differ from that measured in WT optic 
nerve (0.621um, p=0.356, Figure 4.8A,E). That the extent of myelination did not differ between 
the two genotypes was further confirmed by plotting total axon diameter against inner axon 
diameter (Figure 4.8E). The scatter plot revealed the Il-6-/- axon population is shifted to the right 
of the WT population. However, the slopes (g-ratio) of the two populations are similar (Figure 
4.8E).  
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Figure 4.8. Il-6-/- mice have larger axons. (A) Diagram describing how total axon diameter and 
inner axon diameter were measured and how myelin thickness and gRatio were calculated. Scale 
bar= 1μm. (B) Quantification of total axon diameter shows Il-6-/- mice have significantly larger 
axons than WT mice (p<0.001, Mann-Whitney RANK Sum Test, n=300 axons/genotype). (C-D) 
Increase in axon size is attributed to both a larger inner axon diameter (C; p<0.001, Mann-
Whitney RANK Sum Test) and a thicker myelin sheath (D; p<0.001, Mann-Whitney RANK 
Sum Test). (E) Despite, the overall increase in axon size, optic nerve axon g-ratio (inner axon 
thickness/total axon thickness) was similar between WT and Il-6-/- mice (p=0.356, Mann-
Whitney RANK Sum Test). (F) Plots of the total axon diameter (axon + myelin sheath) against 
inner axon diameter (axon) for WT (blue) and Il-6-/- (pink) optic nerves. The slopes of the 
populations, which represent g-ratio, were similar. *=p<0.001. Dashed line in boxplots indicates 
median value. 
______________________________________________________________________________ 
 
IL-6 Deficiency Alters Microtubule Arrangement in RGC Axons 
To determine whether enlargement of RGC axons could be related to delayed axon 
transport, we examined the cytoarchitecture of RGC axons. CTB and WGA are transported in 
anterograde and retrograde fashions through the microtubule network of axons (Kobbert et al., 
2000, Abbott et al., 2013). Microtubules are composed of α- and β- subunits of tubulin along 
with a variety of microtubule associated proteins (MAPs), such as tau (Desai and Mitchison, 
1997). In contrast, actin and neurofilaments contribute to the architecture of the axon, but are not 
directly related to axon transport. Therefore, we examined the arrangement of microtubules, 
neurofilaments and actin in the unmyelinated segment of RGC axons in WT and Il-6-/- mice. We 
found that, in WT mice, immunolabeling against neuronal specific β-tubulin III (TUJ1) exhibited 
a compact, linear pattern parallel with the trajectory of the axon in both peripheral (top panel) 
and central regions (middle/bottom panels) of the retina (Figure 4.9A). However, in Il-6-/- mice, 
β-Tubulin labeling exhibited a zig-zag appearance with evidence of clump-like aggregations 
(Figure 4.9B). This observation was corroborated by a similar aggregation pattern of MAP tau, a 
microtubule-associated protein (Figure 4.9C,D).  
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Fig 4.9. Il-6-/- mice contain disorganized microtubules in retina. (A-B) Representative 100X 
confocal images of β-Tubulin (TUJ1; green) from WT (A) and Il-6-/- (B) un-myelinated axons in 
the peripheral (top) and central (middle) retina. β-Tubulin in axons from Il-6-/- mice presents 
with an aggregated appearance (arrowheads), unlike the linear morphology present in axons from 
WT mice. Scale bars= 20μm. (C-D) Representative 100X confocal images of microtubule 
associated protein Tau (red) from WT (C) and Il-6-/- (D) mice. Similar to β-Tubulin, the 
appearance appears aggregated in axons of Il-6-/- mice compared to WT mice (arrowheads). 
Scale bars= 20μm. Boxed regions were zoomed to highlight aggregations. 
__________________________________________________________________________ 
 
IL-6-related disorganization of the axon cytoskeleton appeared specific to microtubules as 
labeling against actin (Figure 4.10A) and phosphorylated heavy neurofilament (pNF-H; (Figure 
4.10B) revealed a comparable linear architecture in RGC axons from both WT and Il-6-/- mice.  
 
Figure 4.10. Cytoskeletal abnormalities in Il-6-/- mice are restricted to microtubules. (A-B) 
Representative 100X confocal images of (A) Actin and (B) phosphorylated neurofilament heavy 
(pNF-H) localization in axons from WT and Il-6-/- mice. Both WT and Il-6-/- mice show a 
similar linear morphology of both Actin (phalloidin) and pNF-H (SMI-31) in un-myelinated 
RGC axons. Scale bars= 20μm. 
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Figure 4.11. Microtubule abnormalities also occur in hippocampus of Il-6-/- mice. (A) 
Representative examples of whole brains from WT and Il-6-/- mice depict a slight enlargement 
in brain size. (B) Quantification of brain width at two locations (solid lines in A; Line 1: 
0.145mm rostral of Bregma, Line 2: 1.955mm caudal of Bregma) show a significant increase in 
brain width at 1.955mm rostral of Bregma in Il-6-/- mice (p=0.008, two-tailed  t-test, n=8-
9/genotype). Scale bar= 5mm. (C) Representative 4X montages of WT (left) and Il-6-/- (right) 
brain sections labeled for β-Tubulin (TUJ1; green) at Bregma coordinates mentioned above. 
Scale bar= 1mm. (D) Blow up of hippocampi of WT (left) and Il-6-/- (right) mice. Scale bar= 
500μm. (E) Representative 40X (far left) and 100X (middle) confocal images of pyramidal cell 
axon morphology in the CA1 region (boxed region in D) of the hippocampus shows 
disorganization of pyramidal cell axons in Il-6-/- mice (bottom) compared to WT mice (top). 
Zoomed in regions from 100X images (far right) highlight disorganization.  Scale bars= 50μm 
(40X), 20μm (100X and Zoom). 
______________________________________________________________________________ 
 
To determine whether microtubule disorganization was specific to the retina, we examined 
overall morphology and beta-tubulin labeling in coronal sections of brain from Il-6-/- and WT 
mice. We found that the brain of Il-6-/- mice generally appeared broader than that of WT mice, 
particularly towards the center of the brain (Figure 4.11A). Quantification of brain width at a 
rostral (Bregma +0.196mm) and central (Bregma -1.995mm) location, confirmed this increase in 
central (2, p=0.008; Figure 4.11B), but not rostral areas (1, p=0.065; Figure 4.11B). Examination 
of beta-tubulin labeling at low magnification revealed more robust labeling in Il-6-/- mice than 
WT, with pockets of high intensity labeling scattered through structures (Figure 4.11C).  
Interestingly, the aggregated appearance of β-tubulin III was specific to the retina. Examination 
of pyramidal cell axons in the CA1 region of the hippocampus in Il-6-/- mice did not reveal 
aggregations of tubulin, but did show disorganization compared to WT pyramidal cell axons 
(Figure 4.11D,E).  
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Acute Exposure to IL-6 Influences Tubulin Arrangement and Fast Axon Transport  
The Il-6-/- mice utilized in our studies is a germline deficiency and thus, impacts IL-6 
activities both in development and maturity. To examine whether the axon transport and 
microtubule phenotypes noted in Il-6-/- mice arise from developmental or mature activities, we 
provided short-term replacement of recombinant IL-6 in adult Il-6-/- mice and examined axon 
transport and microtubule staining. Il-6-/- mice received a single injection of recombinant IL-6 
(rIL-6; 500ng) or equal volume of 0.1% BSA in the vitreal cavity 24 hours prior to CTB 
injection. Similar to naïve experiments, BSA-treated Il-6-/- mice exhibited impaired transport of 
CTB to the SC after 3 days (median= 77.359%) that resolved when the tracing latency was 
increased to 5 days (median= 95.868%, p=0.003, Figure 4.12A). Pre-treatment with rIL-6 in Il-6-
/- mice significantly increased transport facility with a tracing latency of 3 days (median= 
91.875%; p=0.024; Figure 4.12A). However, transport facility achieved following 3 days tracing 
latency and IL-6 treatment did not quite reach that observed with a latency of 5 days in BSA-
treated mice (p=0.039; Figure 4.12A). Examination of tubulin microstructure revealed that Il-6-/- 
mice receiving either BSA (Figure 4.12B) or rIL-6 (Figure 4.12C) appeared to have an improved 
tubulin microstructure regardless of the quantity of intact SC transport. 
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Figure 4.12. Transport latencies in Il-6-/- mice improve with recombinant IL-6. (A) Boxplots of 
% intact transport of 3 or 5 day CTB tracing from Il-6-/- mice receiving an intravitreal injection 
of 500ng of recombinant murine IL-6 or equal volume 0.1% BSA 24 hours before CTB 
injection. Intravitreal injection of IL-6 24 hours before CTB injection significantly improved 
anterograde transport in Il-6-/- mice after 3 days of tracing compared to Il-6-/- mice with 
intravitreal injections of 0.1% BSA (p=0.024, Mann-Whitney RANK Sum Test, n=12-16 
SC/group). Similar to naïve studies, 5 days of CTB tracing led to significantly improved RGC to 
SC tracing compared to 3 days in Il-6-/- mice injected with 0.1% BSA (p=0.003, Mann-Whitney 
RANK Sum Test, n=11-12 SC/group). Dashed lines in boxplots indicate median value. (B-C) 
Representative 100X confocal images of β-Tubulin and corresponding contralateral 3 day CTB 
transport map in Il-6-/- retinas following injection of BSA (B) or 500ng of IL-6 (C). After BSA 
or IL-6 injection tubulin abnormalities improve in Il-6-/- mice, regardless of intact transport. 
Zoomed in regions from 100X images (bottom) show tubulin improvement. Dashed line in 
boxplots indicates median value. Scale bars= 20μm. *=p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 132 
Discussion 
Cytokine signaling in the CNS, particularly IL-6 signaling, is normally discussed in the 
context of neuroinflammation and its effect on neurodegeneration. However, there is increasing 
evidence that IL-6, along with other gp130 cytokines, is instrumental in proper development and 
maintenance of neurons and glia within the CNS. Here, we show evidence that IL-6 is 
constitutively expressed by RGCs throughout postnatal development into adulthood, suggesting 
a potential relevance for IL-6 signaling in the development of the optic projection (Figure 4.1). 
IL-6 expression from neurons is reported in other neuronal populations. In the healthy CNS 
expression is thought to be initiated by Ca
2+
 influx caused by membrane depolarization or 
glutamate activation of NMDA receptors. As RGCs are constantly depolarizing in response to 
light mediated glutamatergic signaling, it is possible that IL-6 production in RGCs is facilitated 
in a similar fashion. To follow up on this observation, we utilized Il-6-/- mice to ascertain 
functional and structural consequences of IL-6 deficiency, specifically in RGCs, throughout 
development. From our data, we found evidence of rather discreet abnormalities that are centered 
upon RGC function and axon development in response to IL-6 deficiency. Altogether, this data 
provides the first evidence implicating IL-6 signaling in the development of the optic projection.  
In vivo assessment of the retina using SD-OCT suggests that IL-6 deficiency leads to a 
slight, yet significant decrease in overall retinal thickness (Figure 4.2). However, IL-6 deficiency 
does not greatly impact overall structure and morphology of the retina, including that of the GCL 
where RGCs reside. Significant differences in specific retinal layers included decreases in RPE, 
ONL, OPL and increases in the INL. The significant decrease in the former suggests a reduction 
in photoreceptors while an increase in the latter suggests a larger population of bipolar, 
horizontal and amacrine cells. While further studies are needed to confirm this finding, genetic 
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ablation of fellow gp130 cytokines CNTF and LIF also alters photoreceptor and bipolar 
development (Rhee and Yang, 2010) 
Interestingly, these structural changes in the retina were coupled with abnormalities in the 
cortical response to light at certain intensities as measured by FVEPs. The  FVEP waveform 
represents a summed potential of cortical response along the early visual pathway (Ridder and 
Nusinowitz, 2006). Based on studies in multiple sclerosis, the amplitude and latency of the 
N1/P1 components constitutes the strength and speed of the light response as it travels through 
the optic projection (You et al., 2011, You et al., 2012). Assessment of the FVEP waveform in 
Il-6-/- mice revealed an increase in the amplitude and latency of the N1 component at light 
intensities of 1.0 and 5.0 cd.s/m
2
 (Figure 4.3B,C), but not 0.01 cd.s/m
2 
(Figure 4.3A). This 
suggests that IL-6 deficiency results in a stronger electrophysiological response along the optic 
projection (increased N1 amplitude) that travels poorly along the optic projection (increased N1 
latency) at higher light intensities. While additional experiments are needed to elucidate the 
mechanisms behind these differences, evidence from the literature and our data can provide a 
preliminary hypothesis for these observations. For example, the increase in amplitude of the N1 
component seen in the higher light intensities is likely attributed to differences in cone 
photoreceptor mediated activation of RGCs, as they become sensitive to light intensities above 
0.01 cd.s/m
2 
(Heiduschka et al., 2010b). Therefore, the increase seen in Il-6-/- mice may be due 
to a higher population of cones within the retina.  In regards to the observed increases in latency 
of the N1 component, insufficient myelination of axons is thought to contribute to delays in N1 
latency (You et al., 2011). This, coupled with in vitro reports showing that IL-6 signaling is 
involved with oligodendrocyte differentiation and gene expression involved with myelin 
production (Valerio et al., 2002, Zhang et al., 2006, Zhang et al., 2007), indicates that loss of IL-
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6 may lead to deficiencies in RGC axon myelination. Interestingly, our data actually suggests 
that myelinated axons in Il-6-/- mice have increased myelin thickness (Figure 4.8D). However, 
we also noted a 20% decrease in the amount of myelinated axons in our Il-6-/- mice (Figure 
4.7F). While this might be interpreted as a 20% decrease in all axons with the Il-6-/- optic nerve, 
our investigation of optic nerve axons utilized PPD-stained semi-thin sections and light 
microscopy, which only allows assessment of myelinated axons. Therefore, it is possible that 
these absent axons in Il-6-/- mice are indeed unmyelinated axons, which would account for the 
N1 latency delays observed in the Il-6-/- FVEP waveform.  
In addition to the abnormalities seen in the F-VEP, we found that Il-6-/- mice exhibited a 
15-20% deficit in fast anterograde axonal transport three days after CTB/WGA injection, which 
is a significant tracing deficit compared to WT mice (Figure 4.4A-D). These deficits were not 
accompanied with decreases in RGC number (Figure 4.4E-F), deficits in projection terminals 
(Figure 4.5A) or tracer uptake (Figure 4.5C-G) suggesting capacity of transport was not affected. 
Instead, our data suggests that IL-6 influences the rate of axon transport as transport deficits of 
CTB and WGA were resolved following 5 days of tracing. Interestingly, this increase in tracing 
latency was accompanied by structural abnormalities in the RGC axons. In the myelinated 
portion, we found fewer, but larger RGC axons (Figure 4.7, Figure 4.8). In glaucoma, 
enlargement of the axon is an early sign of degeneration, caused by accumulation of cytoskeletal 
components, specifically phosphorylated neurofilaments (Cooper et. al., 2016). While we did not 
note any differences in actin or neurofilament cytoskeletal proteins (Figure 4.10), we did note 
disorganization of microtubule components β-Tubulin and tau (Figure 4.9). Interestingly, these 
abnormalities associated with microtubules were not restricted to the retina as disorganization 
was also noted in β-Tubulin positive axons in the hippocampus (Figure 4.11), a region where 
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previous studies show an important role for IL-6 signaling. Microtubules are composed of α- and 
β- subunits of tubulin and utilize a variety of microtubule associated proteins (MAPs), such as 
tau for stabilization (Desai and Mitchison, 1997). Given the association between microtubules 
and axon transport, it is likely that retardation of fast axon transport and microtubule 
disorganization in Il-6-/- mice are related as the identity and physical characteristics of proteins 
in the axoplasm are known to influence axoplasm resistance (Sabry et al., 1995).  
While IL-6 and BSA treatment both improved microtubule organization in Il-6-/- mice 
(Figure 4.12B,C), only rIL-6 treatment influenced the rate of axon transport (Figure 4.12A). 
Interestingly, changes in microtubule organization were more consistent than those in the rate of 
axon transport. While this result suggests that the microtubule abnormalities are not directly 
responsible for the increase in axon transport latency, the improvement in transport latency 
following IL-6 treatment argues that these effects are specific to IL-6 deficiency.  
Together, our structural and functional analyses in WT and Il-6-/- mice depict an axis of 
IL-6 signaling not involved in an injury response, but revolves around RGCs, particularly the 
development of RGC axons. While our studies describe novel functions of IL-6 in the early 
visual pathway and strongly implicate IL-6 as an important mediator of RGC axon function, we 
utilized global IL-6 deficient mice from homozygous breeding. Thus, our findings are solely in 
the context of how IL-6 deficiency primarily affects development of the early visual system. This 
is important as IL-6 shares the signal transduction receptor gp130 with other IL-6 family 
members and therefore, compensatory mechanisms from other IL-6 family members are 
possible.  To avoid potential confounds from compensatory gp130 signaling during development 
and to delineate between development and maintenance functions of IL-6 in retina, further 
studies using temporal and perhaps, cell type-specific control of IL-6 deficiency are needed.  
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CHAPTER 5 
 
Summary 
 
Purpose of Studies 
 The objective of these studies was to ascertain how the pleotropic cytokine interleukin-6 
(IL-6) affects RGCs during conditions of homeostasis and glaucoma- related neurodegeneration. 
Prior experiments conducted by our laboratory and others showed that IL-6 signaling is relevant 
to glaucomatous pathology and that it influences RGC survival in response to elevated 
hydrostatic pressure in vitro. These studies, coupled with other reports showing IL-6 mediated 
CNS degeneration and nervous system defects in IL-6 deficient mice led us to our hypothesis 
that IL-6 has opposing roles in the healthy and compromised optic projection.  Specifically, we 
proposed that in response to a chronic stressor (i.e. elevated IOP) IL-6 promotes RGC 
degeneration. However, constitutive IL-6 signaling is required for proper development and 
function of the optic projection. This hypothesis was addressed using these three specific aims: 
Aim 1. Establish the expression profile for IL-6 machinery in response to glaucoma-
related stressors. 
Aim 2. Determine whether IL-6 influences RGC degeneration caused by ocular 
hypertension. 
Aim 3. Identify structural and functional outcomes of constitutive IL-6 signaling in the 
naïve optic projection. 
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Aim 1: Outcome and Future Directions 
Establishing the expression profile for IL-6 machinery in response to glaucoma-related 
stressors.  
IL-6 signaling is characterized by the isoform of the IL-6Rα. Classical signaling utilizes 
mIL-6Rα while trans-signaling utilizes sIL-6Rα (Scheller et al., 2011a). Studies in the CNS and 
other organ systems suggest that trans-signaling is associated with pathogenic IL-6 signaling, 
while classical signaling is involved in maintaining homeostasis (Scheller et al., 2011a, Rothaug 
et al., 2016). Examining how glaucoma-related stressors alter the IL-6Rα isoform allowed us to 
better understand the form of IL-6 signaling utilized in response to age and age-dependent 
increases in IOP. As expected, retina from aging (8mo) DBA/2J mice presented with elevations 
in sIL-6Rα compared to young (4mo) DBA/2J mice. Interestingly, this was also seen in aged-
matched C57 controls, suggesting normal aging is sufficient to induce production of the sIL-6Rα 
isoform. Gp130 protein was elevated in aged C57 retina compared to young C57 retina. 
However, no change was seen between young and aged DBA/2J mice, suggesting IOP elevation 
affects age-dependent gp130 elevation.  
In the retina, histological assessment showed that the mIL-6Rα and sIL-6Rα isoforms and 
gp130 localized to RGCs in both young and aging DBA/2J retina. Consistent with the 
biochemical data in total retina, sIL-6Rα was more prevalent in RGCs from aged DBA/2J mice, 
while no change was observed in gp130. As expected, CTB uptake from RGCs was 
compromised in aged DBA2/J compared to young DBA/2J, indicative of poor RGC health. Our 
correlation analysis revealed that sIL-6Rα is localized primarily to compromised RGCs in aging 
DBA/2J mice. Interestingly, no correlation between gp130 intensity and CTB intensity was 
present, suggesting gp130 expression does not reliably predict RGC integrity and sensitivity to 
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IL-6 signaling in the DBA/2J model of glaucoma is primarily facilitated by sIL-6Rα production. 
As sIL-6Rα is attributed to the pathogenic arm of IL-6 signaling known as trans-signaling, these 
results provide support to our hypothesis that IL-6 is detrimental to RGC pathology. 
 
Aim 1: Future Directions 
Future directions for this aim would involve experiments that elucidate 1) the 
concentration and localization of sIL-6Rα later in DBA/2J glaucoma pathology 2) the 
mechanism behind sIL-6Rα production, and 3) downstream targets of IL-6 trans-signaling. First, 
it would be interesting to determine whether sIL-6Rα concentration continues to be elevated 
during later stages of the disease. While our aged time-point (7-8 mo) coincides with onset of 
RGC dysfunction and transport deficits, significant axon pathology doesn’t occur until close to 
12 months of age, with RGC loss occurring later (Buckingham et al., 2008, Crish et al., 2010). 
Therefore, it would be of interest to see not only how sIL-6Rα expression and localization is 
affected at these time points, but whether sIL-6Rα concentration correlates to the severity of 
axon degeneration and RGC loss seen at these time points. This would further validate our 
hypothesis that IL-6 trans-signaling is involved in glaucomatous pathology.  
Second, it would be important to determine the source of sIL-6Rα and mechanisms 
behind sIL-6Rα production in DBA/2J glaucoma. While these data and others show IL-6Rα 
expression from RGCs, studies also report IL-6Rα within microgliaand astrocytes elsewhere in 
the CNS (Erta et al., 2012). Therefore, future experiments would entail using 
immunohistochemistry or flow cytometry to determine whether glial cells within the retina also 
express IL-6Rα. A follow up experiment using primary cell culture, would be to determine 
which cell type(s) are responsible for sIL-6Rα cleavage. In terms of mechanism, it is currently 
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accepted that the matrix metalloproteases, ADAM10 and ADAM17, are responsible for 
facilitating sIL-6Rα cleavage from mIL-6Rα in the mouse (Scheller et al., 2011a, Rothaug et al., 
2016). However, it is unknown whether expression or activation of ADAM10/17 is altered by 
glaucoma- related stressors. Correlating ADAM10/17 expression/ activation to sIL-6Rα 
concentration would corroborate its role in sIL-6Rα production in response to glaucoma specific 
stressors.  Lastly, our data shows that normal aging and aging accompanied by IOP elevation 
leads to increased sIL-6Rα production. However, it is unknown whether IOP elevation alone is 
sufficient to elevate sIL-6Rα. Using the in vivo microbead occlusion model or the in vitro 
hydrostatic pressure chamber model, we can determine whether sIL-6Rα elevation also occurs in 
response to age-independent increases in IOP elevation using the biochemical and histological 
assays utilized in our study.  
Finally, it would be beneficial to determine potential differences in the downstream 
targets for IL-6 classical and trans-signaling, as it would elevate our understanding on whether 
classical and trans-signaling lead to different survival outcomes. By adding soluble gp130 into 
the system, which blocks trans-signaling but not classical signaling, we can compare differences 
in signal transduction cascade activation and subsequent gene expression associated with cellular 
integrity between the two signaling mechanisms.  
  
 
 
 
 
 
 140 
Aim 2: Outcome and Future Directions 
Determine whether IL-6 influences RGC degeneration caused by ocular hypertension. 
 Based on our knowledge that glaucoma related stressors lead to increases in IL-6 and that 
sIL-6Rα localizes to compromised RGCs, we wanted to examine whether IL-6 signaling 
influences measures of RGC axonopathy. To determine the impact of all forms of IL-6 signaling 
on RGC axonopathy, we induced ocular hypertension for 8 weeks using our microbead occlusion 
model in WT and IL-6 deficient mice. As expected, ocular hypertension led to transport deficits 
of CTB in the SC of WT. Interestingly, similar transport deficits were noted in Il-6-/- mice. 
Examination of RGC axons in the distal optic nerve revealed decreases in myelinated axon 
density in microbead injected WT mice. While Il-6-/- mice presented with genotype dependent 
decreases in myelinated axon density, further analysis by electron microscopy is required to 
confirm an actual decrease. As our analysis was done using light microscopy, we could only 
reliable quantify myelinated axons. Therefore, this genotype dependent decrease could be the 
result of more unmyelinated axons in the Il-6-/- optic nerve. Regardless, we saw no microbead 
dependent decreases in myelinated axon density between saline and microbead injected Il-6-/- 
mice. Similarly, unlike WT mice, Il-6-/- mice were spared from microbead induced deficits in 
visual acuity threshold. While resistant to microbead induced axon degeneration and visual 
acuity deficits, Il-6-/- mice were sensitive to corneal injury caused by the intracameral injection. 
Overall, these results further support our hypothesis that IL-6 signaling is detrimental to 
glaucoma mediated RGC pathology. Additionally, it provides evidence that IL-6 signaling 
specifically influences the progression from functional deficits to structural degeneration in 
glaucoma.  
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Aim 2: Future Directions 
 Future directions for this aim would entail a number of experiments describing the impact 
of IL-6 deficiency in more chronic models of glaucoma and characterizing the mechanisms 
behind IL-6 deficiency and its protective effect in RGC axonopathy in glaucoma. The first of 
these experiments would involve replicating these findings in the more chronic DBA/2J model of 
glaucoma. However, this would involve a significant amount of time as we would need to 1) 
backcross the IL-6 mutation onto the DBA/2J genetic background, 2) develop a large enough 
colony to not only ascertain the effect of IL-6 deficiency at different ages, but overcome that 
natural variability of the DBA/2J mouse and 3) wait for several cohorts to reach the age where 
significant axon and RGC pathology is prevalent. However, as the DBA/2J models the 
progressive nature of glaucoma that is seen in humans, these experiments would be extremely 
beneficial.  
Borrowing on the results we obtained regarding sIL-6Rα in the aged DBA/2J mouse, 
another set of experiments would involve determining whether IL-6 trans-signaling is 
responsible for the IL-6 mediated effects seen in our WT mice. This would involve inducing 
ocular hypertension in mice that overexpress soluble gp130. If trans-signaling was responsible, 
we would we would see a similar mitigation of axon degeneration and visual acuity deficits in 
microbead injected sgp130 mice as we did in Il-6-/- mice.  
Third, I would determine the cellular mechanism behind IL-6 mediated RGC axonopathy. 
Specifically, I would conduct a microarray from retinal samples from microbead injected WT 
and Il-6-/- mice exposed to various time periods of ocular hypertension to see if any changes in 
gene expression are apparent. Preliminary results from our lab shows that following 4 weeks of 
ocular hypertension, genes associated with inflammation (i.e. TNFα) and cell health (BCL-XL) 
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differentially altered between microbead injected WT and Il-6-/- mice. Interestingly, the pattern 
of these changes suggests a higher level of inflammation as seen by increased TNFα expression  
(Figure 5.1B) and lower levels of cell survival as seen by decreased anti-apoptotic marker Bcl-
XL in microbead injected retina of Il-6-/- compared to that of WT (Figure 5.1D). While this 
result would suggests that IL-6 deficiency is detrimental, gene expression studies done at 8 
weeks would provide more accurate results. 
 143 
 
 144 
Figure 5.1. IL-6 deficiency influences glaucoma-related changes in gene expression of 
neuroinflammory, cell health and gp130 modulators. (A–E) Percent gene expression of Tnfα (A), 
Il-1β (B), Bcl-xl (C), Bax (D) and Socs3 (E) in WT or Il-6-/- eyes injected with saline (white) or 
microbeads (gray). mRNA levels of gene targets were normalized to Gapdh and compared to 
respective naive expression levels (dotted line) via the ΔΔCt method. Statistical significance 
(p<0.05) is indicated as follows: * naïve versus experimental, ** between genotype comparison, 
# within genotype comparison. 
 
Figure from (Echevarria et al., 2016) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License. 
______________________________________________________________________________ 
 
Finally, it would be beneficial to determine how the other gp130 cytokines impact RGC 
degeneration in glaucoma. Indeed, we have shown previously that all other members of the 
gp130 family are upregulated in response to glaucoma related stressors in the DBA/2J mouse 
(Figure 5.2). Therefore, it would be interesting to see whether genetic ablation of these cytokines 
leads to similar outcomes in RGC pathology.  
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Figure 5.2. Glaucoma-related stressors elevate expression of IL-6 family members in a stressor 
dependent manner. (A-F) Gene expression of Cntf (A), Lif (B), Clcf1 (C), Ctf1 (D), Osm (E) and 
Il-11 (F) in whole retina from young (4mo) and aged (8mo) C57and DBA/2J mice, as 
determined by quantitative PCR. mRNA levels of gene targets were normalized to Gapdh. Data 
are presented as percent change in gene expression relative to expression in young C57 retina 
(ΔΔCT). Asterisks denote statistical significance (p< 0.05), as compared to expression in young 
C57 retina. *= p<0.05. 
 
Figure from (Echevarria et al., 2013) and used in accordance with the Creative Commons 
Attribution-Non Commercial 4.0 International License.  
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Aim 3: Outcome and Future Directions 
 
Identify structural and functional outcomes of constitutive IL-6 signaling in the naïve optic 
projection. 
In vitro, IL-6 facilities neurite extension in RGCs, while IL-6 promotes axon regeneration 
following optic nerve crush (Chidlow et al., 2012, Leibinger et al., 2013, Leibinger et al., 2016). 
Additionally, IL-6 deficiency is attributed to structural and functional deficits in other areas of 
the nervous system (Zhong et al., 1999, Baier et al., 2009, Bowen et al., 2011, Kong et al., 2015). 
Therefore, we utilized a number of structural and functional outcomes to determine whether 
constitutive IL-6 signaling is important in the development and maintenance of the optic 
projection. Our observation that IL-6 is expressed by RGCs throughout post-natal development 
and adulthood provided the first set of evidence implicating IL-6 in post-natal development. 
From there we found that while IL-6 deficiency did not impact overall visual acuity, it perturbed 
the cortical response to light stimuli (FVEP) and led to decreased retinal thickness. Neural 
tracing studies revealed that anterograde axonal transport along the retinocollicular projection 
was slower in Il-6-/- mice compared to WT mice. This apparent decrease in the rate of fast 
axonal transport was not due to gross abnormalities in superior colliculus architecture, retinal 
ganglion cell number or deficiencies in tracer uptake. Examination of cytoskeletal elements 
within the un-myelinated portion of RGC axons revealed disorganization of the axon 
cytoskeleton specific to microtubules, which are responsible for fast axonal transport. 
Examination of the hippocampus revealed similar disruptions in microtubule arrangement. 
Investigation into the myelinated segment of optic nerve axons revealed that IL-6 deficiency led 
to larger axons with thicker myelin sheaths, which was accompanied by a decline in myelinated 
axon density and total number of axons in the optic nerve.  Pharmacological reversal of IL-6 
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deficiency appeared to improve the rate of axon transport while also improving tubulin 
arrangement.  
 
Aim 3: Future Directions 
Similar to the other aims, future directions for this part would entail a number of 
experiments focusing on characterizing the cellular mechanism(s) behind our results. 
Specifically, I would supplement our FVEP data by utilizing other electrophysiological 
paradigms that collect data specifically from RGCs. While the FVEP signal is dependent on 
RGCs connecting to the brain, the message could be perturbed as it travels though the RGC axon 
and into the visual cortex. More accurate RGC signals could be obtained by measuring PERG 
responses directly from the retina. Additionally, individual recording from RGCs via patch 
clamp electrophysiology would provide information regarding the activity of individual RGCs.  
Another set of experiments would be to delineate whether IL-6 related deficits are truly 
the result of a developmental defect. To accomplish this, I would conditionally ablate IL-6 
signaling in the adult mouse and see if similar structural and functional phenotypes. If not, that 
would suggest these defects are associated with IL-6 signaling during development. If that were 
the case, I would ablate IL-6 signaling at different points in development to determine the crucial 
period in which IL-6 signaling is necessary for development of the optic projection. Finally, in 
line with Aim 2, I would test the roles of the other gp130 cytokines in the development of the 
optic projection to see if these abnormalities are IL-6 specific. 
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Potential mechanism behind outcomes of IL-6 signaling in RGC health and disease. 
Our studies utilizing the microbead occlusion model in IL-6 deficient mice suggest that 
constitutive IL-6 signaling is necessary for proper tubulin cyto-architecture and latency of fast 
axonal transport, yet in response to glaucoma related IOP elevation, IL-6 signaling promotes 
axonopathy and vision loss. Based on the literature and our studies in the DBA/2J mouse model 
of glaucoma, we speculate sIL-6Rα may be responsible for transforming IL-6 from a 
constructive signal to a destructive signal in the optic projection. Prior to forming a hypothesis 
on the potential mechanism(s) behind this phenomenon, it is important to understand the 
molecular outcome(s) of IL-6 signaling and how it is affected in neurodegenerative disease. One 
particular outcome of IL-6 signaling involves influx of Ca
2+ 
in the intracellular space (Qiu et al., 
1995, Nelson et al., 2002, Orellana et al., 2005) . This is especially interesting as studies show 1) 
involvement of Ca
2+ 
signaling
 
in axon development (Lohmann, 2009, Rosenberg and Spitzer, 
2011) and 2) dysregulated Ca
2+ 
signaling
 
within RGCs affected by glaucoma (Crish and Calkins, 
2011). 
Ca
2+ 
is an important intracellular signaling ion in the CNS that regulates a variety of 
necessary functions within neurons including gene transcription, neurotransmitter release, 
synaptic plasticity and axon development (Berridge et al., 2000, Lohmann, 2009, Rosenberg and 
Spitzer, 2011) . Interestingly, multiple studies report that incubation of neurons with IL-6 leads 
to increases in intracellular Ca
2+ 
(Qiu et al., 1995, Nelson et al., 2002, Orellana et al., 2005). Our 
studies in naïve IL-6 deficient mice suggest a positive role for IL-6 in microtubule structure and 
axon transport. Indeed, previous studies report that application of IL-6 promotes neurite 
extension in vitro and axon regeneration in vivo (Chidlow et al., 2012, Leibinger et al., 2013, 
Leibinger et al., 2016). While there are currently no reports describing an effect of IL-6 on 
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microtubule integrity directly, neurite extension and alteration of synapses involve changes in 
microtubule assembly (Conde and Caceres, 2009). As Ca
2+ 
signaling is required for proper 
axonal navigation and establishing proper synaptic connections in the developing CNS, one 
could suggest that the phenotypes observed in the Il-6-/- optic projection is due to altered Ca
2+ 
signaling during development and possibly adulthood (Figure 5.3A). An important study would 
be to utilizing Ca
2+ 
imaging or single cell electrophysiology to determine the capacity of Ca
2+ 
signaling in Il-6-/- mice.   
Tight regulation of Ca
2+ 
influx is imperative, as surpassing its normal spatial and 
temporal limits within the cytoplasm can lead to degenerative outcomes, including axon 
degeneration and production of reactive oxygen species (ROS), both of which contribute to 
apoptosis of the cell soma. As with most neurodegenerative diseases, aberrant Ca
2+
 signaling is 
prominent throughout glaucoma pathology (Crish and Calkins, 2011).  While the mechanism 
behind Ca
2+ 
dysregulation in glaucoma is not well understood, it is hypothesized that chronic 
Ca
2+
 influx triggers excessive activation of downstream targets including calpain (Crish and 
Calkins, 2011). Calpain is a protease that leads to phosphorylation of the microtubule associated 
protein tau, which can lead to defects in axon transport and subsequent degeneration of the axon. 
Interestingly, Ca
2+
 mediated phosphorylation of tau in hippocampal neurons is also seen 
following incubation with IL-6, suggesting a connection between IL-6 and Ca
2+ 
mediated effects 
in glaucomatous axonopathy (Orellana et al., 2005). From these data, we can hypothesize that the 
reduction in axonopathy seen in our microbead injected Il-6-/- mice may be due to a mitigation 
in aberrant Ca
2+
 signaling (Figure 5.3B). 
The dichotomous outcomes of IL-6 signaling have been well described in both the CNS 
and the periphery, with classical signaling via mIL-6Rα and trans-signaling via sIL-6Rα 
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implicated in positive and negative outcomes respectively (Scheller et al., 2011a). Our studies in 
the DBA/2J model of glaucoma indicate that sIL-6Rα elevation coincides with axon transport 
deficits, a component of glaucoma pathology that precedes axon degeneration. As our microbead 
studies suggest that IL-6 signaling is involved in glaucoma related axonopathy, it is plausible to 
suggest that the increase in sIL-6Rα changes IL-6 signaling from classical to trans, promoting a 
shift from axon transport deficits to axon degeneration (Figure 5.3B). While  it is not known how 
signaling through sIL-6Rα leads to degeneration directly, it is believed that IL-6 binding to sIL-
6Rα not only increases the circulating half -life of IL-6, but increases the propensity for IL-6 
signaling events to occur in domains where IL-6 is released (Hunter and Jones, 2015).  If indeed 
IL-6 signaling leads to Ca
2+ 
influx, a stronger and longer IL-6 signal brought on by sIL-6Rα 
could lead to the aberrant Ca
2+ 
influx and subsequent pathology seen in glaucoma (Figure 5.3B).  
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Figure 5.3. Proposed mechanism behind outcomes of IL-6 signaling in RGC health and disease. 
(A) In the naïve optic projection, Ca
2+
 influx via IL-6 mediated STAT3 activation facilitates 
proper axon development and maintenance, by directly or indirectly acting on microtubules. (B) 
In response to glaucoma related stressors (e.g. elevated IOP), we propose that the upregulation of 
IL-6 and sIL-6Rα leads to an increase in IL-6 signaling events, causing an unhealthy influx of 
Ca
2+
and overtime leading to axon degeneration.  
 
Figure adapted from (Echevarria et al., 2016) and used in accordance with the Creative 
Commons Attribution-Non Commercial 4.0 International License.  
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Conclusions 
Altogether, these data indicate that IL-6 signaling is detrimental to glaucoma mediated 
RGC pathology, yet necessary for proper development and maintenance of the optic projection. 
In the DBA/2J mouse, age-related increases in IOP lead to increased production of sIL-6Rα that 
localizes primarily to RGCs with poor CTB transport. Due to the age of these mice and the 
known progression of CTB transport deficits, this suggests a relationship between the increased 
prevalence of pathological IL-6 trans-signaling and the time period between axon transport 
deficits and axon degeneration (Figure 5.4). In examining the impact of IL-6 signaling on RGC 
degeneration caused by microbead induced ocular hypertension, IL-6 deficient mice were 
protected against axon degeneration and deficits in visual acuity, yet experienced a similar 
degree of axon transport deficits. Taken together, these results suggest that 1) IL-6 signaling, 
specifically trans-signaling, facilitates axon degeneration in glaucoma (Figure 5.4). Finally, we 
show a role for constitutive IL-6 in optic projection development, particularly in regards to 
maintaining proper axon transport and tubulin cyto-architecture. As a whole, these results 
suggest that IL-6 is likely involved in multiple facets of CNS activity including development and 
degeneration. Furthermore, seemingly disparate outcomes of IL-6 signaling are likely to arise 
from a complex regulatory system that includes transitions between classical and trans-signaling 
pathways that are mediated by receptor isoforms. Together, our findings have significant 
implications for our understanding of IL-6 signaling within the CNS, with particular impact on 
its role as in CNS development and maintenance as well as a potential therapeutic target for 
neurodegenerative disease.   
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Figure 5.4. Integration of results with proposed timeline of glaucomatous RGC degeneration. 
Work in animal models suggests a profile that involves loss of function prior to loss of structure 
and that degeneration occurs in a distal to proximal fashion. For the majority of patients, 
treatment isn’t started until significant disease progression has occurred. Our work in IL-6 
suggests a mechanism in which IL-6 trans-signaling is upregulated early in disease (red arrow) 
and is involved in propagating axon degeneration (green arrow). In these results suggests a 
potential window in which anti-IL-6 signaling therapy could inhibit axon degeneration and 
subsequent vision loss in glaucoma.    
 
Figure modified from (Calkins, 2012) with permission form DJ Calkins and used in accordance 
with Copyright Clearance Center’s RightsLink service.  
 
 
 
 
 
 
 154 
REFERENCES 
 
Abbott CJ, Choe TE, Lusardi TA, Burgoyne CF, Wang L, Fortune B (2013) Imaging axonal 
transport in the rat visual pathway. Biomed Opt Express 4:364-386. 
 
Agorastos A, Hauger RL, Barkauskas DA, Moeller-Bertram T, Clopton PL, Haji U, Lohr JB, 
Geracioti TD, Jr., Patel PM, Chrousos GP, Baker DG (2014) Circadian rhythmicity, 
variability and correlation of interleukin-6 levels in plasma and cerebrospinal fluid of 
healthy men. Psychoneuroendocrinology 44:71-82. 
 
Albon J, Karwatowski WS, Avery N, Easty DL, Duance VC (1995) Changes in the collagenous 
matrix of the aging human lamina cribrosa. Br J Ophthalmol 79:368-375. 
 
Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A, Buisson A, Vivien D (2000) 
Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine 
against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab 
20:956-966. 
 
Alleva E, Cirulli F, Bianchi M, Bondiolotti GP, Chiarotti F, De Acetis L, Panerai AE (1998) 
Behavioural characterization of interleukin-6 overexpressing or deficient mice during 
agonistic encounters. The European journal of neuroscience 10:3664-3672. 
 
Alsarraf O, Fan J, Dahrouj M, Chou CJ, Yates PW, Crosson CE (2014) Acetylation preserves 
retinal ganglion cell structure and function in a chronic model of ocular hypertension. 
Invest Ophthalmol Vis Sci 55:7486-7493. 
 
Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW (2002) 
Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in 
DBA/2J mice. Nat Genet 30:81-85. 
 
Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl C, Sailer CA, 
Uceyler N, Brockhaus J, Martini R, Sommer C, Zeilhofer HU, Muller W, Kuner R, Davis 
JB, Rose-John S, Kress M (2009) A Key Role for gp130 Expressed on Peripheral 
Sensory Nerves in Pathological Pain. Journal of Neuroscience 29:13473-13483. 
 
Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2009) The retina in Parkinson's disease. 
Brain 132:1128-1145. 
 
Armario A, Hernandez J, Bluethmann H, Hidalgo J (1998) IL-6 deficiency leads to increased 
emotionality in mice: evidence in transgenic mice carrying a null mutation for IL-6. J 
Neuroimmunol 92:160-169. 
 
 155 
Arruda JL, Colburn RW, Rickman AJ, Rutkowski MD, DeLeo JA (1998) Increase of interleukin-
6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of 
IL-6 in neuropathic pain. Brain Res Mol Brain Res 62:228-235. 
 
Assali A, Gaspar P, Rebsam A (2014) Activity dependent mechanisms of visual map formation--
from retinal waves to molecular regulators. Semin Cell Dev Biol 35:136-146. 
 
Baier PC, May U, Scheller J, Rose-John S, Schiffelholz T (2009) Impaired hippocampus-
dependent and -independent learning in IL-6 deficient mice. Behav Brain Res 200:192-
196. 
 
Baltan S, Inman DM, Danilov CA, Morrison RS, Calkins DJ, Horner PJ (2010) Metabolic 
vulnerability disposes retinal ganglion cell axons to dysfunction in a model of 
glaucomatous degeneration. J Neurosci 30:5644-5652. 
 
Banitt MR, Ventura LM, Feuer WJ, Savatovsky E, Luna G, Shif O, Bosse B, Porciatti V (2013) 
Progressive loss of retinal ganglion cell function precedes structural loss by several years 
in glaucoma suspects. Invest Ophthalmol Vis Sci 54:2346-2352. 
 
Bauer S, Kerr BJ, Patterson PH (2007) The neuropoietic cytokine family in development, 
plasticity, disease and injury. Nat Rev Neurosci 8:221-232. 
 
Behrens C, Schubert T, Haverkamp S, Euler T, Berens P (2016) Connectivity map of bipolar 
cells and photoreceptors in the mouse retina. Elife 5. 
 
Beirowski B, Babetto E, Coleman MP, Martin KR (2008) The WldS gene delays axonal but not 
somatic degeneration in a rat glaucoma model. The European journal of neuroscience 
28:1166-1179. 
 
Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, Wisniewski SR, 
Whalen MJ, DeKosky ST (1997) Interleukin-6 and interleukin-10 in cerebrospinal fluid 
after severe traumatic brain injury in children. J Neurotrauma 14:451-457. 
 
Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of calcium signalling. 
Nat Rev Mol Cell Biol 1:11-21. 
 
Berry RH, Qu J, John SW, Howell GR, Jakobs TC (2015) Synapse Loss and Dendrite 
Remodeling in a Mouse Model of Glaucoma. PLoS One 10:e0144341. 
 
Beurel E, Jope RS (2009) Lipopolysaccharide-induced interleukin-6 production is controlled by 
glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 6:9. 
 
Birke MT, Birke K, Lutjen-Drecoll E, Schlotzer-Schrehardt U, Hammer CM (2011) Cytokine-
dependent ELAM-1 induction and concomitant intraocular pressure regulation in porcine 
anterior eye perfusion culture. Invest Ophthalmol Vis Sci 52:468-475. 
 
 156 
Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH (2003) Interleukin 6 is 
important for survival after partial hepatectomy in mice. Hepatology 38:674-682. 
 
Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 
beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo 
Parkinson's disease patients. Neurosci Lett 202:17-20. 
 
Blumberg D, Skaat A, Liebmann JM (2015) Emerging risk factors for glaucoma onset and 
progression. Prog Brain Res 221:81-101. 
 
Bluthe RM, Michaud B, Poli V, Dantzer R (2000) Role of IL-6 in cytokine-induced sickness 
behavior: a study with IL-6 deficient mice. Physiol Behav 70:367-373. 
 
Boland B, Platt FM (2015) Bridging the age spectrum of neurodegenerative storage diseases. 
Best Pract Res Clin Endocrinol Metab 29:127-143. 
 
Bond WS, Hines-Beard J, GoldenMerry YP, Davis M, Farooque A, Sappington RM, Calkins DJ, 
Rex TS (2016) Virus-mediated EpoR76E Therapy Slows Optic Nerve Axonopathy in 
Experimental Glaucoma. Mol Ther 24:230-239. 
 
Bosco A, Inman DM, Steele MR, Wu G, Soto I, Marsh-Armstrong N, Hubbard WC, Calkins DJ, 
Horner PJ, Vetter ML (2008) Reduced retina microglial activation and improved optic 
nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. 
Invest Ophthalmol Vis Sci 49:1437-1446. 
 
Bouhenni RA, Dunmire J, Sewell A, Edward DP (2012) Animal models of glaucoma. J Biomed 
Biotechnol 2012:692609. 
 
Bourne RR (2012) The optic nerve head in glaucoma. Community Eye Health 25:55-57. 
 
Bowen KK, Dempsey RJ, Vemuganti R (2011) Adult interleukin-6 knockout mice show 
compromised neurogenesis. Neuroreport 22:126-130. 
 
Bozkurt B, Mesci L, Irkec M, Ozdag BB, Sanal O, Arslan U, Ersoy F, Tezcan I (2012) 
Association of tumour necrosis factor-alpha -308 G/A polymorphism with primary open-
angle glaucoma. Clin Exp Ophthalmol 40:e156-162. 
 
Broadway DC (2012) Visual field testing for glaucoma - a practical guide. Comm Eye Health 
25:66-70 
 
Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, Steele MR, Vetter ML, 
Marsh-Armstrong N, Horner PJ (2008) Progressive ganglion cell degeneration precedes 
neuronal loss in a mouse model of glaucoma. J Neurosci 28:2735-2744. 
 
 157 
Bunt AH, Hendrickson AE, Lund JS, Lund RD, Fuchs AF (1975) Monkey retinal ganglion cells: 
morphometric analysis and tracing of axonal projections, with a consideration of the 
peroxidase technique. J Comp Neurol 164:265-285. 
 
Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT (2005) The optic nerve head as a 
biomechanical structure: a new paradigm for understanding the role of IOP-related stress 
and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin 
Eye Res 24:39-73. 
 
Burroughs SL, Kaja S, Koulen P (2011) Quantification of deficits in spatial visual function of 
mouse models for glaucoma. Invest Ophthalmol Vis Sci 52:3654-3659. 
 
Burton MD, Johnson RW (2012) Interleukin-6 trans-signaling in the senescent mouse brain is 
involved in infection-related deficits in contextual fear conditioning. Brain Behav Immun 
26:732-738. 
 
Burton MD, Rytych JL, Freund GG, Johnson RW (2013) Central inhibition of interleukin-6 
trans-signaling during peripheral infection reduced neuroinflammation and sickness in 
aged mice. Brain Behav Immun 30:66-72. 
 
Burton MD, Sparkman NL, Johnson RW (2011) Inhibition of interleukin-6 trans-signaling in the 
brain facilitates recovery from lipopolysaccharide-induced sickness behavior. J 
Neuroinflammation 8:54. 
 
Butterweck V, Prinz S, Schwaninger M (2003) The role of interleukin-6 in stress-induced 
hyperthermia and emotional behaviour in mice. Behav Brain Res 144:49-56. 
 
Cafferty WB, Gardiner NJ, Das P, Qiu J, McMahon SB, Thompson SW (2004) Conditioning 
injury-induced spinal axon regeneration fails in interleukin-6 knock-out mice. J Neurosci 
24:4432-4443. 
 
Calkins DJ (2012) Critical pathogenic events underlying progression of neurodegeneration in 
glaucoma. Prog Retin Eye Res 31:702-719. 
 
Calkins DJ, Horner PJ (2012) The cell and molecular biology of glaucoma: axonopathy and the 
brain. Invest Ophthalmol Vis Sci 53:2482-2484. 
Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L (1993) 
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 
6. Proc Natl Acad Sci U S A 90:10061-10065. 
 
Campbell IL, Erta M, Lim SL, Frausto R, May U, Rose-John S, Scheller J, Hidalgo J (2014) 
Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in 
the brain. J Neurosci 34:2503-2513. 
 
Cardenas H, Bolin LM (2003) Compromised reactive microgliosis in MPTP-lesioned IL-6 KO 
mice. Brain Res 985:89-97. 
 158 
Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC (2006) CNS immune privilege: hiding 
in plain sight. Immunol Rev 213:48-65. 
 
Cesareo M, Martucci A, Ciuffoletti E, Mancino R, Cerulli A, Sorge RP, Martorana A, Sancesario 
G, Nucci C (2015) Association Between Alzheimer's Disease and Glaucoma: A Study 
Based on Heidelberg Retinal Tomography and Frequency Doubling Technology 
Perimetry. Front Neurosci 9:479. 
 
Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, Jones SA, Rose-John S, Scheller 
J (2007) Apoptosis is a natural stimulus of IL6R shedding and contributes to the 
proinflammatory trans-signaling function of neutrophils. Blood 110:1748-1755. 
 
Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, Savinova O, Roderick TH, 
Heckenlively JR, Davisson MT, John SW (1999) Interacting loci cause severe iris 
atrophy and glaucoma in DBA/2J mice. Nat Genet 21:405-409. 
 
Chen HH, Wei X, Cho KS, Chen GC, Sappington R, Calkins DJ, Chen DF (2011a) Optic 
Neuropathy Due to Microbead-Induced Elevated Intraocular Pressure in the Mouse. 
Invest Ophth Vis Sci 52:36-44. 
 
Chen KH, Wu CC, Roy S, Lee SM, Liu JH (1999) Increased interleukin-6 in aqueous humor of 
neovascular glaucoma. Invest Ophthalmol Vis Sci 40:2627-2632. 
 
Chen SK, Badea TC, Hattar S (2011b) Photoentrainment and pupillary light reflex are mediated 
by distinct populations of ipRGCs. Nature 476:92-95. 
 
Chen YP, Chiao CC (2014) Spatial distribution of excitatory synapses on the dendrites of 
ganglion cells in the mouse retina. PLoS One 9:e86159. 
 
Chevalier-Larsen E, Holzbaur EL (2006) Axonal transport and neurodegenerative disease. 
Biochim Biophys Acta 1762:1094-1108. 
 
Chidlow G, Ebneter A, Wood JPM, Casson RJ (2011) The optic nerve head is the site of axonal 
transport disruption, axonal cytoskeleton damage and putative axonal regeneration failure 
in a rat model of glaucoma. Acta Neuropathol 121:737-751. 
 
Chidlow G, Wood JP, Ebneter A, Casson RJ (2012) Interleukin-6 is an efficacious marker of 
axonal transport disruption during experimental glaucoma and stimulates neuritogenesis 
in cultured retinal ganglion cells. Neurobiol Dis 48:568-581. 
 
Chiu K, Chan TF, Wu A, Leung IY, So KF, Chang RC (2012) Neurodegeneration of the retina in 
mouse models of Alzheimer's disease: what can we learn from the retina? Age (Dordr) 
34:633-649. 
 
 159 
Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M, Schwaninger M, Gass P 
(2006) IL-6 knockout mice exhibit resistance to stress-induced development of 
depression-like behaviors. Neurobiol Dis 23:587-594. 
 
Chucair-Elliott AJ, Conrady C, Zheng M, Kroll CM, Lane TE, Carr DJ (2014) Microglia-
induced IL-6 protects against neuronal loss following HSV-1 infection of neural 
progenitor cells. Glia 62:1418-1434. 
 
Clark WM, Rinker LG, Lessov NS, Hazel K, Eckenstein F (1999) Time course of IL-6 
expression in experimental CNS ischemia. Neurol Res 21:287-292. 
 
Clark WM, Rinker LG, Lessov NS, Hazel K, Hill JK, Stenzel-Poore M, Eckenstein F (2000) 
Lack of interleukin-6 expression is not protective against focal central nervous system 
ischemia. Stroke 31:1715-1720. 
 
Conde C, Caceres A (2009) Microtubule assembly, organization and dynamics in axons and 
dendrites. Nat Rev Neurosci 10:319-332. 
 
Cooper ML, Crish SD, Inman DM, Horner PJ, Calkins DJ (2016) Early Astrocyte redistrbution 
in the optic nerve precedes axonopathy in the DBA/2J mouse model of glaucoma. Exp 
Eye Res 150:22-23. 
 
Crish SD, Calkins DJ (2011) Neurodegeneration in glaucoma: progression and calcium-
dependent intracellular mechanisms. Neuroscience 176:1-11. 
 
Crish SD, Dapper JD, MacNamee SE, Balaram P, Sidorova TN, Lambert WS, Calkins DJ (2013) 
Failure of axonal transport induces a spatially coincident increase in astrocyte BDNF 
prior to synapse loss in a central target. Neuroscience 229:55-70. 
 
Crish SD, Sappington RM, Inman DM, Horner PJ, Calkins DJ (2010) Distal axonopathy with 
structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci U S A 
107:5196-5201. 
 
Cueva Vargas JL, Osswald IK, Unsain N, Aurousseau MR, Barker PA, Bowie D, Di Polo A 
(2015) Soluble Tumor Necrosis Factor Alpha Promotes Retinal Ganglion Cell Death in 
Glaucoma via Calcium-Permeable AMPA Receptor Activation. J Neurosci 35:12088-
12102. 
 
Cvenkel B, Kopitar AN, Ihan A (2010) Inflammatory molecules in aqueous humour and on 
ocular surface and glaucoma surgery outcome. Mediators Inflamm 2010:939602. 
 
Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs 
JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ (2007) Proteomic 
profiling of plasma in Huntington's disease reveals neuroinflammatory activation and 
biomarker candidates. J Proteome Res 6:2833-2840. 
 
 160 
de Vos AF, Klaren VN, Kijlstra A (1994) Expression of multiple cytokines and IL-1RA in the 
uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 
35:3873-3883. 
 
Deleidi M, Jaggle M, Rubino G (2015) Immune aging, dysmetabolism, and inflammation in 
neurological diseases. Front Neurosci 9:172. 
 
Della Santina L, Inman DM, Lupien CB, Horner PJ, Wong RO (2013) Differential progression 
of structural and functional alterations in distinct retinal ganglion cell types in a mouse 
model of glaucoma. J Neurosci 33:17444-17457. 
 
Dengler-Crish CM, Smith MA, Inman DM, Wilson GN, Young JW, Crish SD (2014) 
Anterograde transport blockade precedes deficits in retrograde transport in the visual 
projection of the DBA/2J mouse model of glaucoma. Front Neurosci 8:290. 
 
Desai A, Mitchison TJ (1997) Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 
13:83-117. 
 
Deverman BE, Patterson PH (2009) Cytokines and CNS development. Neuron 64:61-78. 
 
DiStefano PS, Friedman B, Radziejewski C, Alexander C, Boland P, Schick CM, Lindsay RM, 
Wiegand SJ (1992) The neurotrophins BDNF, NT-3, and NGF display distinct patterns of 
retrograde axonal transport in peripheral and central neurons. Neuron 8:983-993. 
 
Domenici L, Origlia N, Falsini B, Cerri E, Barloscio D, Fabiani C, Sanso M, Giovannini L 
(2014) Rescue of retinal function by BDNF in a mouse model of glaucoma. PLoS One 
9:e115579. 
 
Dong HW (2008) Allen Reference Mouse Atlas. Hoboken, New Jersey: John Wyley & Sons, 
Inc. 
 
Douglas RM, Alam NM, Silver BD, McGill TJ, Tschetter WW, Prusky GT (2005) Independent 
visual threshold measurements in the two eyes of freely moving rats and mice using a 
virtual-reality optokinetic system. Vis Neurosci 22:677-684. 
 
Downs JC (2015a) IOP telemetry in the nonhuman primate. Exp Eye Res 141:91-98. 
 
Downs JC (2015b) Optic nerve head biomechanics in aging and disease. Exp Eye Res 133:19-29. 
 
Downs JC, Burgoyne CF, Seigfreid WP, Reynaud JF, Strouthidis NG, Sallee V (2011) 24-hour 
IOP telemetry in the nonhuman primate: implant system performance and initial 
characterization of IOP at multiple timescales. Invest Ophthalmol Vis Sci 52:7365-7375. 
 
Dreher B, Sefton AJ, Ni SY, Nisbett G (1985) The morphology, number, distribution and central 
projections of Class I retinal ganglion cells in albino and hooded rats. Brain Behav Evol 
26:10-48. 
 161 
Du S, Huang W, Zhang X, Wang J, Wang W, Lam DS (2016) Multiplex cytokine levels of 
aqueous humor in acute primary angle-closure patients: fellow eye comparison. BMC 
Ophthalmol 16:6. 
 
Dugan LL, Ali SS, Shekhtman G, Roberts AJ, Lucero J, Quick KL, Behrens MM (2009) IL-6 
mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in 
aged mice through activation of neuronal NADPH oxidase. PLoS One 4:e5518. 
 
Dvoriantchikova G, Barakat DJ, Hernandez E, Shestopalov VI, Ivanov D (2010) Toll-like 
receptor 4 contributes to retinal ischemia/reperfusion injury. Mol Vis 16:1907-1912. 
 
Echevarria F, Walker C, Abella S, Won M, Sappington R (2013) Stressor-dependent Alterations 
in Glycoprotein 130: Implications for Glial Cell Reactivity, Cytokine Signaling and 
Ganglion Cell Health in Glaucoma. J Clin Exp Ophthalmol 4. 
 
Echevarria FD (2014) Interleukin-6 Signaling in the Central Nervous System: Pointing the 
Finger at Trans-signaling in Neuroinflammatory-mediated Neurodegeneration. VRN 6. 
 
Echevarria FD, Rickman AE, Sappington RM (2016) Interleukin-6: A Constitutive Modulator of 
Glycoprotein 130, Neuroinflammatory and Cell Survival Signaling in Retina. J Clin Cell 
Iummunol 7. 
 
Echevarria FD, Formichella CR, Sappington RM (2017) Interleukin-6 Deficiency Attenuates 
Retinal Ganglion Cell Axonopathy and Glaucoma-related Vision Loss. Front. Neuro. 
11:318 
 
El-Danaf RN, Huberman AD (2015) Characteristic patterns of dendritic remodeling in early-
stage glaucoma: evidence from genetically identified retinal ganglion cell types. J 
Neurosci 35:2329-2343. 
 
Ellis EM, Gauvain G, Sivyer B, Murphy GJ (2016) Shared and distinct retinal input to the mouse 
superior colliculus and dorsal lateral geniculate nucleus. Journal of Neurophysiology 
116:602-610. 
 
Engel LA, Muether PS, Fauser S, Hueber A (2014) The effect of previous surgery and topical 
eye drops for primary open-angle glaucoma on cytokine expression in aqueous humor. 
Graefes Arch Clin Exp Ophthalmol 252:791-799. 
 
Erta M, Quintana A, Hidalgo J (2012) Interleukin-6, a major cytokine in the central nervous 
system. Int J Biol Sci 8:1254-1266. 
 
Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A (1998) IL-6-deficient mice resist myelin 
oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 
28:2178-2187. 
 
 162 
Fang XX, Jiang XL, Han XH, Peng YP, Qiu YH (2013) Neuroprotection of interleukin-6 against 
NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT 
signaling pathways. Cell Mol Neurobiol 33:241-251. 
 
Feng L, Chen H, Yi J, Troy JB, Zhang HF, Liu X (2016) Long-Term Protection of Retinal 
Ganglion Cells and Visual Function by Brain-Derived Neurotrophic Factor in Mice With 
Ocular Hypertension. Invest Ophthalmol Vis Sci 57:3793-3802. 
 
Feng L, Zhao Y, Yoshida M, Chen H, Yang JF, Kim TS, Cang JH, Troy JB, Liu XR (2013) 
Sustained Ocular Hypertension Induces Dendritic Degeneration of Mouse Retinal 
Ganglion Cells That Depends on Cell Type and Location. Invest Ophth Vis Sci 54:1106-
1117. 
 
Ferguson LR, Grover S, Dominguez JM, 2nd, Balaiya S, Chalam KV (2014) Retinal thickness 
measurement obtained with spectral domain optical coherence tomography assisted 
optical biopsy accurately correlates with ex vivo histology. PLoS One 9:e111203. 
 
Fernandez DC, Pasquini LA, Dorfman D, Aldana Marcos HJ, Rosenstein RE (2012) Early distal 
axonopathy of the visual pathway in experimental diabetes. Am J Pathol 180:303-313. 
 
Fischer AJ, Zelinka C, Milani-Nejad N (2015) Reactive retinal microglia, neuronal survival, and 
the formation of retinal folds and detachments. Glia 63:313-327. 
 
Fisher J, Mizrahi T, Schori H, Yoles E, Levkovitch-Verbin H, Haggiag S, Revel M, Schwartz M 
(2001) Increased post-traumatic survival of neurons in IL-6-knockout mice on a 
background of EAE susceptibility. J Neuroimmunol 119:1-9. 
 
Formichella C, Abella, SK, Sims,SM, Cathcart, HM, Sappington, RM (2014) Astrocyte 
Reactivity: A Biomarker for Ganglion Cell Health in Retinal Neurodegeneration. Journal 
of Clinical and Cellular Immunology 5:15. 
 
Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G 
(2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y 
Acad Sci 908:244-254. 
 
Franchimont N, Wertz S, Malaise M (2005) Interleukin-6: An osteotropic factor influencing 
bone formation? Bone 37:601-606. 
 
Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the 
flame in neurodegenerative diseases? Mol Neurodegener 4:47. 
 
Freddo TF, Gong H (2009) Etiology of Iop Elevation in Primary Open Angle Glaucoma. Optom 
Glaucoma Soc E J 4. 
 
Gadient RA, Otten U (1993) Differential expression of interleukin-6 (IL-6) and interleukin-6 
receptor (IL-6R) mRNAs in rat hypothalamus. Neurosci Lett 153:13-16. 
 163 
Gadient RA, Otten U (1994a) Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-
6R) mRNAs in rat brain during postnatal development. Brain Res 637:10-14. 
 
Gadient RA, Otten U (1994b) Identification of interleukin-6 (IL-6)-expressing neurons in the 
cerebellum and hippocampus of normal adult rats. Neurosci Lett 182:243-246. 
 
Gadient RA, Otten U (1995) Interleukin-6 and interleukin-6 receptor mRNA expression in rat 
central nervous system. Ann N Y Acad Sci 762:403-406. 
 
Gallego BI, Salazar JJ, de Hoz R, Rojas B, Ramirez AI, Salinas-Navarro M, Ortin-Martinez A, 
Valiente-Soriano FJ, Aviles-Trigueros M, Villegas-Perez MP, Vidal-Sanz M, Trivino A, 
Ramirez JM (2012) IOP induces upregulation of GFAP and MHC-II and microglia 
reactivity in mice retina contralateral to experimental glaucoma. J Neuroinflammation 
9:92. 
 
Garbers C, Jänner N, Chalaris A, Moss ML, Floss DM, Meyer D, Koch-Nolte F, Rose-John S, 
Scheller J (2011) Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 
(IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. 
Journal of Biological Chemistry 286:14804-14811. 
 
Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC (1995) Programmed cell death of retinal 
ganglion cells during experimental glaucoma. Exp Eye Res 61:33-44. 
 
Ghanem A, Arafa L, Elewa A (2011) Tumor Necrosis Factor-α and Interleukin-6 Levels in 
patients with primary open-angle Glaucoma. J Clinic Experiment Ophthalmol 2:2. 
 
Goldblum D, Mittag T (2002) Prospects for relevant glaucoma models with retinal ganglion cell 
damage in the rodent eye. Vision Res 42:471-478. 
 
Grotzinger J, Kernebeck T, Kallen KJ, Rose-John S (1999) IL-6 type cytokine receptor 
complexes: hexamer, tetramer or both? Biol Chem 380:803-813. 
 
Gruol DL, Vo K, Bray JG (2014) Increased astrocyte expression of IL-6 or CCL2 in transgenic 
mice alters levels of hippocampal and cerebellar proteins. Front Cell Neurosci 8:234. 
 
Guo L, Duggan J, Cordeiro MF (2010a) Alzheimer's disease and retinal neurodegeneration. Curr 
Alzheimer Res 7:3-14. 
 
Guo Y, Cepurna WO, Dyck JA, Doser TA, Johnson EC, Morrison JC (2010b) Retinal cell 
responses to elevated intraocular pressure: a gene array comparison between the whole 
retina and retinal ganglion cell layer. Invest Ophthalmol Vis Sci 51:3003-3018. 
 
Guo Y, Johnson E, Cepurna W, Jia L, Dyck J, Morrison JC (2009) Does elevated intraocular 
pressure reduce retinal TRKB-mediated survival signaling in experimental glaucoma? 
Exp Eye Res 89:921-933. 
 
 164 
Hagberg H, Gilland E, Bona E, Hanson LA, Hahin-Zoric M, Blennow M, Holst M, McRae A, 
Soder O (1996) Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and 
bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res 40:603-609. 
 
Hama T, Miyamoto M, Tsukui H, Nishio C, Hatanaka H (1989) Interleukin-6 as a neurotrophic 
factor for promoting the survival of cultured basal forebrain cholinergic neurons from 
postnatal rats. Neurosci Lett 104:340-344. 
 
Hans VH, Kossmann T, Joller H, Otto V, Morganti-Kossmann MC (1999a) Interleukin-6 and its 
soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuroreport 
10:409-412. 
 
Hans VH, Kossmann T, Lenzlinger PM, Probstmeier R, Imhof HG, Trentz O, Morganti-
Kossmann MC (1999b) Experimental axonal injury triggers interleukin-6 mRNA, protein 
synthesis and release into cerebrospinal fluid. J Cereb Blood Flow Metab 19:184-194. 
 
Harwerth RS, Quigley HA (2006) Visual field defects and retinal ganglion cell losses in patients 
with glaucoma. Archives of ophthalmology 124:853-859. 
 
Health Quality O (2006) Routine eye examinations for persons 20-64 years of age: an evidence-
based analysis. Ont Health Technol Assess Ser 6:1-81. 
 
Heavner W, Pevny L (2012) Eye development and retinogenesis. Cold Spring Harb Perspect 
Biol 4. 
 
Heiduschka P, Julien S, Schuettauf F, Schnichels S (2010a) Loss of retinal function in aged 
DBA/2J mice - New insights into retinal neurodegeneration. Exp Eye Res 91:779-783. 
 
Heiduschka P, Schnichels S, Fuhrmann N, Hofmeister S, Schraermeyer U, Wissinger B, Alavi 
MV (2010b) Electrophysiological and histologic assessment of retinal ganglion cell fate 
in a mouse model for OPA1-associated autosomal dominant optic atrophy. Invest 
Ophthalmol Vis Sci 51:1424-1431. 
 
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma 
Trial G (2002) Reduction of intraocular pressure and glaucoma progression: results from 
the Early Manifest Glaucoma Trial. Archives of ophthalmology 120:1268-1279. 
 
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type 
cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 ( Pt 2):297-
314. 
 
Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD (2005) Macrophages and 
neurodegeneration. Brain Res Brain Res Rev 48:185-195. 
 
 165 
Hines-Beard J, Bond WS, Backstrom JR, Rex TS (2016) Virus-mediated EpoR76E gene therapy 
preserves vision in a glaucoma model by modulating neuroinflammation and decreasing 
oxidative stress. J Neuroinflammation 13:39. 
 
Hodes GE, Menard C, Russo SJ (2016) Integrating Interleukin-6 into depression diagnosis and 
treatment. Neurobiol Stress 4:15-22. 
 
Hoene M, Runge H, Haring HU, Schleicher ED, Weigert C (2013) Interleukin-6 promotes 
myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. Am 
J Physiol Cell Physiol 304:C128-136. 
 
Hogan D, Morrow JD, Smith EM, Opp MR (2003) Interleukin-6 alters sleep of rats. J 
Neuroimmunol 137:59-66. 
 
Holcombe DJ, Lengefeld N, Gole GA, Barnett NL (2008) Selective inner retinal dysfunction 
precedes ganglion cell loss in a mouse glaucoma model. Br J Ophthalmol 92:683-688. 
 
Hollands H, Johnson D, Hollands S, Simel DL, Jinapriya D, Sharma S (2013) Do findings on 
routine examination identify patients at risk for primary open-angle glaucoma? The 
rational clinical examination systematic review. JAMA 309:2035-2042. 
 
Hood DC, Kardon RH (2007) A framework for comparing structural and functional measures of 
glaucomatous damage. Prog Retin Eye Res 26:688-710. 
 
Hoon M, Okawa H, Della Santina L, Wong RO (2014) Functional architecture of the retina: 
development and disease. Prog Retin Eye Res 42:44-84. 
 
Horstmann L, Schmid H, Heinen AP, Kurschus FC, Dick HB, Joachim SC (2013) Inflammatory 
demyelination induces glia alterations and ganglion cell loss in the retina of an 
experimental autoimmune encephalomyelitis model. J Neuroinflammation 10:120. 
 
Howell GR, Libby RT, Jakobs TC, Smith RS, Phalan FC, Barter JW, Barbay JM, Marchant JK, 
Mahesh N, Porciatti V, Whitmore AV, Masland RH, John SW (2007a) Axons of retinal 
ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol 
179:1523-1537. 
 
Howell GR, Libby RT, Marchant JK, Wilson LA, Cosma IM, Smith RS, Anderson MG, John 
SW (2007b) Absence of glaucoma in DBA/2J mice homozygous for wild-type versions 
of Gpnmb and Tyrp1. BMC Genet 8:45. 
 
Howell GR, Macalinao DG, Sousa GL, Walden M, Soto I, Kneeland SC, Barbay JM, King BL, 
Marchant JK, Hibbs M, Stevens B, Barres BA, Clark AF, Libby RT, John SWM (2011) 
Molecular clustering identifies complement and endothelin induction as early events in a 
mouse model of glaucoma. Journal of Clinical Investigation 121:1429-1444. 
 
 166 
Howell GR, Soto I, Ryan M, Graham LC, Smith RS, John SW (2013) Deficiency of complement 
component 5 ameliorates glaucoma in DBA/2J mice. J Neuroinflammation 10:76. 
 
Hsu MP, Frausto R, Rose-John S, Campbell IL (2015) Analysis of IL-6/gp130 family receptor 
expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor 
and functional responses to oncostatin M. Glia 63:132-141. 
 
Huang W, Chen S, Gao X, Yang M, Zhang J, Li X, Wang W, Zhou M, Zhang X, Zhang X 
(2014) Inflammation-related cytokines of aqueous humor in acute primary angle-closure 
eyes. Invest Ophthalmol Vis Sci 55:1088-1094. 
 
Huang W, Dobberfuhl A, Filippopoulos T, Ingelsson M, Fileta JB, Poulin NR, Grosskreutz CL 
(2005) Transcriptional up-regulation and activation of initiating caspases in experimental 
glaucoma. Am J Pathol 167:673-681. 
 
Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 
16:448-457. 
 
Iester M, De Feo F, Douglas GR (2012) Visual field loss morphology in high- and normal-
tension glaucoma. J Ophthalmol 2012:327326. 
 
Inman DM, Horner PJ (2007) Reactive nonproliferative gliosis predominates in a chronic mouse 
model of glaucoma. Glia 55:942-953. 
 
Inman DM, Sappington RM, Horner PJ, Calkins DJ (2006) Quantitative correlation of optic 
nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model 
of glaucoma. Invest Ophthalmol Vis Sci 47:986-996. 
 
Inomata Y, Hirata A, Yonemura N, Koga T, Kido N, Tanihara H (2003) Neuroprotective effects 
of interleukin-6 on NMDA-induced rat retinal damage. Biochem Biophys Res Commun 
302:226-232. 
 
Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A (2004) Retinal nerve fiber layer thinning in 
Parkinson disease. Vision Res 44:2793-2797. 
 
Ito YA, Belforte N, Cueva Vargas JL, Di Polo A (2016) A Magnetic Microbead Occlusion 
Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice. J Vis Exp e53731. 
 
Jafarzadehpour E, Radinmehr F, Pakravan M, Mirzajani A, Yazdani S (2013) Pattern 
electroretinography in glaucoma suspects and early primary open angle glaucoma. J 
Ophthalmic Vis Res 8:199-206. 
 
Jakobs TC, Libby RT, Ben Y, John SW, Masland RH (2005) Retinal ganglion cell degeneration 
is topological but not cell type specific in DBA/2J mice. J Cell Biol 171:313-325. 
 
 167 
John SW, Smith RS, Savinova OV, Hawes NL, Chang B, Turnbull D, Davisson M, Roderick 
TH, Heckenlively JR (1998) Essential iris atrophy, pigment dispersion, and glaucoma in 
DBA/2J mice. Invest Ophthalmol Vis Sci 39:951-962. 
 
Johnson EC, Doser TA, Cepurna WO, Dyck JA, Jia L, Guo Y, Lambert WS, Morrison JC (2011) 
Cell proliferation and interleukin-6-type cytokine signaling are implicated by gene 
expression responses in early optic nerve head injury in rat glaucoma. Invest Ophthalmol 
Vis Sci 52:504-518. 
 
Johnson EC, Morrison JC (2009) Friend or foe? Resolving the impact of glial responses in 
glaucoma. J Glaucoma 18:341-353. 
 
Johnson TV, Tomarev SI (2010) Rodent models of glaucoma. Brain Res Bull 81:349-358. 
 
Joos KM, Li C, Sappington RM (2010) Morphometric changes in the rat optic nerve following 
short-term intermittent elevations in intraocular pressure. Invest Ophthalmol Vis Sci 
51:6431-6440. 
 
Ju KR, Kim HS, Kim JH, Lee NY, Park CK (2006) Retinal glial cell responses and Fas/FasL 
activation in rats with chronic ocular hypertension. Brain Res 1122:209-221. 
 
Kalesnykas RP, Sparks DL (1996) The primate superior colliculus and the control of saccadic 
eye movements. Neuroscientist 2:284-292. 
 
Keeley PW, Whitney IE, Madsen NR, St John AJ, Borhanian S, Leong SA, Williams RW, Reese 
BE (2014) Independent Genomic Control of Neuronal Number across Retinal Cell Types. 
Dev Cell 30:103-109. 
 
Khan D, Fernando P, Cicvaric A, Berger A, Pollak A, Monje FJ, Pollak DD (2014) Long-term 
effects of maternal immune activation on depression-like behavior in the mouse. Transl 
Psychiatry 4:e363. 
 
Kim HS, Park CK (2005) Retinal ganglion cell death is delayed by activation of retinal intrinsic 
cell survival program. Brain Res 1057:17-28. 
 
Kitaoka Y, Munemasa Y, Kojima K, Hirano A, Ueno S, Takagi H (2013) Axonal protection by 
Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration. Cell 
Death Dis 4:e860. 
 
Kobbert C, Apps R, Bechmann I, Lanciego JL, Mey J, Thanos S (2000) Current concepts in 
neuroanatomical tracing. Prog Neurobiol 62:327-351. 
 
Kompass KS, Agapova OA, Li W, Kaufman PL, Rasmussen CA, Hernandez MR (2008) 
Bioinformatic and statistical analysis of the optic nerve head in a primate model of ocular 
hypertension. BMC Neurosci 9:93. 
 
 168 
Kong E, Sucic S, Monje FJ, Savalli G, Diao W, Khan D, Ronovsky M, Cabatic M, Koban F, 
Freissmuth M, Pollak DD (2015) STAT3 controls IL6-dependent regulation of serotonin 
transporter function and depression-like behavior. Sci Rep 5:9009. 
 
Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, 
Bluethmann H, Kohler G (1994) Impaired immune and acute-phase responses in 
interleukin-6-deficient mice. Nature 368:339-342. 
 
Kossmann T, Hans V, Imhof HG, Trentz O, Morganti-Kossmann MC (1996) Interleukin-6 
released in human cerebrospinal fluid following traumatic brain injury may trigger nerve 
growth factor production in astrocytes. Brain Res 713:143-152. 
 
Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossmann C (1995) 
Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe 
traumatic brain injuries. Shock 4:311-317. 
 
Lambert WS, Ruiz L, Crish SD, Wheeler LA, Calkins DJ (2011) Brimonidine prevents axonal 
and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener 6:4. 
 
Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human 
fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. 
J Immunol 150:2659-2667. 
 
Lee YB, Nagai A, Kim SU (2002) Cytokines, chemokines, and cytokine receptors in human 
microglia. J Neurosci Res 69:94-103. 
 
Lehtimaki KA, Peltola J, Koskikallio E, Keranen T, Honkaniemi J (2003) Expression of 
cytokines and cytokine receptors in the rat brain after kainic acid-induced seizures. Brain 
Res Mol Brain Res 110:253-260. 
 
Leibinger M, Andreadaki A, Gobrecht P, Levin E, Fischer D (2016) Boosting CNS axon 
regeneration by circumventing limitations of natural cytokine signaling. Mol Ther. 
 
Leibinger M, Muller A, Gobrecht P, Diekmann H, Andreadaki A, Fischer D (2013) Interleukin-6 
contributes to CNS axon regeneration upon inflammatory stimulation. Cell Death Dis 
4:e609. 
 
Levin LA (2001) Relevance of the site of injury of glaucoma to neuroprotective strategies. Surv 
Ophthalmol 45 Suppl 3:S243-249; discussion S273-246. 
 
Levkovitch-Verbin H, Harizman N, Dardik R, Nisgav Y, Vander S, Melamed S (2007) 
Regulation of cell death and survival pathways in experimental glaucoma. Exp Eye Res 
85:250-258. 
 
 169 
Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease ME (2002) 
Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma 
in rats. Invest Ophthalmol Vis Sci 43:402-410. 
 
Libby RT, Anderson MG, Pang IH, Robinson ZH, Savinova OV, Cosma IM, Snow A, Wilson 
LA, Smith RS, Clark AF, John SW (2005a) Inherited glaucoma in DBA/2J mice: 
pertinent disease features for studying the neurodegeneration. Vis Neurosci 22:637-648. 
 
Libby RT, Li Y, Savinova OV, Barter J, Smith RS, Nickells RW, John SW (2005b) 
Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS 
Genet 1:17-26. 
 
Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, Caruso C (2005) 
Innate immunity and inflammation in ageing: a key for understanding age-related 
diseases. Immun Ageing 2:8. 
 
Lin HJ, Tsai FJ, Chen WC, Shi YR, Hsu Y, Tsai SW (2003a) Association of tumour necrosis 
factor alpha -308 gene polymorphism with primary open-angle glaucoma in Chinese. Eye 
(Lond) 17:31-34. 
 
Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N (2003b) Essential involvement of IL-6 in 
the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient 
mice. J Leukoc Biol 73:713-721. 
 
Livingstone M, Hubel D (1988) Segregation of form, color, movement, and depth: anatomy, 
physiology, and perception. Science 240:740-749. 
 
Loddick SA, Turnbull AV, Rothwell NJ (1998) Cerebral interleukin-6 is neuroprotective during 
permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 18:176-179. 
 
Lohmann C (2009) Calcium signaling and the development of specific neuronal connections. 
Prog Brain Res 175:443-452. 
 
London A, Benhar I, Schwartz M (2013) The retina as a window to the brain-from eye research 
to CNS disorders. Nat Rev Neurol 9:44-53. 
 
Lucas SM, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. 
Brit J Pharmacol 147:S232-S240. 
 
Luo C, Yang X, Kain AD, Powell DW, Kuehn MH, Tezel G (2010) Glaucomatous tissue stress 
and the regulation of immune response through glial Toll-like receptor signaling. Invest 
Ophthalmol Vis Sci 51:5697-5707. 
 
Lye-Barthel M, Sun D, Jakobs TC (2013) Morphology of astrocytes in a glaucomatous optic 
nerve. Invest Ophthalmol Vis Sci 54:909-917. 
 
 170 
Maday S, Twelvetrees AE, Moughamian AJ, Holzbaur EL (2014) Axonal transport: cargo-
specific mechanisms of motility and regulation. Neuron 84:292-309. 
 
Maimone D, Guazzi GC, Annunziata P (1997) IL-6 detection in multiple sclerosis brain. J 
Neurol Sci 146:59-65. 
 
Makinodan M, Ikawa D, Miyamoto Y, Yamauchi J, Yamamuro K, Yamashita Y, Toritsuka M, 
Kimoto S, Okumura K, Yamauchi T, Fukami SI, Yoshino H, Wanaka A, Kishimoto T 
(2016) Social isolation impairs remyelination in mice through modulation of IL-6. 
FASEB J 30:4267-4274. 
 
Malsch P, Andratsch M, Vogl C, Link AS, Alzheimer C, Brierley SM, Hughes PA, Kress M 
(2014) Deletion of interleukin-6 signal transducer gp130 in small sensory neurons 
attenuates mechanonociception and down-regulates TRPA1 expression. J Neurosci 
34:9845-9856. 
 
Martin A, Hofmann HD, Kirsch M (2003) Glial reactivity in ciliary neurotrophic factor-deficient 
mice after optic nerve lesion. J Neurosci 23:5416-5424. 
 
Marx MS, Podos SM, Bodis-Wollner I, Lee PY, Wang RF, Severin C (1988) Signs of early 
damage in glaucomatous monkey eyes: low spatial frequency losses in the pattern ERG 
and VEP. Exp Eye Res 46:173-184. 
 
Marz P, Cheng JG, Gadient RA, Patterson PH, Stoyan T, Otten U, Rose-John S (1998) 
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A 
95:3251-3256. 
 
McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA, Kozma SC, 
Drew AF (2010) Differences in wound healing in mice with deficiency of IL-6 versus IL-
6 receptor. J Immunol 184:7219-7228. 
 
McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, 
Ransom NL, Tahzib NG, Reitsamer HA, Levkovitch-Verbin H, Quigley HA, Zack DJ 
(2002) Caspase activation and amyloid precursor protein cleavage in rat ocular 
hypertension. Invest Ophthalmol Vis Sci 43:1077-1087. 
 
Medawar PB (1948) Immunity to homologous grafted skin; the fate of skin homografts 
transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. 
Br J Exp Pathol 29:58-69. 
 
Medeiros FA, Lisboa R, Weinreb RN, Liebmann JM, Girkin C, Zangwill LM (2013) Retinal 
Ganglion Cell Count Estimates Associated with Early Development of Visual Field 
Defects in Glaucoma. Ophthalmology 120:736-744. 
 
Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428-435. 
 
 171 
Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M (1998) Interleukin-6 functions in autoimmune 
encephalomyelitis: a study in gene-targeted mice. Eur J Immunol 28:1727-1737. 
 
Mendonca Torres PM, de Araujo EG (2001) Interleukin-6 increases the survival of retinal 
ganglion cells in vitro. J Neuroimmunol 117:43-50. 
 
Minckler DS, Bunt AH, Johanson GW (1977) Orthograde and retrograde axoplasmic transport 
during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci 16:426-441. 
 
Mo JS, Streilein JW (2001) Immune privilege persists in eyes with extreme inflammation 
induced by intravitreal LPS. Eur J Immunol 31:3806-3815. 
 
Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 
beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in 
ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. 
Neurosci Lett 211:13-16. 
 
Morikawa Y, Tamura S, Minehata K, Donovan PJ, Miyajima A, Senba E (2004) Essential 
function of oncostatin m in nociceptive neurons of dorsal root ganglia. J Neurosci 
24:1941-1947. 
 
Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC (1997) A rat 
model of chronic pressure-induced optic nerve damage. Exp Eye Res 64:85-96. 
 
Morrow JD, Opp MR (2005) Sleep-wake behavior and responses of interleukin-6-deficient mice 
to sleep deprivation. Brain Behav Immun 19:28-39. 
 
Morzaev D, Nicholson JD, Caspi T, Weiss S, Hochhauser E, Goldenberg-Cohen N (2015) Toll-
like receptor-4 knockout mice are more resistant to optic nerve crush damage than wild-
type mice. Clin Exp Ophthalmol 43:655-665. 
 
Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, Kanakis M, Koutsandrea C 
(2011) Morphologic changes and functional retinal impairment in patients with Parkinson 
disease without visual loss. European journal of ophthalmology 21:24-29. 
 
Moschovakis AK (1996) The superior colliculus and eye movement control. Current opinion in 
neurobiology 6:811-816. 
 
Mossbock G, Weger M, Moray M, Renner W, Haller-Schober EM, Mattes D, Schmut O, 
Wegscheider B, El-Shabrawi Y (2006) TNF-alpha promoter polymorphisms and primary 
open-angle glaucoma. Eye (Lond) 20:1040-1043. 
 
Mousa A, Bakhiet M (2013) Role of cytokine signaling during nervous system development. Int 
J Mol Sci 14:13931-13957. 
 
 172 
Mukaino M, Nakamura M, Yamada O, Okada S, Morikawa S, Renault-Mihara F, Iwanami A, 
Ikegami T, Ohsugi Y, Tsuji O, Katoh H, Matsuzaki Y, Toyama Y, Liu M, Okano H 
(2010) Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing 
microglia-dominant inflammation. Exp Neurol 224:403-414. 
 
Murphy PG, Ramer MS, Borthwick L, Gauldie J, Richardson PM, Bisby MA (1999) 
Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and 
changes in neuropeptides associated with chronic nerve constriction in mice. European 
Journal of Neuroscience 11:2243-2253. 
 
Nakano Y, Shimazawa M, Ojino K, Izawa H, Takeuchi H, Inoue Y, Tsuruma K, Hara H (2017) 
Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by 
optic nerve crush in mice. J Pharmacol Sci. 
 
Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, Michaud N, Hafezi-
Moghadam A, Miller JW, Benowitz LI (2006) Tumor necrosis factor-alpha mediates 
oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of 
glaucoma. J Neurosci 26:12633-12641. 
 
Navarro-Partida J, Martinez-Rizo AB, Ramirez-Barrera P, Velazquez-Fernandez JB, 
Mondragon-Jaimes VA, Santos-Garcia A, Benites-Godinez V (2017) Association of Toll-
like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile with the risk 
of primary open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 
 
Nelson TE, Ur CL, Gruol DL (2002) Chronic interleukin-6 exposure alters electrophysiological 
properties and calcium signaling in developing cerebellar purkinje neurons in culture. J 
Neurophysiol 88:475-486. 
 
Nickells RW (2012) The cell and molecular biology of glaucoma: mechanisms of retinal 
ganglion cell death. Invest Ophthalmol Vis Sci 53:2476-2481. 
 
Nongpiur ME, Ku JY, Aung T (2011) Angle closure glaucoma: a mechanistic review. Curr Opin 
Ophthalmol 22:96-101. 
 
Ogai K, Kuwana A, Hisano S, Nagashima M, Koriyama Y, Sugitani K, Mawatari K, Nakashima 
H, Kato S (2014) Upregulation of leukemia inhibitory factor (LIF) during the early stage 
of optic nerve regeneration in zebrafish. PLoS One 9:e106010. 
 
Okuda Y, Sakoda S, Bernard CC, Fujimura H, Saeki Y, Kishimoto T, Yanagihara T (1998) IL-6-
deficient mice are resistant to the induction of experimental autoimmune 
encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol 
10:703-708. 
 
Oppenheim RW, Wiese S, Prevette D, Armanini M, Wang S, Houenou LJ, Holtmann B, Gotz R, 
Pennica D, Sendtner M (2001) Cardiotrophin-1, a muscle-derived cytokine, is required 
for the survival of subpopulations of developing motoneurons. J Neurosci 21:1283-1291. 
 173 
Orellana DI, Quintanilla RA, Gonzalez-Billault C, Maccioni RB (2005) Role of the 
JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in 
hippocampal neurons. Neurotox Res 8:295-304. 
 
Panagis L, Zhao X, Ge Y, Ren L, Mittag TW, Danias J (2011) Retinal gene expression changes 
related to IOP exposure and axonal loss in DBA/2J mice. Invest Ophthalmol Vis Sci 
52:7807-7816. 
 
Pang IH, Clark AF (2007) Rodent models for glaucoma retinopathy and optic neuropathy. J 
Glaucoma 16:483-505. 
 
Parisi V, Miglior S, Manni G, Centofanti M, Bucci MG (2006) Clinical ability of pattern 
electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular 
hypertension and glaucoma. Ophthalmology 113:216-228. 
 
Pavelko KD, Howe CL, Drescher KM, Gamez JD, Johnson AJ, Wei T, Ransohoff RM, 
Rodriguez M (2003) Interleukin-6 protects anterior horn neurons from lethal virus-
induced injury. J Neurosci 23:481-492. 
 
Peng YP, Qiu YH, Lu JH, Wang JJ (2005) Interleukin-6 protects cultured cerebellar granule 
neurons against glutamate-induced neurotoxicity. Neurosci Lett 374:192-196. 
 
Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J (2000) Impaired inflammatory response 
and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-
deficient mice. Glia 32:271-285. 
 
Penkowa M, Giralt M, Lago N, Camats J, Carrasco J, Hernandez J, Molinero A, Campbell IL, 
Hidalgo J (2003) Astrocyte-targeted expression of IL-6 protects the CNS against a focal 
brain injury. Exp Neurol 181:130-148. 
 
Penkowa M, Molinero A, Carrasco J, Hidalgo J (2001) Interleukin-6 deficiency reduces the brain 
inflammatory response and increases oxidative stress and neurodegeneration after kainic 
acid-induced seizures. Neuroscience 102:805-818. 
 
Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, Bluethmann H, Hidalgo J (1999) 
Strongly compromised inflammatory response to brain injury in interleukin-6-deficient 
mice. Glia 25:343-357. 
 
Perigolo-Vicente R, Ritt K, Goncalves-de-Albuquerque CF, Castro-Faria-Neto HC, Paes-de-
Carvalho R, Giestal-de-Araujo E (2014) IL-6, A1 and A2aR: a crosstalk that modulates 
BDNF and induces neuroprotection. Biochem Biophys Res Commun 449:477-482. 
 
Perigolo-Vicente R, Ritt K, Pereira MR, Torres PM, Paes-de-Carvalho R, Giestal-de-Araujo E 
(2013) IL-6 treatment increases the survival of retinal ganglion cells in vitro: the role of 
adenosine A1 receptor. Biochem Biophys Res Commun 430:512-518. 
 
 174 
Pernet V, Joly S, Dalkara D, Jordi N, Schwarz O, Christ F, Schaffer DV, Flannery JG, Schwab 
ME (2013) Long-distance axonal regeneration induced by CNTF gene transfer is 
impaired by axonal misguidance in the injured adult optic nerve. Neurobiol Dis 51:202-
213. 
 
Perry VH, Anthony DC, Bolton SJ, Brown HC (1997) The blood-brain barrier and the 
inflammatory response. Mol Med Today 3:335-341. 
 
Perry VH, Oehler R, Cowey A (1984) Retinal ganglion cells that project to the dorsal lateral 
geniculate nucleus in the macaque monkey. Neuroscience 12:1101-1123. 
 
Porciatti V (2015) Electrophysiological assessment of retinal ganglion cell function. Exp Eye 
Res 141:164-170. 
 
Qiu Z, Parsons KL, Gruol DL (1995) Interleukin-6 selectively enhances the intracellular calcium 
response to NMDA in developing CNS neurons. J Neurosci 15:6688-6699. 
 
Qu J, Wang D, Grosskreutz CL (2010) Mechanisms of retinal ganglion cell injury and defense in 
glaucoma. Exp Eye Res 91:48-53. 
 
Quigley H, Anderson DR (1976) The dynamics and location of axonal transport blockade by 
acute intraocular pressure elevation in primate optic nerve. Invest Ophthalmol 15:606-
616. 
 
Quigley HA (1985) Early detection of glaucomatous damage. II. Changes in the appearance of 
the optic disk. Surv Ophthalmol 30:111, 117-126. 
 
Quigley HA (1993) Open-angle glaucoma. N Engl J Med 328:1097-1106. 
 
Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 
2020. Br J Ophthalmol 90:262-267. 
 
Rangarajan KV, Lawhn-Heath C, Feng L, Kim TS, Cang J, Liu X (2011) Detection of visual 
deficits in aging DBA/2J mice by two behavioral assays. Curr Eye Res 36:481-491. 
 
Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous system. J Clin Invest 
122:1164-1171. 
 
Reyes TM, Fabry Z, Coe CL (1999) Brain endothelial cell production of a neuroprotective 
cytokine, interleukin-6, in response to noxious stimuli. Brain Res 851:215-220. 
 
Rhee KD, Yang XJ (2010) Function and mechanism of CNTF/LIF signaling in retinogenesis. 
Adv Exp Med Biol 664:647-654. 
 
Ridder WH, 3rd, Nusinowitz S (2006) The visual evoked potential in the mouse--origins and 
response characteristics. Vision Res 46:902-913. 
 175 
Ritch R (2002) Exfoliation syndrome: More than meets the eye. Acta Ophthalmol Scan 80:465-
467. 
 
Rojas B, Gallego BI, Ramirez AI, Salazar JJ, de Hoz R, Valiente-Soriano FJ, Aviles-Trigueros 
M, Villegas-Perez MP, Vidal-Sanz M, Trivino A, Ramirez JM (2014) Microglia in mouse 
retina contralateral to experimental glaucoma exhibit multiple signs of activation in all 
retinal layers. J Neuroinflammation 11:133. 
 
Rose-John S (2013) 216: The pro-inflammatory activities of interleukin-6 are mediated by the 
soluble interleukin-6 receptor via trans-signaling. Cytokine 63:294. 
 
Rosenbaum JT, Woods A, Kezic J, Planck SR, Rosenzweig HL (2011) Contrasting ocular effects 
of local versus systemic endotoxin. Invest Ophthalmol Vis Sci 52:6472-6477. 
 
Rosenberg SS, Spitzer NC (2011) Calcium signaling in neuronal development. Cold Spring Harb 
Perspect Biol 3:a004259. 
 
Rothaug M, Becker-Pauly C, Rose-John S (2016) The role of interleukin-6 signaling in nervous 
tissue. Biochim Biophys Acta 1863:1218-1227. 
 
Rubin DC, Shaker A, Levin MS (2012) Chronic intestinal inflammation: inflammatory bowel 
disease and colitis-associated colon cancer. Front Immunol 3:107. 
 
Sabry J, O'Connor TP, Kirschner MW (1995) Axonal transport of tubulin in Ti1 pioneer neurons 
in situ. Neuron 14:1247-1256. 
 
Sakai M, Sakai H, Nakamura Y, Fukuchi T, Sawaguchi S (2003) Immunolocalization of heat 
shock proteins in the retina of normal monkey eyes and monkey eyes with laser-induced 
glaucoma. Jpn J Ophthalmol 47:42-52. 
 
Saleh M, Nagaraju M, Porciatti V (2007) Longitudinal evaluation of retinal ganglion cell 
function and IOP in the DBA/2J mouse model of glaucoma. Invest Ophth Vis Sci 
48:4564-4572. 
 
Salinas-Navarro M, Alarcon-Martinez L, Valiente-Soriano FJ, Ortin-Martinez A, Jimenez-Lopez 
M, Aviles-Trigueros M, Villegas-Perez MP, de la Villa P, Vidal-Sanz M (2009) 
Functional and morphological effects of laser-induced ocular hypertension in retinas of 
adult albino Swiss mice. Mol Vis 15:2578-2598. 
 
Sallmann S, Juttler E, Prinz S, Petersen N, Knopf U, Weiser T, Schwaninger M (2000) Induction 
of interleukin-6 by depolarization of neurons. J Neurosci 20:8637-8642. 
 
Salmon JF (1999) Predisposing factors for chronic angle-closure glaucoma. Prog Retin Eye Res 
18:121-132. 
 
 176 
Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y (1998) IL-6-deficient mice are resistant to 
experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and 
differentiation of autoreactive T cells. J Immunol 161:6480-6486. 
 
Sanchez RN, Chan CK, Garg S, Kwong JM, Wong MJ, Sadun AA, Lam TT (2003) Interleukin-6 
in retinal ischemia reperfusion injury in rats. Invest Ophthalmol Vis Sci 44:4006-4011. 
 
Sappington RM, Calkins DJ (2006) Pressure-induced regulation of IL-6 in retinal glial cells: 
involvement of the ubiquitin/proteasome pathway and NFkappaB. Invest Ophthalmol Vis 
Sci 47:3860-3869. 
 
Sappington RM, Calkins DJ (2008) Contribution of TRPV1 to microglia-derived IL-6 and 
NFkappaB translocation with elevated hydrostatic pressure. Invest Ophthalmol Vis Sci 
49:3004-3017. 
 
Sappington RM, Carlson BJ, Crish SD, Calkins DJ (2010) The microbead occlusion model: a 
paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci 
51:207-216. 
 
Sappington RM, Chan M, Calkins DJ (2006) Interleukin-6 protects retinal ganglion cells from 
pressure-induced death. Invest Ophthalmol Vis Sci 47:2932-2942. 
 
Sappington RM, Sidorova T, Long DJ, Calkins DJ (2009) TRPV1: contribution to retinal 
ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic 
pressure. Invest Ophthalmol Vis Sci 50:717-728. 
 
Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, Kaziro Y (1988) Induction of 
neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol 
Cell Biol 8:3546-3549. 
 
Sawada M, Suzumura A, Marunouchi T (1992) TNF alpha induces IL-6 production by astrocytes 
but not by microglia. Brain Res 583:296-299. 
 
Saxton WM, Hollenbeck PJ (2012) The axonal transport of mitochondria. J Cell Sci 125:2095-
2104. 
 
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011a) The pro- and anti-inflammatory 
properties of the cytokine interleukin-6. Biochim Biophys Acta 1813:878-888. 
 
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011b) The pro-and anti-inflammatory 
properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA)-
Molecular Cell Research 1813:878-888. 
 
Schlamp CL, Li Y, Dietz JA, Janssen KT, Nickells RW (2006) Progressive ganglion cell loss 
and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci 
7:66. 
 177 
Schobitz B, de Kloet ER, Sutanto W, Holsboer F (1993) Cellular localization of interleukin 6 
mRNA and interleukin 6 receptor mRNA in rat brain. The European journal of 
neuroscience 5:1426-1435. 
 
Schobitz B, Voorhuis DA, De Kloet ER (1992) Localization of interleukin 6 mRNA and 
interleukin 6 receptor mRNA in rat brain. Neurosci Lett 136:189-192. 
 
Schuettauf F, Zurakowski D, Quinto K, Varde MA, Besch D, Laties A, Anderson R, Wen R 
(2005) Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells. 
Graefes Arch Clin Exp Ophthalmol 243:1036-1042. 
 
Sebire G, Emilie D, Wallon C, Hery C, Devergne O, Delfraissy JF, Galanaud P, Tardieu M 
(1993) In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human 
embryonic microglial and neural cells. J Immunol 150:1517-1523. 
 
Sehi M, Grewal DS, Goodkin ML, Greenfield DS (2010) Reversal of retinal ganglion cell 
dysfunction after surgical reduction of intraocular pressure. Ophthalmology 117:2329-
2336. 
 
Shibuya E, Meguro A, Ota M, Kashiwagi K, Mabuchi F, Iijima H, Kawase K, Yamamoto T, 
Nakamura M, Negi A, Sagara T, Nishida T, Inatani M, Tanihara H, Aihara M, Araie M, 
Fukuchi T, Abe H, Higashide T, Sugiyama K, Kanamoto T, Kiuchi Y, Iwase A, Ohno S, 
Inoko H, Mizuki N (2008) Association of Toll-like receptor 4 gene polymorphisms with 
normal tension glaucoma. Invest Ophthalmol Vis Sci 49:4453-4457. 
 
Shields MB (2008) Normal-tension glaucoma: is it different from primary open-angle glaucoma? 
Curr Opin Ophthalmol 19:85-88. 
 
Shohami E, Novikov M, Bass R, Yamin A, Gallily R (1994) Closed head injury triggers early 
production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab 14:615-
619. 
 
Shou T, Liu J, Wang W, Zhou Y, Zhao K (2003) Differential dendritic shrinkage of alpha and 
beta retinal ganglion cells in cats with chronic glaucoma. Invest Ophthalmol Vis Sci 
44:3005-3010. 
 
Sims SM, Holmgren L, Cathcart HM, Sappington RM (2012) Spatial regulation of interleukin-6 
signaling in response to neurodegenerative stressors in the retina. Am J Neurodegener 
Dis 1:168-179. 
 
Sivak JM (2013) The aging eye: common degenerative mechanisms between the Alzheimer's 
brain and retinal disease. Invest Ophthalmol Vis Sci 54:871-880. 
 
Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal immune activation alters 
fetal brain development through interleukin-6. J Neurosci 27:10695-10702. 
 
 178 
Soto I, Howell GR (2014) The complex role of neuroinflammation in glaucoma. Cold Spring 
Harb Perspect Med 4. 
 
Soto I, Oglesby E, Buckingham BP, Son JL, Roberson ED, Steele MR, Inman DM, Vetter ML, 
Horner PJ, Marsh-Armstrong N (2008) Retinal ganglion cells downregulate gene 
expression and lose their axons within the optic nerve head in a mouse glaucoma model. J 
Neurosci 28:548-561. 
 
Soto I, Pease ME, Son JL, Shi X, Quigley HA, Marsh-Armstrong N (2011) Retinal ganglion cell 
loss in a rat ocular hypertension model is sectorial and involves early optic nerve axon 
loss. Invest Ophthalmol Vis Sci 52:434-441. 
 
Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW (2006) Interleukin-6 
facilitates lipopolysaccharide-induced disruption in working memory and expression of 
other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 
26:10709-10716. 
 
Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, 
Born J (1998) Acute effects of recombinant human interleukin-6 on endocrine and central 
nervous sleep functions in healthy men. J Clin Endocrinol Metab 83:1573-1579. 
 
Spittau B, Zhou X, Ming M, Krieglstein K (2012) IL6 protects MN9D cells and midbrain 
dopaminergic neurons from MPP+-induced neurodegeneration. Neuromolecular Med 
14:317-327. 
 
Stasi K, Nagel D, Yang X, Wang RF, Ren L, Podos SM, Mittag T, Danias J (2006) Complement 
component 1Q (C1Q) upregulation in retina of murine, primate, and human 
glaucomatous eyes. Invest Ophthalmol Vis Sci 47:1024-1029. 
 
Steele MR, Inman DM, Calkins DJ, Horner PJ, Vetter ML (2006) Microarray analysis of retinal 
gene expression in the DBA/2J model of glaucoma. Invest Ophthalmol Vis Sci 47:977-
985. 
 
Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, 
Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, 
John SW, Barres BA (2007) The classical complement cascade mediates CNS synapse 
elimination. Cell 131:1164-1178. 
 
Straub RH, Schradin C (2016) Chronic inflammatory systemic diseases: An evolutionary trade-
off between acutely beneficial but chronically harmful programs. Evol Med Public Health 
2016:37-51. 
 
Sullivan TA, Geisert EE, Hines-Beard J, Rex TS (2011) Systemic adeno-associated virus-
mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J 
glaucomatous mice. Hum Gene Ther 22:1191-1200. 
 179 
Sun D, Lye-Barthel M, Masland RH, Jakobs TC (2009) The morphology and spatial arrangement 
of astrocytes in the optic nerve head of the mouse. J Comp Neurol 516:1-19. 
 
Tada M, Diserens AC, Desbaillets I, de Tribolet N (1994) Analysis of cytokine receptor 
messenger RNA expression in human glioblastoma cells and normal astrocytes by 
reverse-transcription polymerase chain reaction. J Neurosurg 80:1063-1073. 
 
Takai Y, Tanito M, Ohira A (2012) Multiplex cytokine analysis of aqueous humor in eyes with 
primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis 
Sci 53:241-247. 
 
Takano Y, Shi D, Shimizu A, Funayama T, Mashima Y, Yasuda N, Fukuchi T, Abe H, Ideta H, 
Zheng X, Shiraishi A, Ohashi Y, Nishida K, Nakazawa T, Fuse N (2012) Association of 
Toll-like receptor 4 gene polymorphisms in Japanese subjects with primary open-angle, 
normal-tension, and exfoliation glaucoma. Am J Ophthalmol 154:825-832 e821. 
 
Tezel G (2008) TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 
173:409-421. 
 
Thomas BB, Seiler MJ, Sadda SR, Coffey PJ, Aramant RB (2004) Optokinetic test to evaluate 
visual acuity of each eye independently. J Neurosci Methods 138:7-13. 
 
Tiberio GA, Tiberio L, Benetti A, Cervi E, Montani N, Dreano M, Garotta G, Cerea K, 
Steimberg N, Pandolfo G, Ferrari-Bravo A, Mazzoleni G, Giulini SM, Schiaffonati L 
(2008) IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial 
hepatectomy. Cytokine 42:372-378. 
 
Tong J, Wang J, Sun F (2002) Dual-directional optokinetic nystagmus elicited by the intermittent 
display of gratings in primary open-angle glaucoma and normal eyes. Curr Eye Res 
25:355-362. 
 
Toulmond S, Vige X, Fage D, Benavides J (1992) Local infusion of interleukin-6 attenuates the 
neurotoxic effects of NMDA on rat striatal cholinergic neurons. Neurosci Lett 144:49-52. 
 
Umegaki H, Yamada K, Naito M, Kameyama T, Iguchi A, Nabeshima T (1996) Protective effect 
of interleukin-6 against the death of PC12 cells caused by serum deprivation or by the 
addition of a calcium ionophore. Biochem Pharmacol 52:911-916. 
 
Valerio A, Ferrario M, Dreano M, Garotta G, Spano P, Pizzi M (2002) Soluble interleukin-6 (IL-
6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat 
oligodendroglial lineage cells. Mol Cell Neurosci 21:602-615. 
 
Vallieres L, Rivest S (1997) Regulation of the genes encoding interleukin-6, its receptor, and 
gp130 in the rat brain in response to the immune activator lipopolysaccharide and the 
proinflammatory cytokine interleukin-1beta. J Neurochem 69:1668-1683. 
 
 180 
Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC (2016) Glia-neuron interactions in 
the mammalian retina. Prog Retin Eye Res 51:1-40. 
 
Wang H, Wu M, Zhan C, Ma E, Yang M, Yang X, Li Y (2012) Neurofilament proteins in axonal 
regeneration and neurodegenerative diseases. Neural Regen Res 7:620-626. 
 
Wang X, Tay SSW, Ng YK (2000) An immunohistochemical study of neuronal and glial cell 
reactions in retinae of rats with experimental glaucoma. Experimental Brain Research 
132:476-484. 
 
Ward NJ, Ho KW, Lambert WS, Weitlauf C, Calkins DJ (2014) Absence of transient receptor 
potential vanilloid-1 accelerates stress-induced axonopathy in the optic projection. J 
Neurosci 34:3161-3170. 
 
Wassle H (2004) Parallel processing in the mammalian retina. Nature Reviews Neuroscience 
5:747-757. 
 
Weber AJ, Kaufman PL, Hubbard WC (1998) Morphology of single ganglion cells in the 
glaucomatous primate retina. Invest Ophthalmol Vis Sci 39:2304-2320. 
 
Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, Li X (2012) Brain IL-
6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. 
Biochim Biophys Acta 1822:831-842. 
 
Weinreb RN, Aung T, Medeiros FA (2014) The pathophysiology and treatment of glaucoma: a 
review. JAMA 311:1901-1911. 
 
Weinreb RN, Leung CKS, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR 
(2016) Primary open-angle glaucoma. Nat Rev Dis Primers 16067. 
 
Wenk GL (2003) Neuropathologic changes in Alzheimer's disease. J Clin Psychiat 64:7-10. 
 
Williams PA, Marsh-Armstrong N, Howell GR, Lasker IIoA, Glaucomatous Neurodegeneration 
P (2017) Neuroinflammation in glaucoma: A new opportunity. Exp Eye Res. 
 
Williams PA, Tribble JR, Pepper KW, Cross SD, Morgan BP, Morgan JE, John SW, Howell GR 
(2016) Inhibition of the classical pathway of the complement cascade prevents early 
dendritic and synaptic degeneration in glaucoma. Mol Neurodegener 11:26. 
 
Williams RW, Moody SA (2003) Developmental and genetic control of cell number in the retina. 
The visual neurosciences (Chalupa LM, Werner JS, eds) pp 65-78. 
 
Williams RW, Strom RC, Rice DS, Goldowitz D (1996) Genetic and environmental control of 
variation in retinal ganglion cell number in mice. J Neurosci 16:7193-7205. 
 
 181 
Wilson GN, Inman DM, Dengler Crish CM, Smith MA, Crish SD (2015) Early pro-
inflammatory cytokine elevations in the DBA/2J mouse model of glaucoma. J 
Neuroinflammation 12:176. 
 
Wilson GN, Smith MA, Inman DM, Dengler-Crish CM, Crish SD (2016) Early Cytoskeletal 
Protein Modifications Precede Overt Structural Degeneration in the DBA/2J Mouse 
Model of Glaucoma. Front Neurosci 10:494. 
 
Winter CD, Pringle AK, Clough GF, Church MK (2004) Raised parenchymal interleukin-6 
levels correlate with improved outcome after traumatic brain injury. Brain 127:315-320. 
 
Woiciechowsky C, Schoning B, Cobanov J, Lanksch WR, Volk HD, Docke WD (2002) Early 
IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in 
brain-injured patients. J Trauma 52:339-345. 
 
WoldeMussie E, Ruiz G, Wijono M, Wheeler LA (2001) Neuro-protection of retinal ganglion 
cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophth 
Vis Sci 42:2849-2855. 
 
Wong AA, Brown RE (2012) A neurobehavioral analysis of the prevention of visual impairment 
in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 53:5956-5966. 
 
Xanthos DN, Sandkuhler J (2014) Neurogenic neuroinflammation: inflammatory CNS reactions 
in response to neuronal activity. Nature Reviews Neuroscience 15:43-53. 
 
Xia X, Wen R, Chou TH, Li Y, Wang Z, Porciatti V (2014) Protection of pattern 
electroretinogram and retinal ganglion cells by oncostatin M after optic nerve injury. 
PLoS One 9:e108524. 
 
Xin X, Gao L, Wu T, Sun F (2013) Roles of tumor necrosis factor alpha gene polymorphisms, 
tumor necrosis factor alpha level in aqueous humor, and the risks of open angle 
glaucoma: a meta-analysis. Mol Vis 19:526-535. 
 
Xu WQ, Wang YS (2016) The role of Toll-like receptors in retinal ischemic diseases. Int J 
Ophthalmol 9:1343-1351. 
 
Xu XJ, Hao JX, Andell-Jonsson S, Poli V, Bartfai T, Wiesenfeld-Hallin Z (1997) Nociceptive 
responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve 
section. Cytokine 9:1028-1033. 
 
Yamada M, Hatanaka H (1994) Interleukin-6 protects cultured rat hippocampal neurons against 
glutamate-induced cell death. Brain Res 643:173-180. 
 
Yan HQ, Banos MA, Herregodts P, Hooghe R, Hooghe-Peters EL (1992) Expression of 
interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and 
after injury. Eur J Immunol 22:2963-2971. 
 182 
Yang X, Luo C, Cai J, Powell DW, Yu D, Kuehn MH, Tezel G (2011) Neurodegenerative and 
inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the 
glaucomatous human retina. Invest Ophthalmol Vis Sci 52:8442-8454. 
 
Yaqub M (2012) Visual fields interpretation in glaucoma: a focus on static automated perimetry. 
Community Eye Health 25:1. 
 
You Y, Klistorner A, Thie J, Graham SL (2011) Latency delay of visual evoked potential is a 
real measurement of demyelination in a rat model of optic neuritis. Invest Ophthalmol 
Vis Sci 52:6911-6918. 
 
You Y, Klistorner A, Thie J, Gupta VK, Graham SL (2012) Axonal loss in a rat model of optic 
neuritis is closely correlated with visual evoked potential amplitudes using 
electroencephalogram-based scaling. Invest Ophthalmol Vis Sci 53:3662. 
 
Yu L, Wang L, Chen S (2010) Endogenous toll-like receptor ligands and their biological 
significance. J Cell Mol Med 14:2592-2603. 
 
Yuan L, Neufeld AH (2000) Tumor necrosis factor-alpha: a potentially neurodestructive 
cytokine produced by glia in the human glaucomatous optic nerve head. Glia 32:42-50. 
 
Zhang PL, Izrael M, Ainbinder E, Ben-Simchon L, Chebath J, Revel M (2006) Increased 
myelinating capacity of embryonic stem cell derived oligodendrocyte precursors after 
treatment by interleukin-6/soluble interleukin-6 receptor fusion protein. Mol Cell 
Neurosci 31:387-398. 
 
Zhang PL, Levy AM, Ben-Simchon L, Haggiag S, Chebath J, Revel M (2007) Induction of 
neuronal and myelin-related gene expression by IL-6-receptor/IL-6: a study on 
embryonic dorsal root ganglia cells and isolated Schwann cells. Exp Neurol 208:285-296. 
 
Zhao S, Gu Y, Dong Q, Fan R, Wang Y (2008) Altered interleukin-6 receptor, IL-6R and gp130, 
production and expression and decreased SOCS-3 expression in placentas from women 
with pre-eclampsia. Placenta 29:1024-1028. 
 
Zhong J, Dietzel ID, Wahle P, Kopf M, Heumann R (1999) Sensory impairments and delayed 
regeneration of sensory axons in interleukin-6-deficient mice. J Neurosci 19:4305-4313. 
 
Zhou X, Li F, Kong L, Tomita H, Li C, Cao W (2005) Involvement of inflammation, 
degradation, and apoptosis in a mouse model of glaucoma. J Biol Chem 280:31240-
31248. 
 
 
 
